



# ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment

Philip Kam-Tao Li<sup>1,2</sup> , Kai Ming Chow<sup>1,2</sup> , Yeoungjee Cho<sup>3,4</sup> , Stanley Fan<sup>5</sup>, Ana E Figueiredo<sup>6</sup>, Tess Harris<sup>7</sup>, Talerngsak Kanjanabuch<sup>8,9</sup> , Yong-Lim Kim<sup>10</sup>, Magdalena Madero<sup>11</sup>, Jolanta Malyszko<sup>12</sup>, Rajnish Mehrotra<sup>13</sup>, Ikechi G Okpechi<sup>14</sup>, Jeff Perl<sup>15</sup>, Beth Piraino<sup>16</sup>, Naomi Runnegar<sup>17</sup>, Isaac Teitelbaum<sup>18</sup> , Jennifer Ka-Wah Wong<sup>19</sup>, Xueqing Yu<sup>20,21</sup>  and David W Johnson<sup>3,4</sup> 

## Abstract

Peritoneal dialysis (PD)-associated peritonitis is a serious complication of PD and prevention and treatment of such is important in reducing patient morbidity and mortality. The ISPD 2022 updated recommendations have revised and clarified definitions for refractory peritonitis, relapsing peritonitis, peritonitis-associated catheter removal, PD-associated haemodialysis transfer, peritonitis-associated death and peritonitis-associated hospitalisation. New peritonitis categories and outcomes including pre-PD peritonitis, enteric peritonitis, catheter-related peritonitis and medical cure are defined. The new targets recommended for overall peritonitis rate should be no more than 0.40 episodes per year at risk and the percentage of patients free of peritonitis per unit time should be targeted at >80% per year. Revised recommendations regarding management of contamination of PD systems, antibiotic prophylaxis for invasive procedures and PD training and reassessment are included. New recommendations regarding management of modifiable peritonitis risk factors like domestic pets, hypokalaemia and histamine-2 receptor antagonists are highlighted. Updated recommendations regarding empirical antibiotic selection and dosage of antibiotics and also treatment of peritonitis due to specific microorganisms are made with new recommendation regarding adjunctive oral N-acetylcysteine therapy for mitigating aminoglycoside ototoxicity. Areas for future research in prevention and treatment of PD-related peritonitis are suggested.

<sup>1</sup> Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China

<sup>2</sup> Carol and Richard Yu Peritoneal Dialysis Research Centre, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China

<sup>3</sup> Australasian Kidney Trials Network, University of Queensland, Brisbane, Australia

<sup>4</sup> Department of Nephrology, Princess Alexandra Hospital, Brisbane, Australia

<sup>5</sup> Translational Medicine and Therapeutic, William Harvey Research Institute, Queen Mary University, London, UK

<sup>6</sup> Nursing School Escola de Ciências da Saúde e da Vida Pontificia Universidade Catolica do Rio Grande do Sul, Porto Alegre, Brazil

<sup>7</sup> Polycystic Kidney Disease Charity, London, UK

<sup>8</sup> Division of Nephrology, Department of Medicine, Chulalongkorn University, Bangkok, Thailand

<sup>9</sup> Center of Excellence in Kidney Metabolic Disorders, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

<sup>10</sup> Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, South Korea

<sup>11</sup> Division of Nephrology, Department of Medicine, National Heart Institute, Mexico City, Mexico

<sup>12</sup> Department of Nephrology, Dialysis and Internal Diseases, The Medical University of Warsaw, Poland

<sup>13</sup> Division of Nephrology, Department of Medicine, Harborview Medical Center, University of Washington, Seattle, Washington, DC, USA

<sup>14</sup> Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, South Africa

<sup>15</sup> St Michael's Hospital, University of Toronto, ON, Canada

<sup>16</sup> Department of Medicine, Renal Electrolyte Division, University of Pittsburgh, PA, USA

<sup>17</sup> Infectious Management Services, Princess Alexandra Hospital, University of Queensland, Brisbane, Australia

<sup>18</sup> Division of Nephrology, Department of Medicine, University of Colorado, Aurora, CO, USA

<sup>19</sup> Pharmacy Department, Prince of Wales Hospital, Shatin, Hong Kong, China

<sup>20</sup> Department of Nephrology, Guangdong Provincial People's Hospital, Guangzhou, China

<sup>21</sup> Guangdong Academy of Medical Sciences, Guangzhou, China

## Corresponding authors:

Philip Kam-Tao Li, Carol and Richard Yu Peritoneal Dialysis Research Centre, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.

Email: philipli@cuhk.edu.hk

David Johnson, Department of Nephrology, Level 2, ARTS Building, Princess Alexandra Hospital, 199 Ipswich Road, Woolloongabba, Brisbane, QLD 4102, Australia.

Email: david.johnson2@health.qld.gov.au

## Keywords

Guideline, ISPD, peritonitis, prevention, treatment

## What's new with the 2022 update of the ISPD peritonitis guidelines?

- Revised, clarified definitions for refractory peritonitis, relapsing peritonitis, peritonitis-associated catheter removal, peritonitis-associated haemodialysis transfer, peritonitis-associated death and peritonitis-associated hospitalization (page 5).
- Definitions for new peritonitis categories and outcomes: pre-PD peritonitis, enteric peritonitis, catheter-related peritonitis and medical cure (page 3-4).
- Revised, updated recommendations for calculating and reporting peritonitis rates before and after PD commencement (page 4-6).
- New targets recommended for overall peritonitis rate, proportion of patients free of peritonitis and culture-negative peritonitis (page 5).
- Revised recommendations regarding management of contamination of PD systems (page 7).
- Revised recommendations regarding antibiotic prophylaxis for invasive procedures (page 7).
- Revised recommendations regarding PD training and reassessment (page 8).
- New recommendations regarding PD patients with pets (page 9).
- New recommendations regarding management of modifiable peritonitis risk factors (hypokalaemia, histamine-2 receptor antagonists) (page 10).
- Update on novel diagnostic techniques for peritonitis (page 13).
- Updated recommendations regarding empirical antibiotic selection (page 13) and dosage of antibiotics (page 14).
- New recommendation regarding adjunctive oral N-acetylcysteine therapy for mitigating aminoglycoside ototoxicity (page 14).
- Revised recommendations regarding treatment of peritonitis in patients receiving APD (page 18).
- Revised recommendation regarding consideration of expectant management in patients longer than 5 days if PD effluent white cell count is decreasing towards normal, instead of mandatory PD catheter removal if effluent does not clear up by day 5 (page 19).
- Updated recommendations for treatment of peritonitis due to coagulase-negative staphylococci (page 22, *Corynebacteria* (page 23), *enterococcus* (page 23), *Pseudomonas* (page 24, *Acinetobacter* (page 25), *Stenotrophomonas* (page 25) and non-tuberculous mycobacteria (page 30).

## Introduction

Peritoneal dialysis (PD)-associated peritonitis is a serious complication of PD,<sup>1,2</sup> which is a critically important outcome to all key stakeholders including patients, caregivers, clinicians, researchers and policymakers.<sup>3</sup> It is the most common type of PD-related infection resulting in increased healthcare utilisation and is associated with significant harms including pain, treatment costs, transfer to haemodialysis and death, as well as alterations of the peritoneal membrane and peritoneal adhesions which can make long-term treatment with PD challenging.<sup>4-7</sup>

Recommendations on the prevention and treatment of peritonitis have been published previously under the auspices of the International Society for Peritoneal Dialysis (ISPD) in 1983, 1993, 1996, 2000, 2005, 2010 and 2016.<sup>8-13</sup> The present recommendations are organised into five broad sections focusing on:

1. definitions and measurement of peritonitis;
2. prevention of peritonitis;
3. treatment of peritonitis: initial and subsequent;
4. monitoring response to peritonitis treatment including indications for catheter removal and
5. return to PD after cessation of PD due to peritonitis-related catheter removal.

These recommendations are evidence-based where evidence is available, and if multiple reports are available, findings from the more recent publications have been incorporated by the committee. In general, these recommendations follow the Grades of Recommendation Assessment, Development and Evaluation system for classification of the level of evidence and grade of recommendations in clinical guideline reports.<sup>14</sup> Within each recommendation, the strength of recommendation is indicated as Level 1 (We recommend), Level 2 (We suggest) or Not Graded, and the quality of the supporting evidence if shown as A (high quality), B (moderate quality), C (low quality) or D (very low quality).<sup>14</sup> The recommendations related to treatment are not intended to be implemented indiscriminately and may require adaptation according to local conditions, such as pattern of infection, causative organisms and microbial resistance. Clinicians caring for paediatric PD patients should refer to the latest consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in paediatric patients receiving PD.<sup>15</sup>

## Definition and measurement of peritonitis

### Definition

Standardisation of the definition of outcomes and its measures is pivotal to enabling assessment of the comparative effects of interventions for peritonitis. It also facilitates benchmarking of performance to improve and address practice variations. A systematic review of 77 studies (three randomised controlled trials) demonstrated large variability in definitions of peritonitis (29% of studies did not describe peritonitis definition used and 42% of studies modified ISPD recommended diagnostic criteria for peritonitis) and reporting of outcome measures (e.g. peritonitis rate, peritonitis-related death).<sup>16</sup> In another systematic review, 59 clinical trials of PD-related infections included 383 different outcome measures.<sup>3</sup> The definitions related to peritonitis can be further classified according to cause, association with exit-site/tunnel infections, timing in relation to previous episodes and outcomes.

### Peritonitis

- We recommend that peritonitis should be diagnosed when at least two of the following are present:
  - 1) clinical features consistent with peritonitis, that is, abdominal pain and/or cloudy dialysis effluent;
  - 2) dialysis effluent white cell count  $> 100/\mu\text{L}$  or  $> 0.1 \times 10^9/\text{L}$  (after a dwell time of at least 2 h), with  $> 50\%$  polymorphonuclear leukocytes (PMN);
  - 3) positive dialysis effluent culture (1C).

### Cause-specific peritonitis

- We recommend a diagnosis of peritonitis according to organisms identified on culture (e.g., *Staphylococcus aureus* peritonitis; 1C).
- We suggest culture-negative peritonitis is defined when peritonitis is diagnosed using the criteria above (criteria one and two), but no organism is identified on culture of dialysis effluent (Not Graded).
- We suggest catheter-related peritonitis is defined as peritonitis that occurs in temporal conjunction (within 3 months) with a catheter infection (either exit-site or tunnel<sup>17</sup>) with the same organism at the exit-site or from a tunnel collection and in the effluent or one site sterile in the context of antibiotic exposure (Not Graded).
- We suggest enteric peritonitis be defined as peritonitis arising from an intestinal source involving processes such as inflammation, perforation or ischemia of intraabdominal organs. If a peritonitis episode in this context is culture negative, we suggest that it be classified/recorded as enteric peritonitis rather than as culture-negative peritonitis (Not Graded).

The cause of peritonitis can be broadly divided according to organism or concomitant event (e.g. tunnel infection)

to inform treatment. When no organism is identified after the culture of dialysis effluent, culture-negative peritonitis is diagnosed.<sup>11</sup> All cases of culture-negative peritonitis that meet the ISPD diagnostic criteria for peritonitis should be counted in the peritonitis statistics. Culture-negative peritonitis can be due to infectious or non-infectious causes. For example, infectious causes may occur in the context of recent antibiotic exposure, suboptimal sample collection or culture methods or misclassification from slowly growing atypical organisms (e.g. mycobacteria, fungus). Non-infectious causes may include eosinophilic or chemical (e.g. icodextrin) peritonitis but neutrophil predominance of the elevated white blood cells (WBC) count may not be present.<sup>11</sup> Hemoperitoneum, characterised by the predominant presence of red blood cells in the dialysis effluent, should not be confused with peritonitis.

The association between catheter-related infections, such as exit-site and tunnel infections, and peritonitis is well established.<sup>18,19</sup> Catheter-related peritonitis can be diagnosed with a high degree of certainty when it occurs concomitantly with an exit-site and/or tunnel infection. Alternatively, one site (e.g. exit-site or PD effluent) may be culture negative in catheter-related peritonitis in the context of recent antibiotic exposure for treatment of the initial infection. However, at present, there are no data available to inform the precise temporal criterion for diagnosing catheter-related peritonitis.<sup>20</sup> Interestingly, a case-control study of 962 incident PD patients demonstrated that the odds of peritonitis after an exit-site infection by organism class at 3, 6 and 9 months were significantly more likely to be from the same class of organism at 3 months (odds ratio (OR) at 3 months: 2.00, 95% confidence interval (CI) 1.15–3.47,  $p = 0.01$ ), especially for gram-positive organisms (OR at 3 months: 2.27, 95% CI 1.19–4.31,  $p = 0.01$  compared to at 9 months: OR 1.91, 95% CI 1.29–2.83,  $p = 0.001$ ).<sup>18</sup>

Peritonitis from enteric causes (e.g. strangulated bowel, ischemic colitis, appendicitis) can pose a diagnostic challenge with attendant delays in appropriate treatment and resultant increased morbidity and a mortality rate of approximately 50%.<sup>21,22</sup> Identification of multiple organisms (particularly both gram-positive and gram-negative) is highly suggestive of an enteric cause for peritonitis; however, this has been reported to occur in less than 20% of cases of enteric (sometimes known as 'surgical') peritonitis.<sup>21,23</sup> Enteric peritonitis can present as culture negative if the process involves the peritoneal membrane through a contiguous, non-infective, inflammatory reaction (e.g. pancreatitis).<sup>24</sup>

### Time-specific peritonitis

- Pre-PD peritonitis (before PD commencement)
  - We suggest pre-PD peritonitis be defined as a peritonitis episode occurring after PD catheter insertion and prior to commencement of PD

treatment. The date of PD initiation is defined as the day when the first PD exchange is performed with the intention of continuing long-term PD treatment from that day (i.e. first day of PD training or PD treatment in a hospital or at home with the intention of continuing PD long-term, whichever occurs first). The intermittent flushing of a PD catheter for the purpose of maintaining catheter patency does not qualify as PD initiation (Not Graded).

- For the purpose of pre-PD peritonitis rate reporting, time at risk starts from the day of PD catheter insertion and ends with PD commencement, PD catheter removal or death, whichever comes first (Not Graded).
- PD-related peritonitis (after PD commencement)
  - We suggest that, for the purpose of standard peritonitis rate reporting for PD-related peritonitis, time at risk starts from the day of PD commencement (i.e. first day of PD training or PD treatment in hospital or at home with the intention of continuing PD long-term, whichever occurs first) and continues while a patient remains on PD regardless of the setting (home, hospital, residential aged care facility, etc.) or who is performing the PD exchanges (Not Graded).
- PD catheter insertion-related peritonitis
  - We suggest that PD catheter insertion-related peritonitis be defined as an episode of peritonitis that occurs within 30 days of PD catheter insertion (Not Graded).

Peritonitis occurring prior to PD training is an under-recognised problem. Most units, including clinical registries, only capture peritonitis after patients commence PD. One observational study in Hong Kong reported the incidence of pre-training peritonitis to be 4.2% in 1252 patients newly started on PD.<sup>25</sup> Another long-term study in Germany confirmed that peritonitis incidence would be underestimated by 0.03 per patient-year at risk if peritonitis episodes occurring before completion of PD training were not counted.<sup>26</sup>

In line with the ISPD Guidelines on Creating and Maintaining Optimal PD Access in the Adult Patient,<sup>27</sup> PD catheter insertion-related peritonitis is defined as an episode of peritonitis that occurs within 30 days of PD catheter insertion and should be <5% of PD catheter insertions (Table 1).

#### *Outcome-specific definitions of peritonitis.*

- We recommend using the definitions outlined in Table 2 to describe outcomes following peritonitis (Not Graded). All outcomes associated with the peritonitis episode should be captured.

#### *Measuring, monitoring and reporting peritonitis*

- We recommend that every programme should monitor, at least on a yearly basis, the incidence and outcomes of peritonitis (1C).
- We recommend that the parameters monitored should include the PD-related peritonitis rate, organism-specific peritonitis rates, antimicrobial susceptibilities of the infecting organisms, culture-negative peritonitis and peritonitis outcomes (1C).
- We suggest PD units also measure and report other peritonitis parameters, including mean time to first peritonitis episode (where time counts from the first day of PD commencement), percentage of patients free of peritonitis per unit time (target >80% per year) and pre-PD peritonitis (2C).
- We suggest that the rate of peritonitis be reported as number of episodes per patient-year (Not Graded).
- We suggest that organism-specific peritonitis rates should be reported as absolute rates, that is, as number of episodes per year (Not Graded).
- We recommend that the overall peritonitis rate should be no more than 0.40 episodes per year at risk (1C).
- In addition to reporting peritonitis rate measured as number of episodes per patient-year, we suggest the culture-negative peritonitis be reported as a percentage of all peritonitis episodes per unit time (Not Graded).
- We recommend the proportion of culture-negative peritonitis should be less than 15% of all peritonitis episodes (1C).

At regular intervals, all PD programmes should monitor the incidence of peritonitis as part of a continuous quality improvement (CQI) programme.<sup>28</sup> Application of a standardised metric to measure outcomes is critical to benchmark performance and monitor progress. Peritonitis rate should be measured as number of peritonitis episodes divided by number of patient years at risk (i.e. number of years on PD starting from the time of PD commencement), reported as episodes per patient years. For the purpose of calculating peritonitis rates, PD commencement is defined as the first day on which the first PD exchange was performed with the intention of continuing ongoing PD treatment (i.e. the first day of PD training or PD treatment in a hospital or at home with the intention of continuing PD long-term, whichever occurs first); this does not include intermittent flushing post-surgery to maintain catheter patency. Number of patient years at risk should be fully inclusive counting circumstances such as hospitalisation episodes where patients may not be performing their own PD. In terms of episodes, all subsequent relapsing episodes should be considered as an extension of the original episode and only the original episode captured as part of the

**Table 1.** Outcome specific definition following peritonitis.

Outcome	Definition
Medical cure	Complete resolution of peritonitis together with NONE of the following complications: relapse/ recurrent peritonitis, catheter removal, transfer to haemodialysis for $\geq 30$ days or death
Refractory	Peritonitis episode with persistently cloudy bags or persistent dialysis effluent leukocyte count $> 100 \times 10^9/L$ after 5 days of appropriate antibiotic therapy
Recurrent	Peritonitis episode that occurs within 4 weeks of completion of therapy of a prior episode but with a different organism
Relapsing	Peritonitis episode that occurs within 4 weeks of completion of therapy <sup>a</sup> of a prior episode with the same organism or one sterile (culture negative) episode (i.e. specific organism followed by the same organism, culture negative followed by a specific organism or specific organism followed by culture negative).
Repeat	Peritonitis episode that occurs more than 4 weeks after completion of therapy <sup>a</sup> of a prior episode with the same organism
Peritonitis-associated catheter removal	Removal of PD catheter as part of the treatment of an active peritonitis episode
Peritonitis-associated haemodialysis transfer	Transfer from PD to haemodialysis for any period of time as part of the treatment for a peritonitis episode
Peritonitis-associated death	Death occurring within 30 days of peritonitis onset or death during hospitalisation due to peritonitis
Peritonitis-associated hospitalisation	Hospitalisation precipitated by the occurrence of peritonitis for the purpose of peritonitis treatment delivery

PD: peritoneal dialysis.

<sup>a</sup>Completion of therapy is defined as the last day of antibiotic administration.

**Table 2.** Measurement and reporting of peritonitis.

	Unit of measure	Minimum frequency	Target
Peritonitis rates (overall and organism-specific)	Episodes per patient year	Yearly	<0.4 episodes per patient-year
Culture-negative peritonitis	% of all peritonitis episodes	Yearly	<15% of all peritonitis episodes
Time to first peritonitis episode	Mean unit time to first episode peritonitis	Quarterly (local report)	–
Proportion of patients free of peritonitis	% per unit time	Quarterly (local report)	>80% per year
Pre-PD peritonitis	% of all peritonitis episodes	Quarterly (local report)	–
PD catheter insertion-related peritonitis	% of all PD catheter insertions	Quarterly (local report)	<5%
Medical cure	% of all peritonitis episodes	Quarterly (local report)	–
Recurrent peritonitis	% of all peritonitis episodes	Quarterly (local report)	–
Relapsing peritonitis	% of all peritonitis episodes	Quarterly (local report)	–
Peritonitis-associated catheter removal	% of all peritonitis episodes	Quarterly (local report)	–
Peritonitis-associated haemodialysis transfer	% of all peritonitis episodes	Quarterly (local report)	–
Peritonitis-associated death	% of all peritonitis episodes	Quarterly (local report)	–

PD: peritoneal dialysis.

peritonitis rate determination. Peritonitis episodes that occur during hospitalisations where nurses, patients or caregivers perform PD should also be counted as events for the purpose of calculating peritonitis rates. For quality improvement purposes, they should preferably be identified and characterised separately.

A recent study has proposed an alternative simplified formula for calculating peritonitis rates in which the denominator of patient years at risk is replaced by the average of the numbers of patients at the start and beginning of a year.<sup>29</sup> While this demonstrated reasonable overall agreement against the gold standard method when analysing Australian,

New Zealand and French registry data, we suggest that peritonitis rates only be calculated using the gold standard method (i.e. number of episodes per patient year at risk) for the purpose of benchmarking using a standardised approach, and because the accuracy of the simplified method is sensitive to centre characteristics (i.e. less accurate in smaller centres or when centres are rapidly or unevenly losing or gaining patients over a year). The simplified method has also not been validated over shorter time periods than a year or outside of Australia, New Zealand and France.

Globally, there is a substantial (up to 20-fold) variation in peritonitis rates between PD units in different

countries.<sup>30</sup> The PD Outcomes and Practice Patterns Study (PDOPPS) similarly reported variation in overall peritonitis rates from participating PD units (7051 adult PD patients in 209 facilities from seven countries) ranging from 0.26 (95% CI 0.24–0.27) episodes/patient-year in the United States to 0.40 (95% CI 0.36–0.46) episodes/patient-year in Thailand.<sup>31</sup> In separate studies, peritonitis rates have been reported to be as low as 0.16–0.20 episodes/patient-year in some PD units in China.<sup>32–34</sup> In a systematic review based on a random-effects Poisson model of registries from 33 countries, the peritonitis rate has been steadily decreasing from 0.60 to 0.30 episodes/patient-year from 1992 to 2019.<sup>35</sup> We recommend that the overall peritonitis rate should be no more than 0.40 episodes per year at risk.<sup>13</sup> This is an improvement of standard of 0.5 episodes per year at risk as endorsed in the 2016 guideline.<sup>13</sup> From global review of data of reports from registries and studies, this is an achievable standard and should be used as an initiative to reduce peritonitis rates worldwide.

In addition to overall peritonitis rates, regular monitoring of organism-specific peritonitis and associated antimicrobial sensitivities can be helpful in informing appropriate empirical antibiotic regimens at a local level. Culture-negative peritonitis has been reported to affect between 13.4% and 40% of all episodes of peritonitis.<sup>36–38</sup> The large variability in incidence of culture-negative peritonitis has been attributed to differences in the definition and technique of microbiological isolation.<sup>39</sup> Direct inoculation of sediment from centrifuged PD effluent into culture bottles has been shown to be most effective in identifying organisms responsible for peritonitis where appropriate resources are accessible.<sup>39</sup> The culture-negative peritonitis rate should be reported as percentage of all peritonitis episodes. We recommend the proportion of culture-negative peritonitis should be less than 15% of all peritonitis episodes.

We also suggest PD units measure and report other peritonitis parameters including, time to first peritonitis episode (where time counts from the first day of PD training/commencement), percentage of patients free of peritonitis per unit time (target >80% per year) and pre-PD peritonitis (episodes per year). Death associated with peritonitis may also be collected at a unit level, which can be defined as described in Table 1.<sup>5</sup> These additional outcomes may be captured and reported at a unit level on a monthly basis or at least quarterly to inform local practice (Table 2).

## Prevention of peritonitis

### Catheter placement

- We recommend that systemic prophylactic antibiotics be administered immediately prior to catheter placement (1A).

Detailed description of the recommended practice of PD catheter insertion has been covered in the 2019 ISPD

position paper.<sup>27</sup> There are four randomised, controlled trials on the use of perioperative intravenous cefuroxime,<sup>40</sup> gentamicin,<sup>41</sup> vancomycin<sup>42</sup> and cefazolin<sup>41,42</sup> as compared to no treatment. The overall benefit of prophylactic perioperative intravenous antibiotics was confirmed by a systematic review of these four trials, but its effect on the risk of exit-site/tunnel infection is uncertain.<sup>43</sup> Although first-generation cephalosporin may be slightly less effective than vancomycin,<sup>42</sup> the former is still commonly used because of the concern regarding vancomycin resistance. Each PD programme should determine its own choice of antibiotic for prophylaxis after considering the local spectrum of antibiotic resistance. No data exist on the effectiveness of routine screening and eradication of *S. aureus* nasal carriage before catheter insertion (such as intranasal mupirocin).

### Exit-site care

Detailed description of exit-site care to prevent peritonitis should be referred to another guideline from ISPD.<sup>17</sup> At present, topical application of antibiotic cream or ointment to the PD catheter exit site is recommended although such practice varied among centres internationally.<sup>44</sup> Proper PD catheter immobilisation and avoidance of mechanical stress on the exit site may be useful to lower exit-site infection rate.<sup>45</sup> Prompt treatment of exit-site or catheter tunnel infection is mandatory to reduce subsequent peritonitis risk.<sup>17–19</sup>

### Contamination of PD system

- We suggest advice be sought immediately from the treatment team if contamination during PD exchange is noted (Not Graded).
- We suggest prophylactic antibiotics after wet contamination of the PD system to prevent peritonitis (2D).

PD patients should be instructed to immediately seek advice from their dialysis centre if the sterility of PD exchange has been breached. When patients report contamination during an exchange procedure, the need for treatment is driven by distinguishing ‘dry contamination’ (contamination outside a closed PD system, such as disconnection distal to a closed clamp) from ‘wet contamination’ (referring to contamination with an open system, when either dialysis fluid is infused after contamination or if the catheter administration set has been left open for an extended period). Examples of wet contamination include leaks from dialysate bags, leaks or breaks in tubing proximal to the tubing clamp, breach of aseptic technique or touch contamination of the connection during a PD exchange. Prophylactic antibiotics is only recommended after wet contamination.<sup>46,47</sup> If it is unclear whether the tubing clamp was closed or open during contamination, wet

contamination should be considered, for benefit of doubt. The common practice is thus change of a sterile transfer set. A PD effluent should preferably be obtained for cell count and culture after wet contamination.<sup>47</sup> A wet contamination should be monitored closely for an extended period, and a broader spectrum of organisms might lead to peritonitis, particularly in tropical centers.<sup>48</sup>

One retrospective study involving 548 episodes of touch contamination revealed a relatively low rate of peritonitis (3.1%), and peritonitis occurred only after wet contamination (5.6%). Most episodes were coagulase-negative staphylococcal or culture-negative episodes, and the risk was significantly reduced by prophylactic antibiotics.<sup>46</sup> There is no standard regimen of prophylactic antibiotic.

Although short course of oral fluoroquinolones has been used previously,<sup>46</sup> the drug has now been discouraged by Food and Drug Administration (FDA)<sup>49</sup> unless there is no alternative options. One dose of intraperitoneal (IP) cefazolin is a reasonable option.

### Invasive gastrointestinal and gynaecological procedures

- We suggest antibiotic prophylaxis prior to colonoscopy (2C) and invasive gynaecological procedure (2D).
- We suggest drainage of PD fluid to keep the abdomen empty before endoscopic gastrointestinal and invasive or instrumental gynaecological procedures (2D).

Peritonitis commonly follows endoscopic gastrointestinal and invasive or instrumental gynaecological procedures (e.g. gastroscopy, colonoscopy, hysteroscopy) in PD patients.<sup>50–57</sup> The highest peritonitis complication rate after endoscopic or instrumental procedures is reported after invasive gynaecological procedures, ranging from 26.9%<sup>57</sup> to 38.5%.<sup>58</sup> Reported rates of peritonitis after colonoscopy without antibiotic prophylaxis ranged between 3.4% and 8.5%.<sup>55,56</sup> The rates of peritonitis after gastroscopy in PD patients range from 1.2%<sup>58</sup> to 3.9%.<sup>59</sup>

Concerns about invasive or instrumental gynaecological procedures and peritonitis in PD patients come from the proximity of the pelvis to the peritoneal cavity. The most commonly reported bacterial pathogens in reported cases are *Streptococcus*, followed by *Escherichia coli*, *Enterococcus*, *Staphylococcus* and infrequently *Candida*.<sup>57</sup> Data supporting antibiotic prophylaxis come from two small retrospective studies.<sup>57,58</sup> In a retrospective study of 26 gynaecological procedures on 18 PD patients, none of the 11 procedures with antibiotic prophylaxis was followed by peritonitis, as opposed to a peritonitis occurrence of 47% among those procedures performed without antibiotic prophylaxis.<sup>57</sup> An earlier study reported a similar finding of less common peritonitis occurrence after antibiotic prophylaxis, but the difference did not reach

statistical significance: none of four patients with prophylactic antibiotic administration developed peritonitis whereas 55.6% without antibiotic prophylaxis developed peritonitis.<sup>58</sup> Because of limited data, there is no standardised recommendation of antibiotic choice and administration route. However, reasonable regimens should cover gram-positive and gram-negative (aerobic and anaerobic) bacterial isolates from the upper tract of female reproductive tracts. Examples include intravenous cefazolin or ceftriaxone before the procedure or oral cefadroxil 500 mg once daily for 3 days.<sup>57</sup>

More than half of reported peritonitis episodes occurring after colonoscopy are caused by *E. coli*.<sup>55,60</sup> In a single-centre study of 97 colonoscopies performed in 77 continuous ambulatory peritoneal dialysis (CAPD) patients, none of the 18 patients having a colonoscopy procedure with antibiotic prophylaxis developed peritonitis, as opposed to a 6.3% peritonitis occurrence among those undergoing colonoscopy without antibiotic prophylaxis.<sup>50</sup> This is consistent with a more extensive multicentre study of 236 colonoscopy procedures, in which none of the 65 patients who received antibiotic prophylaxis developed peritonitis, compared to a peritonitis rate of 3.8% for those without prophylactic antibiotics.<sup>55</sup> Furthermore, therapeutic procedures, such as polypectomy and endoscopic mucosal resection, are predictive of peritonitis.<sup>55,60</sup> The optimal antibiotic regimen for preventing peritonitis after colonoscopy has not been determined by clinical study. The only randomised controlled trial of prophylactic antibiotics used IP ceftazidime (1 g IP 1 h before the procedure) and recruited 93 patients receiving APD without a history of peritonitis in the last 12 months from a single centre in Saudi Arabia. The peritonitis rate did not differ with (6.5%) and without (8.5%) IP ceftazidime prophylaxis ( $p = 0.27$ ).<sup>56</sup> For intravenous antibiotic prophylaxis, potential choices include cephalosporins (such as ceftriaxone or ceftazidime), amoxicillin–clavulanate, ampicillin–sulbactam, ampicillin plus aminoglycoside,<sup>50,58</sup> with an aim to target most of the organisms described above that cause peritonitis after colonoscopy. Interestingly, the alternative option of oral antibiotic prophylaxis was suggested by a recent case series of 49 PD patients who received oral ampicillin 1000 mg, ciprofloxacin 500 mg and/or metronidazole 250 mg 1 to 2 h before colonoscopy and did not experience any post-procedure episodes of peritonitis.<sup>61</sup> Finally, PD effluent should be drained to keep patient's abdomen empty before colonoscopy (and gynaecological) procedure.<sup>62</sup> The argument for emptying the abdomen before colonoscopy is to enhance host defence,<sup>63</sup> because the peritoneal macrophage phagocytic function and polymorphonuclear cell function are suppressed by the presence of dialysate.<sup>64</sup> Furthermore, high fluid volumes can compromise efficiency of bacterial killing by disrupting the volume-to-surface-area ratio.<sup>65</sup>

The risk of PD patients developing peritonitis after gastroscopy is more uncertain. Other than case reports<sup>66,67</sup> and

a small case series,<sup>58</sup> a single-centre observational study of 408 gastroscopy procedures in 216 PD patients showed a 3.9% incidence of peritonitis within 1 week of endoscopy.<sup>59</sup> Patient's age and the number of endoscopic biopsies predicted peritonitis risk. One-quarter of the 16 peritonitis episodes were polymicrobial, commonly caused by organisms either enteric in origin or arising from the oral cavity, such as *Streptococcus*.<sup>59</sup> Although there is insufficient evidence to recommend antibiotic prophylaxis prior to gastroscopy in PD patients, the study confirmed a lower odds of peritonitis after gastroscopy, after adjustment for confounding factors, when antibiotics were used within 7 days of gastroscopy.<sup>59</sup>

### Training programme

- We suggest that the characteristics of an optimal PD training programme (how, how long, where, when and by whom) remain uncertain (2C).
- We recommend that PD exchange technique and knowledge be regularly reassessed and updated, with an emphasis on direct inspection of practice of PD technique (1C).

Detailed description on the recommended practice of PD training has been covered in another ISPD guideline,<sup>68,69</sup> which each PD programme should consult while preparing the trainer and developing a specific curriculum for PD training. Unfortunately, limited data are available to guide when, how or how long PD training is optimal. The PDOPPS noted marked variation in training practices across 120 facilities across seven countries; timing of commencement, duration of training, location or use of competency assessments were not predictive of peritonitis risk.<sup>70</sup> Taken together, flexibility should be allowed to deliver training according to local resources and individualised to patients' needs. Furthermore, distance learning and remote monitoring have been increasingly utilised. Previously, hybrid PD education programme with online video material has been developed and shown to be associated with lower peritonitis rate.<sup>71</sup> On the other hand, a single-centre study reported that face-to-face patient–doctor contact intervals less frequent than every 2 months was associated with higher peritonitis rate.<sup>72</sup>

In essence, all PD trainers should receive adequate education to perform training and further education to update and hone their teaching skills. Each programme should have an established curriculum that is followed in teaching the patient the procedure, theory of PD and self-care, taking into account the individual's learning style. Testing the patient's practical skills at the end of training is essential.

After PD training is completed and patients are started on home PD, a home visit by the PD nurse is often helpful in detecting problems with exchange technique, adherence to protocols and other environmental and behaviour issues which increase the risk of peritonitis. Observational studies

reported a non-significantly lower peritonitis rates associated with home visit programmes in paediatric<sup>73</sup> and adult<sup>74</sup> PD patients. Another registry data set showed an independent association of nurse visits before starting PD with a lower likelihood of peritonitis.<sup>75</sup>

In addition to the initial training, refresher course or retraining plays an important role in reducing mistakes according to learning specialists.<sup>76</sup> Previous studies showed that adherence with exchange protocols was significantly associated with peritonitis rate,<sup>76</sup> which applied even during the coronavirus pandemic when behaviour for personal hygiene is anticipated to be enhanced.<sup>77</sup> The purpose of retraining is to target patients who have begun to take shortcuts or simply deviate from the standard steps which they were taught previously. An observational study found that 6 months after the initiation of PD, around half of the patients took shortcuts, modified the standard exchange method, failed to follow appropriate hand hygiene protocols properly or follow the aseptic technique.<sup>78</sup> Despite common usage of the term 'retraining' in literature, the healthcare providers should be mindful of the implicit negative connotation of this word. Emphasis for updating of knowledge and technique should be used to address the benefit. Home visits by PD nurses or trained personnel may be a good way to determine which patients require retraining.<sup>76</sup> Other indications of retraining are listed in Table 3.<sup>68,79</sup> Certainly, all patients must be retrained whenever the equipment to perform PD is changed. Evidence for retraining PD is evolving as an increasing number of randomised controlled trials have been completed.<sup>80–82</sup> The optimal timing and frequency of retraining remain uncertain but a randomised controlled trial lends strong support for more frequent retraining at home. As compared to 53 PD patients receiving conventional retraining (two home visits within two months after starting dialysis), 51 incident PD patients randomised to frequent retraining (regular repeated home visits every 1–3 months over 2 years) showed a significantly lower rates of exit site infection and peritonitis.<sup>80</sup> Moreover, subgroup analysis demonstrated a significant beneficial effect on the first episode of peritonitis in patients older than 60 years.<sup>80</sup> Their results were not able to be replicated in another randomised controlled trial, with a larger sample size, of retraining intervention targeting incident PD patients who failed regular testing of PD knowledge and practical PD skill assessment.<sup>81</sup> Furthermore, it has been proposed that practical assessment of PD technique is more important than testing of theory. Patients might not be aware of their making mistakes in PD procedures until the visiting nurse discovers them. The best support for emphasis on practical assessment of patients' techniques comes from a controlled trial randomising incident PD patients to retraining via technique inspection, oral education or usual care.<sup>82</sup> The oral education group (retraining every 2 months using a checklist and focus on knowledge) did not reduce the risk of peritonitis, whereas the technique inspection group



**Table 3.** Indications for PD Retraining.

<ul style="list-style-type: none"> <li>■ Following prolonged hospitalisation</li> <li>■ Following peritonitis and/or catheter infection</li> <li>■ Following change in dexterity, vision or mental acuity</li> <li>■ Following change to another supplier or a different type of connection</li> <li>■ Following change in caregiver for PD exchange</li> <li>■ Following other interruption in PD (e.g. period of time on haemodialysis)</li> </ul>
--

PD: peritoneal dialysis.

(retraining every 2 months and focus on behaviour by nurses' inspection of PD technique) demonstrated a lower risk of first non-enteric peritonitis.<sup>82</sup> In other words, the most effective learning is through direct feedback immediately after return demonstration of PD steps.

### Domestic pet and zoonotic infection

- We recommend PD patients take extra precautions to prevent peritonitis if domestic pets are kept (1C).
- We suggest pets not be allowed in the room where PD exchange takes place, and where dialysis tubing, equipment and machine are stored (2A).

PD patients should be asked about pets during training and home visits or after a diagnosis of unusual organisms suspicious of zoonoses because peritonitis due to zoonotic organisms can occur in the context of close contact with companion animals.<sup>83,84</sup>

With regard to cats, more than 40 cases of *Pasteurella multocida* peritonitis have been reported in the literature.<sup>85</sup> Despite the name 'cat-bite peritonitis',<sup>86</sup> the aerobic gram-negative coccobacillus *P. multocida* is found in the upper respiratory tract and oral cavity of many domestic and wild animals including dogs and hamsters. Direct contact with animals, either through close contact with PD equipment or patient, bites or scratches, can be implicated in PD-related infections. The prevalence of colonisation with *P. multocida* is higher in cats, including their claws.<sup>87</sup> Other cat-related organisms include *Capnocytophaga canimorsus*, *Capnocytophaga cynodegmi* and *Neisseria* species.<sup>84,88</sup> The frequency of cat-related peritonitis is higher in patients on APD than CAPD, possibly secondary to the longer tubing required or the prolonged environmental contact time of equipment for APD. Cycler tubing moving with the action of the cycler pump is another stimulus that may entice a cat to play with the instrument. Furthermore, cats enjoy the warmth of the cycler heat plate and may lay on the dialysis machines.<sup>85</sup>

The hidden pet-related damage to PD tubing that occurs when animals bite or scratch the tubing should be emphasised as the damage may go unnoticed when APD patients are sleeping. The small pinhole-shaped damage, as opposed to a complete tear, can also be

challenging to detect until leakage of PD solution occurs. Such minor but serious tubing defects have been reported in PD patients who cohabitate with pets including cats, hamsters and cockatoo.<sup>86,88-93</sup>

With the bonds between owners and domestic pets being potentially very strong, and possible emotional and quality-of-life benefits, it is not always possible to discourage keeping pets. Around one-fifth of PD patients surveyed in a single PD centre were keeping pets.<sup>94</sup> To minimise the risk of pet-related peritonitis, PD patients should adhere to stringent hand washing before and after PD exchanges and handling pets, as well as ensuring high home environment hygiene standards. Domestic pets should be strictly kept away from the dialysis equipment and should not be allowed into the room during the dialysis treatment procedure.

### Other modifiable risk factors

- We suggest that avoidance and treatment of hypokalaemia may reduce the risk of peritonitis (2C).
- We suggest that avoiding or limiting the use of histamine-2 receptor antagonists may prevent enteric peritonitis (2C).

A number of other modifiable risk factors for PD peritonitis have been described. One of the investigation tools is the undertaking of a large international cohort study, such as the Peritoneal Dialysis and Outcomes Practice Patterns Study (PDOPPS), to collect detailed information in a uniform manner.<sup>31,70,95,96</sup> The results obtained from PDOPPS provide a high-level overview of peritonitis risk factors and outcomes across countries and PD centres but require further prospective interventional studies to establish causation.

Gastrointestinal problems, such as constipation and enteritis, have been reported to be associated with peritonitis due to enteric organisms.<sup>97</sup> PDOPPS also reported an association of higher peritonitis risk with gastrointestinal bleeding.<sup>31</sup> A previous study reported an association of hypokalaemia with a higher risk of enteric peritonitis.<sup>98</sup> International data from seven countries, under PDOPPS, showed that hypokalaemia persistent for 4 months was associated with 80% higher subsequent peritonitis rates after adjustment for confounders.<sup>95</sup> The causative organisms underpinning the excess of peritonitis were mostly gram positive and culture negative. This concurs with another Brazilian propensity-matched score study linking hypokalaemia with higher infection-related mortality and peritonitis risk.<sup>99</sup> In addition to the degree of hypokalaemia, the duration of hypokalaemia was associated with the risk of peritonitis in PD patients.<sup>100</sup> Although there is no compelling evidence that treatment of hypokalaemia, constipation or gastroenteritis mitigates the risk of peritonitis, such problems, which are common in the PD setting, merit treatment in their own right. Based on previous

observational and mechanistic studies of hypokalaemia in PD studies, the main contributory factor of hypokalaemia is low dietary potassium intake, rather than increased potassium excretion or intracellular shift.<sup>101,102</sup> Dietary intervention is recommended to mitigate hypokalaemia. Observational data from a single-centre study suggested that regular lactulose use is associated with a lower rate of peritonitis.<sup>103</sup> However, the benefit of lactulose to reduce peritonitis rate, compared with sennosides, has not been confirmed in a single-centre randomised controlled trial.<sup>104</sup>

There are emerging data to suggest that gastric acid suppression, especially with histamine-2 receptor antagonists, is a modifiable risk factor for enteric peritonitis in PD patients. The hazard ratio for enteric peritonitis, as demonstrated in an observational cohort of 119 PD patients on histamine-2 receptor antagonists, was 1.67 (95% confidence interval 1.02–2.80). The increase in infectious mortality among histamine-2 receptor antagonist users further supported the burden of this risk.<sup>105</sup> However, the risk of peritonitis associated with proton pump inhibitors is less consistently reported.<sup>106–108</sup> A similar finding of heightened risk conferred by the use of histamine-2 receptor antagonists, but not proton pump inhibitors, was found in a case series of peritonitis after gastroscopy. Of note, histamine-2 receptor antagonist users had a significantly higher post gastroscopy peritonitis rate (9.4%) compared to non-users (2.9%).<sup>59</sup> A meta-analysis of six non-randomised studies involving pooled data of 829 PD patients showed that histamine-2 receptor antagonist use was associated with an increased odds of enteric peritonitis (OR 1.4, 95% CI 1.01–1.93).<sup>108</sup> Notably, even though the association between proton pump inhibitor use and peritonitis is less compelling, other concerns with proton pump inhibitors (including but not limited to *Clostridioides* infection) do not justify a routine switching of histamine-2 receptor antagonist to proton pump inhibitor therapy.

### Secondary prevention

- To prevent fungal peritonitis, we recommend that anti-fungal prophylaxis be co-prescribed whenever PD patients receive an antibiotic course, regardless of the indication for that antibiotic course (1B).

The majority of fungal peritonitis episodes are preceded by courses of antibiotics.<sup>109–112</sup> A number of observational studies<sup>113–120</sup> and randomised trials<sup>121,122</sup> have examined the use of either oral nystatin (500,000 units qid) or fluconazole (200 mg every 48 h) as prophylaxis during antibiotic therapy. In essence, two randomised control trials<sup>121,122</sup> and a systematic review<sup>43</sup> showed a significant benefit. Most of the other reports on the prophylactic use of antifungals during antibiotic administration were non-randomised studies and have yielded mixed results. Unfortunately, nystatin is not available in some countries.


Observational data<sup>118–120</sup> and one randomised controlled trial<sup>122</sup> showed that prophylactic fluconazole is effective. The randomised controlled trial of oral fluconazole included patients who received antibiotics for treating exit-site and tunnel infection, in addition to the treatment of peritonitis<sup>122</sup>. However, there are potential problems (including drug interactions, emergence of resistant strains) with fluconazole prophylaxis. Overall, a Cochrane meta-analysis of the two randomised controlled studies on anti-fungal prophylaxis with oral nystatin or fluconazole showed a risk ratio of 0.28 (95% CI 0.12–0.63) for fungal peritonitis occurring after a patient has had an antibiotic course.<sup>43</sup>

Furthermore, each episode of peritonitis should be considered a preventable event and hence evaluated.<sup>47</sup> The CQI programme provides a means in secondary prevention. For each peritonitis episode, a root-cause analysis should be performed to determine the aetiology and, whenever possible, an intervention directed against any reversible risk factor should be made to prevent another episode. For example, *Streptococcal viridans* peritonitis could have indicated dental problems although such link is based on isolated case reports only.<sup>123,124</sup> Peritonitis episodes caused by coagulase-negative staphylococcal species are associated with touch contamination, while *S. aureus* infections have been associated with touch contamination or catheter infections. Identification of aetiology may involve review of the exchange technique. Retraining is sometimes necessary. Rarely, an outbreak of culture-negative peritonitis or peritonitis secondary to unusual organisms should trigger epidemiological investigation and field visit to look for environment risk factors such as PD fluid, hospital air or water contamination.<sup>125–127</sup>

### Initial presentation and management of peritonitis

The algorithm of initial management for PD patients presenting with a clinical diagnosis is summarised in Figure 1.

- We recommend that peritonitis always be diagnosed when at least two of the following are present: (1) clinical features consistent with peritonitis, that is, abdominal pain and/or cloudy dialysis effluent; (2) dialysis effluent white cell count >100/μL or >0.1 × 10<sup>9</sup>/L (after a dwell time of at least 2 h), with >50% PMN; and (3) positive dialysis effluent culture (1C).
- We recommend that PD effluent be tested for cell count, differential, gram stain and culture whenever peritonitis is suspected (1B).
- We recommend that PD patients presenting with cloudy effluent be presumed to have peritonitis and treated as such until the diagnosis can be confirmed or excluded (1C).



**Figure 1.** The algorithm of initial management for PD patients presenting with a clinical diagnosis of peritonitis. PD: peritoneal dialysis.

Patients with peritonitis usually present with cloudy PD effluent and abdominal pain. Cloudy effluent almost always represents infectious peritonitis, although there are other differential diagnoses classified according to cellular and non-cellular causes (Table 4).<sup>128</sup> Some patients present with cloudy effluent but no or minimal abdominal pain. On the other hand, peritonitis should also be included in the differential diagnosis of the PD patient presenting with abdominal pain, even if the effluent is clear. In addition to the presenting symptoms, the patient should be questioned about any recent contamination, accidental disconnection, endoscopic or gynaecological procedures, as well as the presence of constipation or diarrhoea. In addition, the patient should be questioned about past history of peritonitis and exit-site infection.

On physical examination, abdominal tenderness is typically generalised and is less often associated with a rebound. Localised pain or tenderness should raise the suspicion of underlying surgical pathology. Physical examination should also include a careful inspection of the catheter tunnel and exit site. Any discharge from the exit site should be cultured. Erythema, tenderness and the presence of fluid collections (which may be confirmed with ultrasound) along the PD catheter tunnel may be indicative of a tunnel infection. The degrees of abdominal pain and tenderness are important factors in deciding whether a patient requires hospital admission. In general, patients with minimal pain could be treated on an outpatient basis with IP antibiotic therapy if this can be arranged. Follow-up within 3 days is

advisable to confirm resolution and appropriateness of the antibiotic choice.

When peritonitis is suspected, dialysis effluent should be drained, carefully inspected and sent for cell count with differential, Gram stain and culture.<sup>129</sup> An effluent cell count with WBC > 100/ $\mu$ L (after a dwell time of at least 2 h), with > 50% PMN, is highly suggestive of peritonitis.<sup>130</sup> Abdominal X-ray is generally not necessary and may be potentially misleading since pneumoperitoneum is common (around one-third of CAPD patients)<sup>131</sup> secondary to air entry into the peritoneal cavity via the PD catheter during exchanges. Peripheral blood cultures are usually negative<sup>132</sup> and can be omitted unless the patient is clinically septic<sup>133</sup> or on immunosuppression.<sup>134</sup> Bacteraemia during peritonitis should raise the possibility of other intra-abdominal events.<sup>135,136</sup> To prevent delay in treatment, antibiotic therapy (see below) should be initiated once the appropriate dialysis effluent specimens have been collected, without waiting for the results of laboratory testing.

The WBC count in the effluent depends in part on the length of the dwell. For patients on APD with rapid cycle treatment, the clinician should use the percentage of PMN rather than the absolute WBC count to diagnose peritonitis, and a proportion above 50% PMN is strong evidence of peritonitis, even if the absolute WBC count is less than 100/ $\mu$ L.<sup>130</sup> On the other hand, APD patients without a daytime exchange presenting with abdominal pain during the daytime may have no effluent to drain. In this case, 1 L of

**Table 4.** Differential diagnosis of cloudy effluent.**Cellular causes**

- PMN leucocytes
  - Culture-positive infectious peritonitis
  - Infectious peritonitis with sterile cultures
  - Chemical peritonitis
- Eosinophils
  - Dialysate eosinophilia
  - Chemical peritonitis
- Monocyte/macrophages
  - Specimen taken from 'dry' abdomen (after prolonged peritoneal rest)
- Red blood cells
  - Hemoperitoneum
- Malignant cells
  - Lymphoma
  - Peritoneal metastasis

**Non-cellular causes**

- Fibrin
- Triglycerides (milky white appearance of effluent)
  - Calcium channel blockers
  - Lymphatic obstruction
  - Acute pancreatitis

PMN: polymorphonuclear.

dialysis solution should be infused, dwelled for 2 h, and then drained for inspection and laboratory testing.

**Identification of causative organisms**

- We recommend that the blood culture bottle(s) be the preferred technique for bacterial culture of PD effluent (1C).
- We suggest that sampling and culture methods be reviewed and improved if more than 15% of peritonitis episodes are culture negative (2C).

Gram stain of the PD effluent should be performed even though the result is often negative.<sup>137,138</sup> An additional benefit of Gram stain is its effectiveness in early detection of fungal elements, facilitating timely diagnosis and management of fungal peritonitis.<sup>139</sup> The diagnostic yield of the Gram stain is increased if it is performed on a centrifuged specimen. An appropriate method of culturing PD effluent is the most important step in establishing the causative organism. In some specialised centres, it has been possible to achieve a culture-negative peritonitis rate of less than 10%. Identification of the organism and subsequent antibiotic sensitivities help to guide the choice of antibiotic, and the type of organism often indicates the possible source of infection. Bedside inoculation of 5–10 mL effluent in two (aerobic and anaerobic) blood-culture bottles has a reasonable sensitivity, and the culture-negative rate is typically around 10–20%.<sup>140–143</sup> The yield of peritoneal fluid culture is enhanced by inoculating the fluid directly into rapid blood-culture bottle kits (e.g. BACTEC, Kent, UK; Septi-Chek, Roche Diagnostics, Basel, Switzerland; BacT/

Alert, Biomerieux, Inc., Basingstoke, UK), centrifuging PD fluid and culturing the pellet or the lysis centrifugation technique as compared to inoculation into standard blood-culture bottles. Specifically, centrifugation of 50 mL PD effluent at 3000 g for 15 min, followed by resuspension of the sediment in 3–5 mL supernatant and inoculation on solid culture media or standard blood-culture media, increases the yield by 5–10 times.<sup>39,142,143</sup> The combination of water lysis, Tween-80 blood agar and Triton-X treatment of the PD effluent is also a sensitive culture method.<sup>144,145</sup> The specimens should arrive at the laboratory within 6 h. If immediate delivery to the laboratory is not possible, the inoculated culture bottles should ideally be incubated at 37°C. Inoculated bottles should not be refrigerated or frozen, since it may kill or retard the growth of some microorganisms.<sup>146</sup> The solid media should be incubated in aerobic, microaerophilic and anaerobic environments. To fully assess yeast and filamentous fungal pathogens, appropriate fungal media should be selected; incubation of inoculated media under two temperature conditions (room temperature and 35–37°C) can increase the diagnostic yield.<sup>146</sup>

The speed with which bacteriological diagnosis can be established is very important. Concentration methods not only facilitate microbial identification, but also reduce the time needed for a positive culture. In over 75% of cases, microbiologic diagnosis can be established in less than 3 days. When the causative microorganism has been identified, subsequent cultures for monitoring may be performed by only inoculating the effluent in blood-culture bottles.

In a prospective study using facility-level data over 22 PD centres, immediate transfer of specimens or inoculated bottles to laboratories and the practice of PD effluent centrifugation are associated with lower culture-negative peritonitis rates.<sup>146</sup> Notably, experience of the centre is important because culture-negative peritonitis rates frequently show an inverse relationship with the PD centre size.<sup>38,146</sup>

When cultures remain negative after 3–5 days of incubation, PD effluent should be sent for repeat cell count, differential count, fungal and mycobacterial culture. In addition, subculture on media with aerobic, anaerobic and microaerophilic incubation conditions for a further 3–4 days may help to identify slow-growing fastidious bacteria and yeasts that are undetectable in some automated culture systems. Furthermore, culture of the PD catheter can improve the diagnostic yield, especially for detection of fungi and enterococci.<sup>147</sup>

**Other novel diagnostic techniques**

A number of novel diagnostic techniques have been explored for the early diagnosis of peritonitis, including leucocyte esterase reagent strips,<sup>148</sup> biomarker assays (matrix metalloproteinase-8 and -9,<sup>149</sup> neutrophil gelatinase-associated lipocalin<sup>150</sup> and procalcitonin), polymerase chain

reaction (PCR) for bacterial-derived DNA fragments, PCR/electrospray ionisation–mass spectrometry assay,<sup>151</sup> 16 S rRNA gene sequencing,<sup>152</sup> matrix-assisted laser desorption ionisation–time of flight mass spectrometry<sup>153</sup> and pathogen-specific ‘immune fingerprints’.<sup>154,155</sup> However, none of them has been proved to be superior to conventional techniques. Immune fingerprint, for instance, by multicolour flow cytometry and multiplex enzyme-linked immunosorbent assay, has been shown to discriminate between culture-negative, gram-positive, gram-negative episodes of peritonitis but provides no information on antibiotic resistance.<sup>155</sup> Further refinement using mathematical machine-learning algorithms can characterise specific pathogens like streptococcal species and coagulase-negative staphylococci in a point-of-care manner.<sup>154</sup> Utility of PD effluent phenotyping approach or immune fingerprinting remains to be validated before application to clinical use. In addition, a point-of-care device measuring levels of matrix metalloproteinase-8 and interleukin-6 has been tested to expedite diagnosis of peritonitis but is more useful to exclude peritonitis with a high negative predictive value over 98%.<sup>156</sup>

For rapid diagnosis of fungal peritonitis, PD effluent and serum galactomannan index might offer a faster turnaround time than the conventional culture method, but with a diagnostic accuracy of 65.2% sensitivity, 85.0% specificity only.<sup>157,158</sup> False-positive galactomannan results<sup>159</sup> leading to unnecessary use of antifungals is a definite concern.

### Empiric antibiotic selection

- We recommend that empirical antibiotic therapy be initiated as soon as possible, using either IP or systemic route, after appropriate microbiological specimens have been obtained (1B).
- We recommend that empirical antibiotic regimens be centre-specific and cover both gram-positive and gram-negative organisms (1C).
- We recommend that gram-positive organisms be covered by a first-generation cephalosporin or vancomycin and gram-negative organisms by a third-generation cephalosporin or an aminoglycoside (1B).
- We suggest that cefepime monotherapy may be an acceptable alternative for empirical antibiotic regimens (2B).

Once the diagnostic investigations have been completed, empirical antibiotics should be started to achieve rapid resolution of inflammation, reduction of pain and preservation of the peritoneal membrane. No single antibiotic regimen has been proven to be superior to others,<sup>160</sup> and the choice should be centre-specific. There should be adequate coverage for both gram-positive and gram-negative organisms. A national registry confirmed that centres with higher proportions of peritonitis episodes

receiving complete empirical coverage for both gram-positive and gram-negative organisms at presentation had higher odds of peritonitis cure by antibiotics.<sup>161</sup> For the coverage of gram-positive organisms, vancomycin or first-generation cephalosporin is recommended. Cefazolin might be preferred to vancomycin when there is concern about emergence of organisms resistant to the latter. However, vancomycin should be considered in centres with a high prevalence of methicillin-resistant organisms.<sup>162</sup> The threshold prevalence of methicillin resistance that justifies empirical use of vancomycin remains controversial. No discernible difference in peritonitis cure rate was found between empirical cefazolin and vancomycin use for gram-positive or culture-negative peritonitis, according to observational data from PDOPPS.<sup>96</sup> For the gram-negative coverage, third-generation cephalosporin or aminoglycoside is suggested. Observational studies<sup>163,164</sup> and one randomised controlled trial<sup>165</sup> showed that aminoglycoside does not accelerate the loss of residual kidney function. However, repeated or prolonged aminoglycoside treatment was associated with a high incidence of vestibular toxicity or ototoxicity.<sup>166</sup> It is also important to mention that treatment failure with ceftazidime is high with rising prevalence of extended-spectrum beta-lactamases (ESBL)-producing organisms. A recent analysis from PDOPPS reported that, for treatment of gram-negative peritonitis, empirical aminoglycoside was associated with a higher likelihood of medical cure than ceftazidime.<sup>96</sup> Monotherapy for empirical treatment of peritonitis, instead of combination therapy, has now been accepted as an effective strategy. Two randomised controlled trials<sup>167,168</sup> and one observational prospective study<sup>169</sup> testing the use of IP cefepime monotherapy have been published. Although there were differences in cefepime dosing (intermittent, continuous, with and without adjustment for residual kidney function), all three studies showed primary response rates exceeding 80% on day 10.<sup>167–169</sup> In particular, the largest study used a non-inferiority design and specified adjustment for residual kidney function by increasing the loading and maintenance doses of cefepime by 25% for urine volume more than 100 mL daily. Cefepime monotherapy was shown to be effective and non-inferior to standard dual therapy with cefazolin plus ceftazidime.<sup>168</sup> In contrast, monotherapy with quinolones is not recommended because of the concern with emergence of resistant organisms and declining effectiveness.<sup>162,170</sup>

It is important to note that prompt administration of antibiotics has been consistently shown to be associated with better outcome of peritonitis treatment. In a prospective multicentre study of 159 peritonitis episodes in Western Australia, the contact-to-treatment time was independently associated with treatment failure, defined as either catheter removal or death at 30 days. For each hour of delay in administering antibiotic therapy from the time of presentation to a hospital facility, the risk of PD failure or death was higher by 5.5%.<sup>171</sup> In another

retrospective study of 109 peritonitis episodes, a delay of starting IP or intravenous antibiotics treatment from the sign of peritonitis by 24 h conferred a threefold risk of peritoneal catheter removal by multivariate analysis.<sup>172</sup> For logistics consideration, immediate IP antibiotic administration might not be feasible in the emergency department or wards in which staff are not familiar with PD. In order to avoid the adverse outcome of delayed peritonitis treatment, the systemic route should be started as a temporary measure when there is a foreseeable delay, such as long wait for dialysis unit bed or presentation outside the working hours of the ambulatory PD unit. However, the route of administering antibiotics should still be switched to IP as soon as possible.

### Dosage of antibiotics

- We recommend that IP antibiotics be the preferred route of administration as long as the compatibility and stability of the IP antibiotics allow, unless the patient has features of systemic sepsis (1B).
- We suggest that IP aminoglycoside be administered as daily intermittent dosing (2B).
- We recommend that prolonged courses of IP aminoglycoside be avoided (1C).
- We suggest that adjunctive oral N-acetylcysteine therapy may help to prevent aminoglycoside ototoxicity (2B).
- There is insufficient evidence to make a recommendation as to whether patients on APD should be temporarily switched to CAPD during treatment of peritonitis (Not Graded).

The recommended dosage of antibiotics for the treatment of PD-related peritonitis is summarised in Table 5 (IP antibiotics) and Table 6 (systemic antibiotics). However, the recommended dosages of many antibiotics are based on published clinical experience rather than formal pharmacokinetic studies. Most studies of IP antibiotics have been conducted in patients on CAPD rather than in patients on APD.

The importance of adequate dosing of antibiotics was supported by an observational study of 339 episodes of gram-positive, gram-negative and culture-negative PD-related peritonitis, in which treatment failure was higher for patients with greater residual kidney function defined as urinary creatinine clearance more than 5 mL/min.<sup>247</sup> The observation suggests that better clearance of antibiotics might lead to lower concentration of antibiotics, and hence the reduced time above the minimum inhibitory concentration (MIC). Optimal dosing of antibiotics in patients with significant residual kidney function remains unknown, although fixed dosing irrespective of residual kidney function might not be the best solution for antibiotics (such as cephalosporin) that exhibit time-dependent killing effects. Limited data are available to guide the adjustment of antibiotics dosing, except a recent randomised controlled

study advocating a 25% increase in the loading and maintenance dose of cefepime, cefazolin and ceftazidime when PD patients have residual urine volumes of more than 100 mL daily.<sup>168</sup>

Vancomycin is the drug of choice in centres with a high prevalence of methicillin resistant gram-positive bacteria or for directed therapy in patients with relevant pathogens. IP administration is preferred because nearly 90% is absorbed in the presence of peritonitis.<sup>248</sup> The superiority of treatment success rate with IP versus intravenous vancomycin is supported by Cochrane systematic review.<sup>160</sup> Optimal dosing of IP vancomycin is unknown, and guideline recommendations are variable regarding whether to prefer fixed dosing or target-guided dosing according to serum trough level. Although fixed dosing of IP vancomycin had been reported in a randomised controlled trial,<sup>234</sup> it is unknown whether inter-individual variability of vancomycin bioavailability warrants adjustment of maintenance dose according to therapeutic drug monitoring of steady-state serum vancomycin concentration. A retrospective study reported that 60% of patients had subtherapeutic trough level following the loading dose after a fixed dosing of IP vancomycin 30 mg/kg every 5 days for CAPD and every 3 days for CCPD, irrespective of the residual renal function. However, all subsequent serum vancomycin levels were above 15 mg/L.<sup>249</sup> Several observational studies did not show correlation between trough levels and cure rates of peritonitis.<sup>250,141</sup> On the other hand, one observational study reported a higher rate of peritonitis relapse with intravenous vancomycin use when the cumulative 4-week mean trough vancomycin levels were less than 12 mg/L.<sup>251</sup> Another study of peritonitis due to methicillin-resistant coagulase-negative staphylococci showed that higher serum trough vancomycin levels achieved by IP vancomycin were associated with a lower relapse rate.<sup>252</sup> Regarding the practice of trough-guided vancomycin dosing, there was no consensus on the preferred timing of obtaining trough vancomycin concentration. Based on a retrospective analysis of 61 episodes of gram-positive or culture-negative peritonitis, serum vancomycin levels lower than 10.1 mg/L on day 5, but not the level on day 3, were associated with worse outcomes (including transfer to haemodialysis, death, persistent infection and relapse).<sup>208</sup> Recently, trough-guided vancomycin dosing has been increasingly replaced by the area under the 24-h time-concentration curve (AUC)-guided dosing to optimise the management of severe *S. aureus* infection. Although the clinical significance of AUC pharmacokinetic parameters for monitoring vancomycin dosing in peritonitis treatment is incompletely understood, accumulating evidence suggests that trough level might not be the best option. A recent study of anuric patients on APD reported that peak serum concentration level (30 min after IP administration), but not trough vancomycin level, was associated with cure of gram-positive peritonitis.<sup>212</sup>

**Table 5.** IP antibiotic dosing recommendations for treatment of peritonitis.

Antibiotic	Intermittent (1 exchange daily for at least 6 h)	Continuous (all exchanges)
<b>Aminoglycosides</b>		
Amikacin	2 mg/kg daily <sup>173</sup>	Not advised
Gentamicin	0.6 mg/kg daily <sup>174,175</sup>	Not advised
Netilmicin	0.6 mg/kg daily <sup>165</sup>	Not advised
Tobramycin	0.6 mg/kg daily	Not advised
<b>Cephalosporins</b>		
Cefazolin	15 mg/kg daily (for long dwell) <sup>176,177</sup> 20 mg/kg daily (for short dwell) <sup>178,176</sup>	LD 500 mg/L, MD 125 mg/L <sup>d 168,179</sup>
Cefepime	1000 mg daily	LD 500 mg/L, MD 125 mg/L <sup>d 168</sup>
Cefoperazone	No data	LD 500 mg/L, MD 62.5–125 mg/L <sup>180</sup>
Cefotaxime	500–1000 mg daily <sup>181</sup>	no data
Ceftazidime	1000–1500 mg daily (for long dwell) 20 mg/kg daily (for short dwell) <sup>178</sup>	LD 500 mg/L, MD 125 mg/L <sup>d 168,182</sup>
Ceftriaxone	1000 mg daily <sup>183</sup>	No data
<b>Penicillins</b>		
Penicillin G	No data	LD 50,000 unit/L, MD 25,000 unit/L <sup>13</sup>
Amoxicillin	No data	MD 150 mg/L <sup>184</sup>
Ampicillin <sup>a</sup>	4 gm daily <sup>185</sup>	MD 125 mg/L <sup>186</sup>
Ampicillin/ sulbactam		LD 1000 mg/500 mg, MD 133.3 mg/66.7 mg <sup>187,188</sup>
Piperacillin/ tazobactam	No data	LD 4 gm/0.5 gm, MD 1 gm/0.125 gm <sup>189</sup>
Ticarcillin/clavulanic acid	No data	LD 3 gm/0.2 gm, MD 300 mg/20 mg/L <sup>190</sup>
<b>Others</b>		
Aztreonam	2 gm daily <sup>191</sup>	LD 500 mg/L <sup>192</sup> , MD 250 mg/L <sup>192,193</sup>
Ciprofloxacin	No data	MD 50 mg/L <sup>194</sup>
Clindamycin	No data	MD 600 mg/bag <sup>195</sup>
Daptomycin	300 mg daily <sup>196</sup>	LD 100 mg/L <sup>197,198,199</sup> , MD 20 mg/L <sup>197,200</sup>
Fosfomycin	4 g daily <sup>201,202</sup>	No data
Imipenem/cilastatin	500 mg in alternate exchange <sup>203</sup>	LD 250 mg/L, MD 50 mg/L <sup>182</sup>
Ofloxacin	No data	LD 200 mg, MD 25 mg/L <sup>204</sup>
Polymyxin B	No data	MD 300,000 unit (30 mg)/bag <sup>188</sup>
Quinupristin/ dalbapristin	25 mg/L in alternate exchanges <sup>b205</sup>	No data
Meropenem	500 mg daily (for long dwell in APD) <sup>207</sup> 1000 mg daily (for short dwell in CAPD) <sup>208,209</sup>	MD 125 mg/L <sup>206</sup>
Teicoplanin	15 mg/kg every 5 days <sup>210</sup>	LD 400 mg/bag, MD 20 mg/L <sup>211,140</sup>
Vancomycin	15–30 mg/kg every 5–7 days <sup>c141,212</sup> for CAPD 15 mg/kg every 4 days <sup>213</sup> for APD	LD 20–25 mg/kg, MD 25 mg/L <sup>214</sup>
<b>Antifungal</b>		
Fluconazole	IP 150–200 mg every 24 to 48 h <sup>215,216</sup> (oral route is preferred: see Table 6)	No data
Voriconazole	IP 2.5 mg/kg daily <sup>217</sup> (oral route is preferred: see Table 6)	No data

LD: loading dose in mg; MD: maintenance dose in mg; IP: intraperitoneal; APD: automated peritoneal dialysis.

<sup>a</sup>IP ampicillin is not recommended for treatment of enterococcal peritonitis.<sup>218</sup>

<sup>b</sup>Given in conjunction with 500 mg intravenous twice daily.

<sup>c</sup>Supplemental doses may be needed for APD patients and dwell time of at least 6 h is preferred.

<sup>d</sup>Increase in doses by 25% may be needed for patients with significant residual kidney function.<sup>168</sup>

Aminoglycosides remain useful for treating gram-negative peritonitis. Since aminoglycosides exhibit concentration-dependent activity, their maximal bacterial killing occurs at high peak drug concentrations. In addition, aminoglycosides continue to suppress bacterial growth even after drug concentration falls below MIC of the bacteria, a characteristic known as the post-antibiotic effect.<sup>253</sup> As a result of the post-antibiotic effect and concentration-

dependent bactericidal characteristics, we favour intermittent daily dosing of IP aminoglycosides to minimise toxicity and adaptive resistance while maintaining drug efficacy. This has been confirmed in a randomised controlled trial comparing once-daily gentamicin dose versus continuous dosing; treatment success and relapse rate did not differ between the two regimens. The once-daily dosing strategy, nevertheless, was associated with lower trough

**Table 6.** Systemic antibiotic dosing recommendations for treatment of peritonitis.

Drug	Dosing
<b>Antibacterial</b>	
Amoxicillin	Oral 500 mg thrice daily <sup>219</sup>
Ciprofloxacin	Oral 500–750 mg daily <sup>220</sup>
	Oral 750 mg BD for CCPD <sup>221</sup>
Clarithromycin	Oral 250 mg BD <sup>222,223</sup>
Colistin	IV 300 mg loading (for critically ill patients), then 60–200 mg daily <sup>b224–226</sup>
Dalbavancin	IV 1500 mg over 30 min single dose <sup>227</sup>
Daptomycin	IV 4–6 mg/kg every 48 h <sup>228</sup>
Ertapenem <sup>a</sup>	IV 500 mg daily <sup>229</sup>
Levofloxacin	Oral 250 mg daily <sup>230</sup> or 500 mg every 48 h
Linezolid	IV or oral 600 mg BD <sup>231,232</sup> for 48 h, then 300 mg BD <sup>233</sup>
Moxifloxacin	Oral 400 mg daily <sup>234,235</sup>
Rifampicin	Oral or IV 450 mg daily for BW <50 kg; 600 mg daily for BW ≥50 kg
Ticarcillin/clavulanic acid	IV 3 gm/0.2 gm every 12 h
Tigecycline	IV 100 mg loading, then 50 mg every 12 h <sup>236,237</sup>
Trimethoprim/sulfamethoxazole	Oral 160 mg/800 mg BD <sup>238,239</sup>
<b>Anti-fungal</b>	
Amphotericin B desoxycholate	IV 0.75–1.0 mg/kg/day over 4–6 h <sup>240</sup>
Amphotericin B (liposomal)	IV 3–5 mg/kg/day <sup>241,242</sup>
Anidulafungin	IV 200 mg loading, then 100 mg daily <sup>243,244</sup>
Caspofungin	IV 70 mg loading, then 50 mg daily <sup>243</sup>
Fluconazole	Oral 200 mg loading, then 100 mg daily <sup>240</sup>
Flucytosine	Oral 1 gm daily <sup>240</sup>
Isavuconazole	Oral or IV 200 mg every 8 h for 6 doses (48 h) loading, then 200 mg daily
Micafungin	IV 100 mg daily <sup>243,245</sup>
Posaconazole	Oral tablet 300 mg every 12 h loading for two doses, then 300 mg daily <sup>246</sup>
Voriconazole	Oral 200 mg every 12 h

BD: twice a day; IV: intravenous; BW: body weight.

<sup>a</sup>Ertapenem is not active against *Pseudomonas* or *Acinetobacter* species.

<sup>b</sup>Expressed as colistin base activity in mg.

serum gentamicin level.<sup>174</sup> After the initiation of IP aminoglycosides, a significant fraction of the drug can be absorbed into the systemic circulation, especially when the peritoneal solute transfer rate is increased during the acutely inflamed phase. High mass active transfer coefficients for IP gentamicin and tobramycin were consistently reported in pharmacokinetic studies of patients with active peritonitis.<sup>175,254</sup> In a case series of 24 PD patients with peritonitis, 76% of the IP gentamicin dose was absorbed into the systemic circulation and was higher among those with high and high average membrane solute transfer rates.<sup>175</sup> Two studies in which outcomes were compared between patients with different gentamicin levels have not demonstrated any difference in gram-negative or culture-negative peritonitis cure rates.<sup>141,255</sup> A major concern with aminoglycoside use in PD patients is ototoxicity. At the currently recommended peritonitis treatment dosage of aminoglycosides, ototoxicity could occur in PD patients, resulting in either vestibular or cochlear damage. Such ototoxicity was reported even in the context of therapeutic serum concentrations.<sup>256,257</sup> Not unexpectedly, ototoxicity occurs with IP aminoglycosides, similar to systemic administration, as confirmed in both animal models<sup>258</sup> and human.<sup>259,260</sup> According to an observational study of PD

patients, risk factors for hearing loss include older age, episodes of peritonitis and cumulative doses of amikacin and vancomycin.<sup>166</sup> The mechanism of aminoglycoside ototoxicity is incompletely understood. Besides genetic predisposition, reactive oxygen species damage to the inner ear is the most accepted hypothesis. Based on three randomised controlled trials of N-acetylcysteine, the preventive approach with antioxidant protection of aminoglycoside-induced ototoxicity appears promising. The largest study involved 60 CAPD patients who received IP vancomycin and amikacin. Compared with the control group, patients randomly assigned to oral N-acetylcysteine 600 mg twice daily had significantly better protection from ototoxicity as measured by pure tone audiometry assessment of high-frequency hearing function at the first and fourth weeks.<sup>261</sup> Similar findings were reported in two other randomised trials of N-acetylcysteine for PD patients receiving amikacin.<sup>262,263</sup> Only one of the three trials included a control group with a placebo; the other two were open-label. A protective benefit using the same dose strategy of oral N-acetylcysteine on high tone frequency ototoxicity had also been demonstrated in haemodialysis patients receiving intravenous gentamicin for dialysis catheter-related bloodstream infection.<sup>264</sup> None of these randomised



controlled trials assessed vestibular function. The pooled relative risk for otoprotection at 4–6 weeks was 0.14 (95% CI 0.05 to 0.45) according to meta-analysis.<sup>265</sup> Notwithstanding the potential risks of bias of these trials with relatively small sample size, it is reasonable to consider co-administration of N-acetylcysteine at 600 mg twice daily for PD patients requiring aminoglycoside. In the absence of high-quality evidence to ameliorate potentially irreversible aminoglycoside ototoxicity, the best measure is to minimise prolonged or repeated administration. When an alternative drug of choice is available, early switch has been shown to have comparable clinical outcomes compared with continuing IP gentamicin.<sup>141</sup> In other words, avoiding prolonged aminoglycoside should be advocated to prevent aminoglycoside ototoxicity.

Fluoroquinolones, including ciprofloxacin<sup>266</sup> and moxifloxacin,<sup>267</sup> have been confirmed to be compatible with PD solutions and shown to be highly active and bactericidal in PD fluids with concentration-dependent activity.<sup>268</sup> A small randomised controlled study supported the safety and efficacy of IP vancomycin plus oral moxifloxacin but was not powered to be a non-inferiority trial.<sup>234</sup> Oral administration is an alternative and more convenient choice for susceptible organisms, as both ciprofloxacin and moxifloxacin can achieve adequate levels within the peritoneum.<sup>235,221</sup> Oral ciprofloxacin should be administered in a once-daily dose of 500–750 mg instead of as a 250 mg twice daily dosing regimen,<sup>220</sup> although higher dosing at 750 mg every 12 h has been suggested in CCPD patients.<sup>221</sup> Patients should be instructed to avoid concomitant use of aluminium-containing antacids and oral phosphate binders (including calcium carbonate, lanthanum<sup>269</sup> and sevelamer<sup>270</sup>) to avoid interference with absorption (and hence lower peak concentration) of fluoroquinolones.<sup>271</sup>

### Antibiotic delivery and stability

Stability and compatibility of antibiotics in PD solution (Table 7), as reviewed recently,<sup>272</sup> is one of the factors which influences treatment success.

Gentamicin is stable for 14 days both at room temperature and under refrigeration in both dextrose-based and icodextrin-based PD solutions, but the duration of stability is reduced by admixture with heparin.<sup>13,273,274</sup>

Cefazolin is stable for 8 days at room temperature or for 14 days if refrigerated in dextrose-based PD solutions; addition of heparin has no adverse effect.<sup>13,275</sup> In icodextrin-based PD solution, cefazolin is stable for 7 days at room temperature or for 14 days if refrigerated.<sup>273</sup> Ceftazidime is stable for 4 days at room temperature or 7 days if refrigerated in dextrose-based PD solutions. It is stable in icodextrin-based PD solution for 2 days at room temperature or 14 days at refrigerated temperature.<sup>273</sup> Cefepime is stable for 14 days in dextrose-based PD solutions when refrigerated.<sup>13,276</sup>

Vancomycin is stable for 28 days in dextrose-based PD solutions at room temperature, but the duration of stability is reduced at higher ambient temperatures.<sup>274</sup> Stability of vancomycin in icodextrin-based PD solution has been confirmed for 14 days at 4°C and 25°C.<sup>273</sup>

For compatibility of combined antibiotics in PD solutions, aminoglycosides and penicillins should not be added to the same bag due to chemical incompatibility.<sup>275</sup> There are several antibiotics which can be mixed in the same PD bag; gentamicin is compatible with cefazolin or vancomycin, and ceftazidime is compatible with cefazolin or vancomycin.<sup>272,273,277</sup>

Emerging data of piperacillin/tazobactam showed that, when admixed with heparin in dextrose-based and icodextrin-based PD solutions, both drugs are stable for 7 days when refrigerated.<sup>278</sup>

Data on the stability of newer antibiotics and PD solutions are important to prepare the readiness for clinical use. Potential candidates include ceftolozane-tazobactam for gram-negative bacilli producing ESBL and *Pseudomonas aeruginosa*; the drug's stability in PD solution has been confirmed.<sup>279</sup>

### Special considerations for APD

Extrapolation of antibiotic dosing from CAPD to APD is not recommended. First, patients on APD may have greater peritoneal antibiotic clearance. The implication of shorter antibiotic half-lives during the cyclical exchanges is inadequate serum and dialysate drug concentrations throughout 24 h.

An important concern for treating APD patients with peritonitis is the potential of underdosing, especially for antibiotics that exhibit time-dependent killing. Under such circumstances, it is important to use a dosing strategy that allows antibiotic concentrations to exceed the MIC for at least 50% of treatment time.

Sufficient dwell time should be allowed for drug absorption. Limited data are available to guide the optimal dwell time of antibiotics. A close correlation between vancomycin dwell time and bioavailability has been shown in pharmacokinetic study of APD patients.<sup>213</sup> Minimal dwell time of 4 h should be used for vancomycin to achieve adequate peritoneal concentration according to previous APD experience,<sup>280</sup> although dwelling for 6 h may be a more reasonable strategy.<sup>212</sup>

While conversion to CAPD is not always feasible for pragmatic reasons, this may be considered for antibiotics requiring continuous dosing. When the conversion to CAPD is difficult to implement, the treatment dose of IP antibiotics administered to short dwells should ideally be validated. For short-dwell automated cycling exchanges, cefazolin and ceftazidime can still be used based on pharmacokinetic studies on patients with<sup>281</sup> and without peritonitis.<sup>178</sup>

**Table 7.** Summary of IP antibiotics stability.

Antibiotics	PD solutions		Stability	Storage conditions		Remarks <sup>a</sup>	
	Dextrose-based	Icodextrin-based		Room temperature	Under refrigeration	Tested for	Stable for
Gentamicin	✓		14 days	✓	✓	14 days	
Cefazolin	✓	✓	14 days	✓	✓	14 days	8 days
	✓		8 days	✓			
Ceftazidime		✓	14 days		✓	14 days	7 days
	✓	✓	7 days	✓	✓	14 days	4 days
	✓		4 days	✓			7 days
		✓	7 days		✓		2 days
		✓	2 days	✓		14 days	
Cefepime	✓		14 days		✓	14 days	
Vancomycin	✓		28 days	✓			N/A
Piperacillin/ tazobactam + Heparin		✓	14 days	✓	✓	14 days	
	✓	✓	7 days		✓	7 days	

PD: peritoneal dialysis.

<sup>a</sup>'Stable for X days' indicates that the antibiotic concentration retained at least 90% of its initial concentration up to day X. 'Tested for X days' indicates the antibiotic concentration retained at least 90% of its initial concentration up to the study duration set for X days only.

Stability (Stable for X days) is interpreted according to the type of PD solutions and storage conditions specified.

### Adjunctive treatments

- We suggest that augmented peritoneal lavage should not be performed for the purpose of improving peritonitis cure (2B).
- We suggest that icodextrin be considered for volume overload which occurs during acute peritonitis (2C).

Many patients with PD-related peritonitis could be managed on an outpatient basis. According to a PDOPPS analysis of 1689 episodes of peritonitis internationally, only half of them had a hospitalisation within 14 days of peritonitis onset.<sup>31</sup> The decision to hospitalise a patient depends on many factors, including social support, hemodynamic status of the patient, severity of signs and symptoms and, for APD patients, the type of treatment schedule chosen as well as the ability to provide IP antibiotics as an outpatient and the reliability of the patient. The rationale for anti-fungal prophylaxis has been discussed in a previous section (see Secondary prevention section).

Patients with cloudy effluent may benefit from the addition of heparin 500 units/L IP to prevent occlusion of the catheter by fibrin. Depending on the severity of symptoms, some patients require analgesics for pain control. At the initial presentation and before IP antibiotics are initiated, one or two rapid PD exchanges are often performed for pain relief, although there are no data supporting this approach. Two randomised controlled trials showed that more extensive rapid-cycle peritoneal lavage, during the first 24 h of peritonitis<sup>282</sup> or from day 3 to 5,<sup>283</sup> did not improve the rate of complete cure or relapse.

IP urokinase has been advocated for the treatment of biofilm, which may be the cause of refractory or relapsing

peritonitis. A retrospective study found that IP urokinase and oral rifampicin, in addition to conventional antibiotics, could facilitate catheter salvage among patients with persisting asymptomatic infection following coagulase-negative staphylococcus peritonitis.<sup>284</sup> However, three randomised controlled trials failed to show any benefit of IP urokinase for the treatment of refractory peritonitis.<sup>285–287</sup> The rates of complete cure, catheter removal or relapsing episodes as well as overall mortality were not affected by adjunctive treatment with IP urokinase. In contrast, one randomised controlled study showed that simultaneous catheter removal and replacement was superior to IP urokinase in reducing relapsing peritonitis episodes.<sup>288</sup>

Peritoneal permeability to water and solutes typically increases during peritonitis. Reduced ultrafiltration is commonly observed and may result in the complication of fluid overload. In addition to temporary use of hypertonic exchanges, management of fluid overload might require short dwell times, which can theoretically compromise local defence mechanisms (owing to decreased macrophage phagocytic capacity and immunoglobulin G concentration).<sup>289</sup> Temporary use of icodextrin solution during acute peritonitis has been shown to be a better therapeutic option in one randomised controlled study.<sup>290</sup> The primary cure rate of peritonitis was similar between the icodextrin and original glucose-based dialysis solution treatment groups in the study,<sup>290</sup> although PDOPPS reported that icodextrin use was associated with a higher cure rate.<sup>96</sup> Because of rapid glucose absorption, glycemic control may worsen in diabetic patients. Blood glucose monitoring with appropriate adjustments of insulin dosage may be needed. Protein loss during peritonitis is also increased. Screening for malnutrition should be

undertaken in patients with prolonged peritoneal inflammation. There are currently no high-quality, randomised studies that have examined the effects of dietary interventions or nutrition supplements in patients with peritonitis.

### Subsequent management of peritonitis

- We recommend that antibiotic therapy be adjusted once results and sensitivities are known (1C).

The management algorithms for bacteria identified in dialysis effluent are summarised in Figures 2 to 4. Within 48 h of initiating therapy, most patients with PD-related peritonitis will show considerable clinical improvement. The effluent should be visually inspected regularly to determine if clearing is occurring. Catheter lumen and exit site, tunnel should be re-examined. If there is no improvement after 48 h, cell counts and repeat cultures should be performed. In addition, monitoring of WBC count in PD effluent may also predict treatment response. A retrospective study with a validation cohort showed that dialysis effluent WBC count  $\geq 1090/\mu\text{L}$  on day 3 was an independent prognostic marker for treatment failure.<sup>291</sup> Another retrospective study further confirmed a prediction model incorporating a dialysis effluent WBC count  $>1000/\mu\text{L}$  on day 3–4 is associated with a substantially higher likelihood of treatment failure.<sup>292</sup>

Nonfermenting gram-negative bacilli are important nosocomial pathogens contributing to serious peritonitis. Notably, *P. aeruginosa*, *Acinetobacter baumannii* and *Stenotrophomonas maltophilia* are known to have a high intrinsic resistance and deserve special attention in relation to the choice of antimicrobial agents (see below).

### Refractory peritonitis

- We recommend that PD catheter be removed in refractory peritonitis episodes, defined as failure of the PD effluent to clear after 5 days of appropriate antibiotics (1D).
- We suggest that observation for antibiotic effect longer than 5 days is appropriate if PD effluent white cell count is decreasing towards normal, instead of mandatory PD catheter removal if effluent does not clear up by day 5 (2C).

After initiation of antibiotic treatment, there is usually clinical improvement in 72 h. Refractory peritonitis is defined as failure of the PD effluent to clear up after 5 days of appropriate antibiotics (Table 1). Catheter removal is indicated in cases of refractory peritonitis, or earlier if the patient's clinical condition is deteriorating, in order to preserve the peritoneum for future PD as well as prevent morbidity and mortality. Prolonged attempts to treat refractory peritonitis by antibiotics without catheter removal are associated with extended hospital stay, peritoneal membrane

damage, increased risk of fungal peritonitis and excessive mortality.<sup>293,294</sup>

The cut-off of 5 days in deciding PD catheter removal should be considered an arbitrary reference tool. Data to compare long-term outcomes between 5-day decision rule and longer wait for antibiotic effect are lacking. In a single-centre study including 190 consecutive peritonitis episodes, substantial variation of PD effluent white cell count was reported.<sup>295</sup> The approach to less virulent organisms should probably be less aggressive to minimise premature or unnecessary PD catheter removal. Instead of a 'one-size-fits-all' rule on day 5, the trajectory of effluent white cell count should be taken into consideration. A large observational study of 644 peritonitis episodes tracked the longitudinal change of effluent white cell count. Three patterns of treatment outcome were analysed: early response, delayed response (defined by gradual decline in effluent white cell count but still above  $100/\mu\text{L}$  on day 5) and treatment failure (defined as peritonitis not cured by antibiotics, change to haemodialysis either temporarily or permanently or peritonitis-associated death).<sup>296</sup> This study highlighted the varying rate or trajectory of effluent white cell count decline. In one-fifth of the cases, patients showed delayed response with 34% reduction of effluent white cell count by day 5, without the need for PD catheter removal.<sup>296</sup> Thus, expectant of peritonitis episodes with longer antibiotic treatment duration without immediate catheter removal can be an option if the effluent white cell count is decreasing, albeit not reaching the nadir  $100/\mu\text{L}$  by day 5.

### Relapsing, recurrent and repeat peritonitis

- We recommend timely PD catheter removal be considered for relapsing, recurrent or repeat peritonitis episodes (1C).
- We suggest that simultaneous PD catheter removal and reinsertion be considered after culture of the PD effluent has become negative and the PD effluent white cell count is below  $100/\mu\text{L}$ , in the absence of concomitant exit site or tunnel infection (2C).

The definitions of relapsing, recurrent and repeat peritonitis are summarised in Table 1. Retrospective studies showed that relapsing, recurrent and repeat peritonitis episodes are caused by different species of bacteria and probably represent distinct clinical entities.<sup>297–301</sup> When compared to non-relapsing episodes, relapsing ones are associated with a lower rate of cure, more ultrafiltration problems and higher rates of technique failure.<sup>297</sup> Recurrent peritonitis episodes had a worse prognosis than relapsing ones.<sup>297,298</sup> Centres with larger PD sizes are associated with lower rates of relapsing and recurrent peritonitis.<sup>161</sup>

To manage or reduce the risk of relapsing, recurrent or repeat peritonitis, simultaneous removal and reinsertion of PD catheters have been proposed.<sup>302</sup> This allows a




Figure 2. Management algorithm for *Staphylococcus aureus* peritonitis.





Figure 3. Management algorithm for *Streptococci* identified in dialysis effluent.



**Figure 4.** Management algorithm for other gram-positive organism including coagulase-negative *Staphylococcus* identified in dialysis effluent.

continuation of PD without transfer to HD. Such a strategy should be considered only after culture of PD effluent has been confirmed negative following appropriate treatment, with a PD effluent white cell count lower than 100/ $\mu\text{L}$  and in the absence of concomitant exit-site or tunnel infection.<sup>27</sup> Before the bacterial culture became negative, it would be inappropriate to attempt simultaneous removal and reinsertion of catheter because there could still be planktonic bacteria. To optimise the eradication success rate, we suggest deferring the procedure until the culture is negative, indicating absence of planktonic bacteria (when the bacteria are sequestered in biofilm). The simultaneous removal and reinsertion of catheter procedure should be carried out under perioperative antibiotic coverage.<sup>27,303</sup> The long-term benefit of simultaneous removal and reinsertion of PD catheters has been replicated in several series, with reported 1-year technique survival of 64%<sup>304</sup> and median technique survival of more than 5 years.<sup>303</sup>

On the other hand, prolonged antibiotic treatment is not recommended. A randomised controlled study showed that extending antibiotic treatment duration for an additional week beyond that recommended by the ISPD is not advisable because such a strategy does not reduce the risk of relapsing, recurrent or repeat peritonitis and may increase the risk of repeat peritonitis. Another downside to prolonged antibiotic use is the risk of developing secondary fungal peritonitis.<sup>305</sup>

A previous study suggested that bacterial DNA fragment levels in PD effluent are significantly higher 5 days before

and on the date of completion of antibiotics amongst patients who subsequently develop relapsing or recurrent peritonitis.<sup>306</sup> Despite the prognostic value of bacterial DNA fragments, a subsequent study showed that bacterial DNA levels do not decrease significantly with extended antibiotic therapy.<sup>305</sup>

### Coagulase-negative *Staphylococcus*

- We suggest that coagulase-negative staphylococci be treated with IP cephalosporin or vancomycin, according to susceptibility, for a period of 2 weeks (2C).
- We suggest that retraining be considered for patients with coagulase-negative staphylococcal peritonitis (Not Graded).

The leading cause of pathogenic coagulase-negative staphylococci peritonitis is *Staphylococcus epidermidis*, followed by *Staphylococcus haemolyticus*.<sup>307</sup>

Despite lower virulence properties than *S. aureus*, coagulase-negative staphylococci are more common, partly because host fibrinogen antimicrobial defences can eliminate the former but not coagulase-negative staphylococci.<sup>308</sup> Coagulase-negative staphylococcal peritonitis is also challenging due to the large proportion of methicillin-resistant strains and biofilm formation. The methicillin resistance rate of coagulase-negative *Staphylococcus* causing peritonitis has been increasing to more than 50% in most centres<sup>309–311</sup> and up to 70%.<sup>162,307</sup> Such a high prevalence

of methicillin resistance is now considered a rationale to use empirical vancomycin for coagulase-negative staphylococci peritonitis in some centres. As long as adequate antibiotic levels are achieved, a treatment duration of 2 weeks is generally sufficient (Figure 4). There was no difference in primary response rate or complete cure rate between episodes treated with 2 and 3 weeks of antibiotics.<sup>312</sup> However, there is a high risk of relapse when cephalosporin-resistant cases were not treated with vancomycin despite clinical improvement with cefazolin,<sup>313</sup> or when adequate vancomycin levels were not achieved.<sup>252</sup>

They key to the success in managing coagulase-negative staphylococci is handling the root cause of infection. Patient's exchange technique should be reviewed to prevent further touch contamination and peritonitis recurrence. Another concern in relation to tackling coagulase-negative staphylococci is the high risk of refractory and repeat peritonitis, often in the second month after the completion of antibiotic treatment.<sup>314</sup> Reported rates of repeat coagulase-negative staphylococci peritonitis were around 12% in two large case series.<sup>307,312</sup> These episodes are likely secondary to colonisation of the PD catheter with biofilm, in particular, with the presence of *mecA* gene (which encodes a low-affinity penicillin-binding protein) and biofilm-related gene *icaAD*.<sup>307</sup> Under these situations, catheter removal should be considered. When the PD effluent becomes clear with antibiotic therapy and culture became negative, many of these patients could have simultaneous re-insertion of a new catheter as a single procedure under antibiotic coverage.<sup>315</sup> This strategy obviates interruption of PD, and temporary haemodialysis could therefore be avoided. Other suggested options include adjunctive antibiotics and fibrinolytic therapy.<sup>314</sup> One series reported use of intraluminal urokinase 100,000 IU for 2 h and oral rifampicin 600 mg daily for 3 weeks; the success rate of catheter salvage was 64%.<sup>284</sup> Another smaller series suggested intraluminal alteplase 6 mg for 6 h, plus IP vancomycin, IP gentamicin, oral rifampicin 300 mg twice daily for 3 weeks; eradication of infection was achieved in all four cases of repeat coagulase-negative staphylococci peritonitis.<sup>316</sup>

#### *Staphylococcus aureus*.

- We suggest that *S. aureus* peritonitis be treated with effective antibiotics for 3 weeks (2C).

Peritonitis episodes caused by *S. aureus* are often secondary to exit-site or tunnel infection, although touch contamination can be contributory. Figure 2 refers to the suggested treatment algorithm. If the bacterial isolate is methicillin-sensitive, a first-generation cephalosporin is the drug of choice. Two retrospective studies, with more than 700 cases in total, found that the initial empiric antibiotic choice between vancomycin and cefazolin had similar clinical outcomes.<sup>317,318</sup>

If the isolate is methicillin-resistant, IP vancomycin is the drug of choice. Another study showed that the use of adjuvant

rifampicin for 5 to 7 days was associated with a 50% relative risk reduction in relapse or repeat *S. aureus* peritonitis.<sup>317</sup>

Observational data suggest that treatment with effective antibiotics for 3 weeks is needed.<sup>317,318</sup> If the response to vancomycin is unfavorable, IP daptomycin with or without oral rifampicin can be used as salvage therapy.<sup>197</sup> For patients with concomitant *S. aureus* exit-site or catheter tunnel infection, however, catheter removal should be considered.

Teicoplanin is not preferred because its activity on MRSA biofilm is impaired in PD solutions.<sup>319</sup>

#### *Streptococcal peritonitis*

- We suggest that streptococcal peritonitis be treated with appropriate antibiotics for 2 weeks (2C).

The reported cure rate of streptococcal peritonitis exceeds 85%, and most patients can continue PD.<sup>320,321</sup>

An increasing trend of streptococcal peritonitis has been observed in longitudinal studies,<sup>321,322</sup> mostly secondary to viridans groups (including *oralis*, *sanguis* and *gordonii*). For viridans group *streptococci*, there is emerging evidence of mixed or polymicrobial strains with lower susceptibility to ampicillin, penicillin and ceftriaxone being encountered.<sup>162,322</sup>

Peritonitis episodes caused by streptococci usually respond well to antibiotic treatment (Figure 3), but viridans streptococcal peritonitis poses a higher risk of relapse.<sup>323</sup>

#### *Corynebacterium peritonitis*

- We suggest that *Corynebacterium* peritonitis be treated with effective antibiotics for 2 weeks (2D).
- We suggest that peritonitis due to beta-lactam-resistant strains, such as *Corynebacterium jeikeium*, should be treated with vancomycin (2C).

*Corynebacterium* species are gram-positive bacilli and belong to the natural flora of the skin. Infections due to *Corynebacterium* have been increasingly recognised over the past decades, largely due to improved recognition and microbiological techniques. Three outcome studies of *Corynebacterium* peritonitis came to somewhat differing conclusions as to whether antibiotics should be extended beyond 2 weeks. The cure rate for *Corynebacterium* peritonitis, according to the largest study of 162 episodes, did not differ between cases with initial treatment with vancomycin and cefazolin.<sup>324</sup> Catheter removal rate was 15%, and treatment duration beyond 14 days did not confer additional benefit.<sup>324</sup> Another retrospective study supported a treatment duration of 2 weeks, but advocated for early instead of delayed catheter removal if the patient did not show clinical improvement.<sup>325</sup> Otherwise, there was a high chance of permanent haemodialysis transfer if the catheter was removed more than one week after the onset of peritonitis. For patients who had initial clinical response,

another study reported that nearly half developed repeat *Corynebacterium* peritonitis after stopping antibiotics; such repeat episodes were usually able to be managed with a 3-week course of IP vancomycin.<sup>326</sup>

The controversy regarding antibiotics treatment duration could have been related to different isolates of corynebacteria and antibiotic susceptibility; species determination within the genus *Corynebacterium* was not available in the previously published series.<sup>324–326</sup> In particular, we believe treatment should be vancomycin for species characterised by increasing antimicrobial resistance to beta-lactams, such as *Corynebacterium jeikeium* and *Corynebacterium striatum*.<sup>327–329</sup> For patients with concomitant exit-site or catheter tunnel infection caused by *Corynebacterium*, early catheter removal should be considered.

### *Enterococcus peritonitis*

- We suggest that enterococcal peritonitis be treated for 3 weeks with oral amoxicillin (for ampicillin-susceptible enterococci) or IP vancomycin (2C).
- For peritonitis due to vancomycin-resistant *Enterococcus* (VRE) which are ampicillin-resistant, we suggest treatment with oral or intravenous linezolid or IP daptomycin, or teicoplanin if susceptibility is confirmed (2D).

Enterococci causing intra-abdominal infections are often enteric in origin,<sup>330</sup> and sometimes enter the slime layer of intra-abdominal portion of PD catheter forming biofilm.<sup>331,332</sup> Enterococci coexisting with other organisms can cause polymicrobial infection episodes, which have much worse outcomes than single-organism *Enterococcus* peritonitis episodes. Single-organism enterococcal peritonitis and polymicrobial enterococcal peritonitis appear to behave as two disease entities with different clinical courses and severities according to three large cohorts.<sup>330,186,219</sup> Polymicrobial enterococcal peritonitis has been reported to consistently cause longer hospitalisation, lower primary response rates and higher catheter removal rates. Notably, there is a threefold<sup>330</sup> to fourfold<sup>219</sup> higher mortality rate for polymicrobial than for single-organism enterococcal peritonitis.

In addition to distinguishing between single-organism and polymicrobial enterococcal peritonitis, proper selection of antibiotics is needed (Figure 5). Specifically, cephalosporin should not be used to treat enterococcal peritonitis because of intrinsic resistance. Oral amoxicillin treatment for 2–3 weeks has been shown to have primary response and complete cure rates of 76% and 56%, respectively, for enterococcal peritonitis.<sup>219</sup> This convenient treatment option, with comparable response to IP vancomycin for *Enterococcus faecalis*, should be considered if the local prevalence of ampicillin resistance is not high. Because vancomycin exposure is a known risk factor for VRE colonisation among PD patients,<sup>333,334</sup> there now exists a strong

rationale for using oral amoxicillin for ampicillin-susceptible enterococci isolates to minimise the risk of provoking vancomycin-resistant strains. Oral amoxicillin is less preferred in polymicrobial enterococcal peritonitis and not recommended for *Enterococcus faecium*.<sup>219</sup> IP vancomycin is reserved for peritonitis due to ampicillin-resistant enterococci with susceptibility to vancomycin.

For VRE causing peritonitis, infectious disease specialists or microbiologists should be consulted for advice. Aminoglycosides are not suggested because enterococci are relatively impermeable to aminoglycosides; very high concentrations of aminoglycosides would have been required to achieve bactericidal activity. Oral or intravenous linezolid<sup>231,232,335</sup> and IP daptomycin<sup>198,336</sup> have been used with variable success. Before the availability of these new treatment options, the mortality of VRE peritonitis was more than 50% when chloramphenicol was used.<sup>337</sup> Among previously suggested treatment options, quinupristin/dalfopristin<sup>205</sup> is less preferred because the peritoneal concentration achieved by intravenous dosing might not be adequate to exceed the MIC of VRE<sup>338</sup>; moreover, its prior approval of VRE infection treatment by US FDA has been removed. The efficacy of quinupristin/dalfopristin against *E. faecalis* is even lower. Daptomycin, on the other hand, has established stability in PD solutions (including dextrose, amino acid-based fluids and icodextrin)<sup>218</sup> and effective peritoneal concentrations have been achieved by IP administration.<sup>196</sup>


With the emergence of VRE isolates showing resistance to currently available drugs, newer agents, including dalbavancin<sup>227</sup> and combination treatment strategies (including tigecycline, fosfomycin), are potential options.

Notably, the IP route administration for ampicillin and linezolid is not recommended because there is a dramatic reduction of their bacteriostatic effects on *E. faecalis* by the peritoneal fluid.<sup>218</sup> IP use of dalbavancin is also not recommended because of the concern about chemical peritonitis.<sup>227</sup>

### *Pseudomonas peritonitis*

- We suggest that *Pseudomonas* peritonitis be treated with 2 antibiotics with different mechanisms of action and to which the organism is sensitive for 3 weeks (2C).
- We suggest that *Pseudomonas* peritonitis with concomitant exit-site and tunnel infection be treated with catheter removal (2D).
- If there is no clinical response after 5 days of effective antibiotic treatment, we suggest that *Pseudomonas* peritonitis be treated with early catheter removal instead of using three antibiotics as an attempt to salvage (2D).

*Pseudomonas* peritonitis is often severe and associated with less than 50% complete cure rate.<sup>339,340</sup> *Pseudomonas aeruginosa* accounts for the majority of the species,



**Figure 5.** Management algorithm for enterococcal peritonitis.

followed by *Pseudomonas stutzeri*.<sup>294,339</sup> Retrospective studies show that PD can be resumed in less than 40% of cases requiring catheter removal,<sup>294,339</sup> but the chance of returning to PD was nominally higher for those with early catheter removal than deferred removal.<sup>294,339</sup> Furthermore, catheter removal was associated with a lower risk of death after *Pseudomonas* peritonitis.<sup>339</sup>

Although the antibiotic resistance rate of *Pseudomonas* species causing peritonitis has been stable over the years,<sup>294,339</sup> the unfavourable response of *Pseudomonas* peritonitis with high chances of hospitalisation and catheter removal suggest other virulence factors such as biofilm production. Among different non-fermenting gram-negative bacilli (Figure 6), *Pseudomonas* species are associated with the highest rate of biofilm production,<sup>173</sup> partly accounting for the high treatment failure rate to antibiotics even when the in vitro susceptibility of planktonic cells to antibiotics suggests otherwise.

Retrospective case series showed that the use of two anti-pseudomonal antibiotics is associated with better outcomes,<sup>339</sup> but the use of three anti-pseudomonal antibiotics does not further improve complete cure or relapse rate.<sup>294</sup> Instead of using three antibiotics, catheter removal is often needed to minimise prolonged peritoneal inflammation or repeat peritonitis episodes. Another observed untoward effect of protracted antibiotic treatment of *Pseudomonas* peritonitis is a significant decline in residual kidney function.<sup>294</sup>

### *Acinetobacter peritonitis*


- We suggest that carbapenem-resistant *Acinetobacter* peritonitis be treated with aminoglycoside and a sulbactam-containing agent (2C).

Outcomes of *Acinetobacter* peritonitis are considered more favourable than those of *Pseudomonas* peritonitis.<sup>341</sup> Empirical antibiotic therapy for *Acinetobacter* should be selected based on local susceptibility patterns (Figure 6) and should consist of a broad spectrum cephalosporin, a combination beta-lactam/beta-lactamase inhibitor (combination including sulbactam) or a carbapenem (except ertapenem). Although carbapenems and aminoglycosides are the potential treatment of choice of *Acinetobacter baumannii*, these organisms are increasingly reported to possess aminoglycoside-modifying enzymes and carbapenemases. Epidemiologic studies in Asia and South American countries have demonstrated an increasing prevalence of multi-drug resistant and carbapenem-resistant *Acinetobacter* peritonitis.<sup>173,342</sup>

### *Stenotrophomonas maltophilia peritonitis*

- We suggest that *Stenotrophomonas maltophilia* peritonitis be treated with trimethoprim-sulfamethoxazole (2D).
- We suggest that *S. maltophilia* peritonitis be treated with two different classes of antibiotics for at least 3 weeks (2D).





**Figure 6.** Management algorithm for non-fermenting or environmental gram-negative bacteria including *Pseudomonas*, *Acinetobacter* and *Stenotrophomonas* identified in dialysis effluent. CRAB: Carbapenem-resistant *Acinetobacter baumannii*

Clinical efficacy data for the use of antibiotics in the setting of *S. (Xanthomonas) maltophilia* peritonitis are limited<sup>343–345</sup>; the approach is extrapolated from data for other infection (Figure 6).<sup>150</sup> The recommended first-line agent is trimethoprim–sulfamethoxazole at the higher end of the dosing range to achieve bactericidal effect.<sup>150,344,346</sup> However high-dose trimethoprim–sulfamethoxazole is generally not recommended<sup>347</sup> or utilised<sup>348</sup> in patients with renal failure. Therefore standard-dose trimethoprim–sulfamethoxazole in combination with fluoroquinolones<sup>349</sup> (levofloxacin or moxifloxacin), intravenous ticarcillin/clavulanic acid, minocycline or tigecycline and ceftazidime is suggested.<sup>346</sup> These can be used as alternatives if trimethoprim–sulfamethoxazole is contraindicated or not tolerated. Most case reports of successful treatment of *S. maltophilia* peritonitis are combination antibacterial therapy.<sup>344,345</sup> Based on these limited observational data, we suggest therapy with two antibiotics for at least 3 weeks.

### Enteric gram-negative bacteria peritonitis

- We suggest that enteric gram-negative peritonitis be treated with effective antibiotics for at least 3 weeks (2C).


Besides non-fermenting gram-negative bacilli with high resistance to antibiotics, several *Enterobacteriales* species,

such as *E. coli*, are reported to have increasing resistance and treatment failure rates.<sup>350</sup> The *Enterobacteriales* order comprises several bacteria genera, including *E. coli*, *Klebsiella* and *Enterobacter* species. *E. coli*, the commonest member,<sup>162,346</sup> accounts for one-third of single-organism non-*Pseudomonas* gram-negative peritonitis in Australia.<sup>351</sup>

Treatment algorithms of enteric gram-negative peritonitis depend on the resistance pattern (Figure 7).

Extended-spectrum beta-lactamases are a heterogeneous family of primarily plasmid-mediated enzymes that inactivate beta-lactam antibiotics. ESBL producers are associated with worse clinical outcomes. Many ESBL producing strains are also resistant to fluoroquinolones and aminoglycosides.<sup>352</sup> The ESBL-producing *E. coli* strains causing peritonitis has increased to 47% in China,<sup>350</sup> whereas resolution of *E. coli* peritonitis occurred in less than half of cases in Brazil.<sup>353</sup> The treatment failure rate of *E. coli* peritonitis correlates with resistance to second- and third-generation cephalosporins and fluoroquinolones.<sup>354</sup> For such susceptibility patterns, there should be a low threshold for PD catheter removal.

Chromosomally encoded ampicillin hydrolysing (AmpC) enzymes are variably induced on exposure to beta-lactam antibiotics such as cephalosporins. ‘SPICE’



**Figure 7.** Management algorithm for enteric gram-negative bacteria identified in dialysis effluent.

organisms (namely, *Serratia*, *Providencia*, indole-positive *Proteus*, *Citrobacter freundii* and *Enterobacter* species) are the primary producers of AmpC enzymes, although they are also found in other *Enterobacteriales* organisms.<sup>355</sup> Because the production of AmpC can lead to clinical failure with cephalosporins, peritonitis caused by such bacteria (Figure 7) should be assumed to be resistant to early-generation cephalosporins even with in vitro susceptibility.<sup>356</sup> Fourth-generation cephalosporin (cefepime), quinolones or carbapenem should be considered.

In case of peritonitis caused by carbapenemase-producing *Enterobacteriales* (Figure 7), early consultation with microbiology or infectious disease experts is recommended, as optimal microbiological therapy will be determined by the specific carbapenemase genes detected.<sup>357</sup>

#### Peritonitis from bacteria not otherwise specified


Treatment duration for peritonitis from unusual organisms should preferably be guided by published literature and microbiologists. An example is peritonitis secondary to *Gordonia*, which should be treated by combination of carbapenem and aminoglycosides for at least 3 weeks.<sup>358,359</sup>

Peritonitis secondary to *Pasteurella multocida*, a gram-negative coccobacillus mostly related to domestic cats and sometimes dogs, can be treated with ceftazidime or oral amoxicillin-clavulanic acid for 14 days.<sup>360</sup>

#### Polymicrobial peritonitis

When multiple enteric organisms are grown from the PD effluent, there is a possibility of intra-abdominal pathology (Figure 8). Presentation with hypotension, sepsis, lactic acidosis or elevated dialysis effluent amylase level usually represents an abdominal catastrophe.<sup>361</sup> When a surgical cause of peritonitis is suspected, the antibiotics of choice are metronidazole plus vancomycin, in combination with ceftazidime or an aminoglycoside. Monotherapy with a carbapenem or piperacillin/tazobactam may also be considered. Assessment by a surgeon is needed. Computed tomographic (CT) scan may help to identify the pathology, especially in the presence of haemodynamic instability. A study in which abdominal imaging (mostly CT scan) was performed in 68 cases of peritonitis, abnormalities were detected in nearly half of them, including bowel obstruction, intra-abdominal collection and biliary abnormalities. The peritonitis organism did not help predict imaging abnormalities, whereas ICU admission was highly predictive of imaging abnormalities.<sup>362</sup> If laparotomy is needed, the PD catheter is usually removed and antibiotics are continued intravenously.

In contrast, polymicrobial peritonitis due to multiple gram-positive organisms often has a favourable prognosis. In a case series of 39 consecutive polymicrobial peritonitis episodes secondary to only gram-positive organisms, about 90% showed a primary response, and more than half had a



**Figure 8.** Management algorithm for polymicrobial peritonitis.

complete cure.<sup>23,363</sup> Similar conclusions were reached in another report of polymicrobial peritonitis in which pure gram-positive peritonitis had the best clinical outcomes.<sup>23</sup> In general, their clinical behaviour is similar to peritonitis episodes caused by single gram-positive organisms, and the aetiology may well be touch contamination. Conservative management with antibiotic therapy is often effective without catheter removal.<sup>363</sup> In other words, the higher hospitalisation rate, surgical intervention requirement and mortality of polymicrobial peritonitis appear to be limited to those episodes with isolation of enteric bacteria, fungus and/or *E. faecium*.<sup>364</sup>

### Fungal peritonitis

- We recommend immediate catheter removal when fungi are identified in PD effluent (1C).
- We suggest that treatment with an appropriate antifungal agent be continued for at least 2 weeks after catheter removal (2C).

Treatment failure and mortality rates of fungal peritonitis remain high, despite a slightly improved outcome with early catheter removal based on observational studies.<sup>365,366</sup>

Because identification of the fungi can take time, diagnosis of fungal peritonitis can be supported by the Gram stain. Prompt empirical treatment with antifungal therapy should be initiated even based on the Gram stain. The subsequent choice of antifungal regimen depends on the correct identification of the pathogens and their susceptibility profiles. *Candida albicans* and *Candida parapsilosis* are the most common pathogens, although the frequency of the latter is reported to exceed that of *C. albicans* species.<sup>111</sup> The antifungal treatment of choice for *C. albicans* is usually fluconazole, whereas other *Candida* organisms sometimes require an echinocandin (caspofungin, micafungin or anidulafungin) or voriconazole.<sup>367,215</sup> The route of echinocandins administration should be intravenous<sup>243</sup> because of the concern that PD fluid significantly impairs the activity of echinocandins against *Candida* species biofilm.<sup>368</sup> Voriconazole administration is preferably oral, because of the concern with accumulation of the intravenous vehicle cyclodextrin in dialysis patients. Furthermore, oral voriconazole has been shown to quickly achieve good peritoneal concentration with minimal peritoneal clearance.<sup>369</sup>

*Aspergillus* peritonitis treatment requires intravenous amphotericin B or new azole derivatives such as voriconazole, posaconazole or isavuconazole.<sup>370</sup> Drug-drug interactions during therapy with these new azoles require careful review of patient's concurrent medication use. Figure 9 is a proposed algorithms for choosing antifungal treatment.

Despite the availability of newer antifungal drugs, catheter removal remains the cornerstone of managing fungal peritonitis. Previous studies have reported a mortality of 50%<sup>110</sup> to 91%<sup>109</sup> among patients without catheter removal; the fatality rate is about two to three times that of those who are treated with catheter removal. Furthermore, early catheter removal should be encouraged as this has been reported to be associated with lower mortality and a better chance of resuming PD.<sup>110,366</sup> The benefit of early versus late catheter removal, on the other hand, was not confirmed in another study in Australia, where late removal was defined as more than 5 days after diagnosis of fungal peritonitis.<sup>371</sup> In view of the high biofilm production observed in fungal peritonitis,<sup>367</sup> we recommend immediate catheter removal as the best option to reduce the high mortality of fungal peritonitis.

Although there are insufficient data regarding the antifungal treatment duration, it should be continued for at least 2 weeks after catheter removal, and sometimes up to 4 weeks.<sup>109</sup> Irrespective of the treatment duration, catheter reinsertion and resumption of PD have been reported after a median period of 15 weeks in less than one-third of cases.<sup>365</sup>

### Culture-negative peritonitis

Reported risk factors for culture-negative peritonitis include recent antibiotic usage and improper culture technique.<sup>37,38,372</sup>

Data regarding the treatment outcomes of culture-negative peritonitis based on large case series were in general favourable. Many culture-negative peritonitis episodes resolved with medical therapy; the cure rate by antibiotics alone ranged from 67.5% to 82.3%.<sup>37,373,374</sup> For culture-negative peritonitis episodes which improve promptly with antibiotics, they are probably caused by gram-positive organisms and initial therapy should be continued (Figure 10). Duration of therapy should be limited to 2 weeks because treatment outcomes were similar between episodes with treatment durations of 2 weeks and 3 weeks.<sup>373</sup>

On the other hand, for patients whose PD effluent yields no growth after 3 days, a repeat WBC count with differential should be obtained, together with special culture request to exclude unusual organisms such as mycobacteria, nocardia, filamentous fungus and other fastidious bacteria. The results of recent or concurrent exit-site cultures might not provide adequate information to adjust the antibiotic based on published study correlating the organisms between exit-site infection and subsequent peritonitis.<sup>19</sup> Although there was a six-fold higher hazard

of peritonitis (around 20% being culture negative) within 30 days of exit-site infection, the respective causative organisms were often different.<sup>19</sup> Reported regimens for culture-negative peritonitis with suboptimal initial responses include a combination of ampicillin-sulbactam and amikacin, which demonstrated a response in 80% of 10 cases.<sup>187</sup>


PD catheter removal was required in around 10% of cases of culture-negative peritonitis.<sup>37,373</sup>

### Tuberculous peritonitis

- We suggest antituberculous therapy, instead of PD catheter removal, as the primary treatment of peritonitis caused by *Mycobacterium tuberculosis* (2C).

The presenting symptoms of tuberculous peritonitis are abdominal pain in 89% and fever in 81% of PD patients.<sup>375</sup> Tuberculous peritonitis could mimic bacterial peritonitis, leading to delay in appropriate treatment. Difficulty in recognising the diagnosis is the common presentation with polymorphonuclear cell predominant pleocytosis of dialysate during the initial phase of the disease, as reported in 65 to 78% of published cases.<sup>375-377</sup> Since requests for cultures for acid-fast bacilli are often delayed and the times for the cultures (current gold standard for diagnosis) to become positive are lengthy, the mean time from presentation to initiation of treatment of tuberculous peritonitis was 6.7 weeks in a review of 52 PD patients.<sup>378</sup> Measurement of adenosine deaminase in the peritoneal dialysate is a screening test but its specificity is not sufficiently high enough. Another reliable and more rapid adjunctive tool is PCR analysis to detect *M. tuberculosis* DNA,<sup>377,379</sup> although its sensitivity is insufficient to exclude tuberculosis.

The recommended dosages of drugs for treating tuberculous peritonitis in PD patients are depicted in Table 8. In general, initial drug treatment of pan-susceptible tuberculosis consists of four drugs for a total of 2 months followed by two drugs (isoniazid and rifampicin) given for at least a total of 12 months. There is a paucity of scientific evidence regarding the optimal drug dosage of tuberculous peritonitis treatment, but preliminary pharmacokinetics data show no need for dose adjustment of isoniazid and pyrazinamide in PD patients whose peritoneal fluid drug concentrations were maintained above the MICs for *M. tuberculosis*.<sup>380</sup> However, oral rifampicin might not be able to achieve satisfactory peritoneal fluid concentration.<sup>380</sup> Furthermore, PD patients started on oral rifampicin should be monitored for blood pressure control because of its potent inducer activity of hepatic cytochrome p450 leading to reduced levels of most antihypertensive agents (including amlodipine and metoprolol).<sup>180</sup> With the need for prolonged treatment, PD patients should be monitored for side effects such as retrobulbar neuritis related to ethambutol and isoniazid-induced neuropathy characterised by paresthesia and burning symptoms of extremities.<sup>381</sup> Ethambutol should be



**Figure 9.** Management algorithm for fungal peritonitis.

omitted or suspended if or when *M. tuberculosis* is known to be fully susceptible to other agents.


Many patients respond to anti-tuberculous therapy without catheter removal, although an attributable mortality of 15% has been reported.<sup>378</sup> In a scoping review 216 cases of *Mycobacterium tuberculosis* peritonitis in patients on PD,<sup>377</sup> catheter removal occurred in 52.4% of cases. Most of the cases requiring catheter removal were empirical, based on the rationale of failed treatment of 'bacterial' peritonitis before the diagnosis of tuberculous peritonitis was recognised. PD catheter removal was not associated with an increased probability of survival.<sup>377</sup> Early diagnosis is essential in the management of tuberculous peritonitis complicating PD because treatment delay is the only significant factor predicting mortality.

### Non-tuberculous mycobacterial peritonitis

- We suggest that Ziehl–Neelsen staining for acid-fast bacilli be requested when there is a clinical suggestion of non-tuberculous mycobacterial (NTM) peritonitis, including persistent culture-negative peritonitis (2D).
- We suggest that NTM peritonitis be treated with both effective antibiotics and catheter removal (2D).

*Mycobacterium fortuitum* and *chelonae* account for the majority of NTM peritonitis episodes.<sup>383–385</sup> Published case series have highlighted the pitfall of late NTM diagnosis, with a median delay ranging from 6 to 30 days.<sup>384,386</sup> Given the chance for these organisms to be mistaken for diphtheroids or *Corynebacterium* species on Gram stain, examination for acid-fast bacilli by Ziehl–Neelsen staining should be requested on peritoneal dialysate fluid. Negative cultures with persistent symptoms of peritonitis, often with concomitant exit-site infection, should also raise concern for the possibility of NTM infection. When suspected, the laboratory should be notified to prolong the incubation times of standard bacterial cultures to 7 days, in addition to using specific mycobacterial culture media.<sup>386</sup>

There are few data on the optimal treatment duration of antibiotic therapy for NTM peritonitis. An observational study of 27 consecutive episodes showed a low complete cure rate of 14.8% despite treatment durations of more than 2 months.<sup>384</sup> Most experts recommend two agents to which the isolate is susceptible for a minimum of 6 weeks.<sup>387</sup> Antibiotic therapy should be guided by the isolated species (hence the susceptibility pattern) and then in vitro antimicrobial sensitivities. Microbiologists or infectious disease specialists should be consulted in the selection of combination antimycobacterial therapy. The majority of NTM are



**Figure 10.** Management algorithm for culture-negative peritonitis.

**Table 8.** Drug dosing recommendations for treatment of tuberculous peritonitis.

Drug	Dosing
Isoniazid	Oral 5 mg/kg daily (maximum dose 300 mg daily) <sup>382</sup>
Rifampicin	Oral 450 mg daily for BW <50 kg; 600 mg daily for BW ≥50 kg
Pyrazinamide	Oral 30 mg/kg three times weekly
Levofloxacin	Oral 250 mg every 48 h
Ofloxacin	Oral 200 mg daily <sup>375</sup>
Ethambutol	Oral 15 mg/kg every 48 h <sup>382</sup>
Moxifloxacin	Oral 400 mg daily <sup>234,235</sup>
Pyridoxine	Oral 50–100 mg daily <sup>375,382</sup>

BW: body weight.

sensitive to amikacin, but in vivo resistance to clarithromycin often occurs due to active inducible macrolide resistance genes.<sup>384,388</sup> Although aminoglycoside trough level monitoring for PD peritonitis treatment is not mandatory (see above), therapeutic drug monitoring might be considered if amikacin is used, given the prolonged drug treatment requirement for NTM.<sup>389</sup> Based on the principle of managing NTM, surgical source control or removal of the infected source is the recommended approach. In addition

to our suggestion to remove PD catheters for the treatment of NTM, previous studies showed that less than 20% of patients could be resumed on PD.<sup>383–386,390</sup>

## Future research

Like all evidence-based guidelines, the current 2022 ISPD guideline is limited by the available evidence for monitoring and managing peritonitis.

In particular, evidence is lacking on how best to reduce culture-negative peritonitis or peritonitis episodes without identification of organisms. Studies examining novel diagnostic tools other than traditional microbiological culture are under way. Diagnostic difficulty with microbiological culture test alone has spurred interest in proteomics research.<sup>391</sup> These new biomarkers can potentially serve the prognostic purpose, and further guideline treatment decisions. Pathogen-specific immune fingerprints are promising clinical applications,<sup>154,155,392</sup> although machine learning application remains underutilised in nephrology research.<sup>393,394</sup>

There is a paucity of research on IP drug dosing for APD, as opposed to CAPD. Further pharmacokinetic data are needed for managing peritonitis in patients on APD because it is not always feasible to convert such patients

to CAPD. Furthermore, randomised controlled trials are needed to compare the efficacy and safety of different anti-biotic regimens.

We also recognise the need of better strategies to prevent peritonitis. Notwithstanding the recognition of risk factors of peritonitis from observational data including international results from PDOPPS,<sup>31</sup> lack of interventional randomised controlled trials often lowers the level of evidence for the proposed recommendations. Clinical trials are also required in order to assess the benefit and harm of antibiotic prophylaxis before gastroscopy and dental procedures. Patients' perspectives and understandings of peritonitis should be addressed. While recommendations for swimming, water sports or saunas have been published by the Global Renal Exercise Network,<sup>39,5</sup> many remain supported by a limited evidence base. Research in this area would benefit PD patients.

### Authors' note

Philip Kam-Tao Li and David W Johnson are Co-Chairs of the ISPD Peritonitis Guidelines Working Group.








### Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

### Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

### ORCID iDs

Philip Kam-Tao Li  <https://orcid.org/0000-0001-9879-8388>  
 Kai Ming Chow  <https://orcid.org/0000-0001-5310-5197>  
 Yeoungjee Cho  <https://orcid.org/0000-0002-2996-8934>  
 Talerngsak Kanjanabuch  <https://orcid.org/0000-0002-6495-0430>  
 Isaac Teitelbaum  <https://orcid.org/0000-0002-7526-6837>  
 Xueqing Yu  <https://orcid.org/0000-0001-8624-744X>  
 David W Johnson  <https://orcid.org/0000-0001-5491-3460>

### References

- Davenport A. Peritonitis remains the major clinical complication of peritoneal dialysis: the London, UK, peritonitis audit 2002-2003. *Perit Dial Int* 2009; 29(3): 297-302.
- Brown MC, Simpson K, Kerssens JJ, et al. Peritoneal dialysis-associated peritonitis rates and outcomes in a national cohort are not improving in the post-millennium (2000-2007). *Perit Dial Int* 2011; 31(6): 639-650.
- Manera KE, Johnson DW, Craig JC, et al. Establishing a core outcome set for peritoneal dialysis: report of the SONG-PD (Standardized Outcomes In Nephrology-Peritoneal Dialysis) consensus workshop. *Am J Kidney Dis* 2020; 75(3): 404-412.
- Ghali JR, Bannister KM, Brown FG, et al. Microbiology and outcomes of peritonitis in Australian peritoneal dialysis patients. *Perit Dial Int* 2011; 31(6): 651-662.
- Boudville N, Kemp A, Clayton P, et al. Recent peritonitis associates with mortality among patients treated with peritoneal dialysis. *J Am Soc Nephrol* 2012; 23(8): 1398-1405.
- Cho Y, Badve SV, Hawley CM, et al. Peritoneal dialysis outcomes after temporary haemodialysis transfer for peritonitis. *Nephrol Dial Transplant* 2014; 29(10): 1940-1947.
- Hsieh YP, Chang CC, Wen YK, et al. Predictors of peritonitis and the impact of peritonitis on clinical outcomes of continuous ambulatory peritoneal dialysis patients in Taiwan-10 years' experience in a single center. *Perit Dial Int* 2014; 34(1): 85-94.
- Keane WF, Everett ED, Golper TA, et al. Peritoneal dialysis-related peritonitis treatment recommendations. 1993 update. The ad hoc advisory committee on peritonitis management. International society for peritoneal dialysis. *Perit Dial Int* 1993; 13(1): 14-28.
- Keane WF, Alexander SR, Bailie GR, et al. Peritoneal dialysis-related peritonitis treatment recommendations: 1996 update. *Perit Dial Int* 1996; 16(6): 557-573.
- Keane WF, Bailie GR, Boeschoten E, et al. Adult peritoneal dialysis-related peritonitis treatment recommendations: 2000 update. *Perit Dial Int* 2000; 20(4): 396-411.
- Piraino B, Bailie GR, Bernardini J, et al. Peritoneal dialysis-related infections recommendations: 2005 update. *Perit Dial Int* 2005; 25(2): 107-131.
- Li PK, Szeto CC, Piraino B, et al. Peritoneal dialysis-related infections recommendations: 2010 update. *Perit Dial Int* 2010; 30(4): 393-423.
- Li PK, Szeto CC, Piraino B, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment. *Perit Dial Int* 2016; 36(5): 481-508.
- Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. *BMJ* 2004; 328(7454): 1490.
- Warady BA, Bakkaloglu S, Newland J, et al. Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update. *Perit Dial Int*. 2012; 32(Suppl 2): S32-S86.
- Sahlawi MA, Wilson G, Stallard B, et al. Peritoneal dialysis-associated peritonitis outcomes reported in trials and observational studies: a systematic review. *Perit Dial Int* 2020; 40(2): 132-140.
- Szeto CC, Li PK, Johnson DW, et al. ISPD catheter-related infection recommendations: 2017 Update. *Perit Dial Int* 2017; 37(2): 141-154.
- Lloyd A, Tangri N, Shafer LA, et al. The risk of peritonitis after an exit site infection: a time-matched, case-control study. *Nephrol Dial Transplant* 2013; 28(7): 1915-1921.
- van Diepen AT, Tomlinson GA and Jassal SV. The association between exit site infection and subsequent peritonitis among peritoneal dialysis patients. *Clin J Am Soc Nephrol* 2012; 7(8): 1266-1271.
- Gupta B, Bernardini J and Piraino B. Peritonitis associated with exit site and tunnel infections. *Am J Kidney Dis* 1996; 28(3):415-419.

21. Kern EO, Newman LN, Cacho CP, et al. Abdominal catastrophe revisited: the risk and outcome of enteric peritoneal contamination. *Perit Dial Int* 2002; 22(3): 323–334.
22. Shrestha BM, Brown P and Wilkie M. Surgical peritonitis in patients on peritoneal dialysis. *Perit Dial Int* 2008; 28(4): 331–334.
23. Barraclough K, Hawley CM, McDonald SP, et al. Polymicrobial peritonitis in peritoneal dialysis patients in Australia: predictors, treatment, and outcomes. *Am J Kidney Dis* 2010; 55(1): 121–131.
24. de Freitas DG and Gokal R. Sterile peritonitis in the peritoneal dialysis patient. *Perit Dial Int* 2005; 25(2): 146–151.
25. Ma TK, Chow KM, Kwan BC, et al. Peritonitis before peritoneal dialysis training: analysis of causative organisms, clinical outcomes, risk factors, and long-term consequences. *Clin J Am Soc Nephrol* 2016; 11(7): 1219–1226.
26. Balzer MS, Claus R, Haller H, et al. Are ISPD guidelines on peritonitis diagnosis too narrow? A 15-year retrospective single-center cohort study on PD-associated peritonitis accounting for untrained patients. *Perit Dial Int* 2019; 39(3): 220–228.
27. Crabtree JH, Shrestha BM, Chow KM, et al. Creating and maintaining optimal peritoneal dialysis access in the adult patient: 2019 update. *Perit Dial Int* 2019; 39(5): 414–436.
28. Nataatmadja M, Cho Y and Johnson DW. Continuous quality improvement initiatives to sustainably reduce peritoneal dialysis-related infections in Australia and New Zealand. *Perit Dial Int*. 2016; 36(5): 472–477.
29. Marshall MWG and Verger C. Peritoneal dialysis associated peritonitis rate – validation of a simplified formula. *Bull Dial Domic* 2012; 4(4): 245–257.
30. Kopriva-Altfahrt G, Konig P, Mundle M, et al. Exit-site care in Austrian peritoneal dialysis centers – a nationwide survey. *Perit Dial Int* 2009; 29(3): 330–339.
31. Perl J, Fuller DS, Bieber BA, et al. Peritoneal dialysis-related infection rates and outcomes: results from the peritoneal dialysis outcomes and practice patterns study (PDOPPS). *Am J Kidney Dis* 2020; 76(1): 42–53.
32. Fang W, Qian J, Lin A, et al. Comparison of peritoneal dialysis practice patterns and outcomes between a Canadian and a Chinese centre. *Nephrol Dial Transplant* 2008; 23(12): 4021–4028.
33. Ye H, Zhou Q, Fan L, et al. The impact of peritoneal dialysis-related peritonitis on mortality in peritoneal dialysis patients. *BMC Nephrol* 2017; 18(1): 186.
34. Tian Y, Xie X, Xiang S, et al. Risk factors and outcomes of high peritonitis rate in continuous ambulatory peritoneal dialysis patients: a retrospective study. *Medicine (Baltimore)* 2016; 95(49): e5569.
35. Marshall MR. A systematic review of peritoneal dialysis-related peritonitis rates over time from national or regional population-based registries and databases. *Perit Dial Int* 2022; 42(1): 39–47.
36. Brown F, Liu WJ, Kotsanas D, et al. A quarter of a century of adult peritoneal dialysis-related peritonitis at an Australian medical center. *Perit Dial Int*. 2007; 27(5): 565–574.
37. Szeto CC, Wong TY, Chow KM, et al. The clinical course of culture-negative peritonitis complicating peritoneal dialysis. *Am J Kidney Dis* 2003; 42(3): 567–574.
38. Fahim M, Hawley CM, McDonald SP, et al. Culture-negative peritonitis in peritoneal dialysis patients in Australia: predictors, treatment, and outcomes in 435 cases. *Am J Kidney Dis* 2010; 55(4): 690–697.
39. Sewell DL, Golper TA, Hulman PB, et al. Comparison of large volume culture to other methods for isolation of microorganisms from dialysate. *Perit Dial Int* 1990; 10(1): 49–52.
40. Wikdahl AM, Engman U, Stegmayr BG, et al. One-dose cefuroxime i.v. and i.p. reduces microbial growth in PD patients after catheter insertion. *Nephrol Dial Transplant*. 1997; 12(1): 157–160.
41. Lye WC, Lee EJ and Tan CC. Prophylactic antibiotics in the insertion of tenckhoff catheters. *Scand J Urol Nephrol* 1992; 26(2): 177–180.
42. Gadallah MF, Ramdeen G, Mignone J, et al. Role of preoperative antibiotic prophylaxis in preventing postoperative peritonitis in newly placed peritoneal dialysis catheters. *Am J Kidney Dis* 2000; 36(5): 1014–1019.
43. Campbell D, Mudge DW, Craig JC, et al. Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients. *Cochrane Database Syst Rev* 2017; 4: CD004679.
44. Boudville N, Johnson DW, Zhao J, et al. Regional variation in the treatment and prevention of peritoneal dialysis-related infections in the peritoneal dialysis outcomes and practice patterns study. *Nephrol Dial Transplant* 2019; 34(12): 2118–2126.
45. Lin J, Ye H, Li J, et al. Prevalence and risk factors of exit-site infection in incident peritoneal dialysis patients. *Perit Dial Int* 2020; 40(2): 164–170.
46. Yap DY, Chu WL, Ng F, et al. Risk factors and outcome of contamination in patients on peritoneal dialysis—a single-center experience of 15 years. *Perit Dial Int* 2012; 32(6): 612–616.
47. Bender FH, Bernardini J and Piraino B. Prevention of infectious complications in peritoneal dialysis: best demonstrated practices. *Kidney Int Suppl* 2006; 70: S44–S54.
48. Jaroenpattawut B, Poonvivatchaikarn U, Kanjanabuch T, et al. Phytopathogen transmitted from plant to human causing peritoneal dialysis-associated peritonitis. *Perit Dial Int*. Epub ahead of print 3 September 2021. DOI: 10.1177/08968608211048063.
49. Sankar A, Swanson KM, Zhou J, et al. Association of fluor-quinolone prescribing rates with black box warnings from the US food and drug administration. *JAMA Netw Open* 2021; 4(12): e2136662.
50. Yip T, Tse KC, Lam MF, et al. Risks and outcomes of peritonitis after flexible colonoscopy in CAPD patients. *Perit Dial Int* 2007; 27(5): 560–564.
51. Machuca E, Ortiz AM and Rabagliati R. Streptococcus viridans-associated peritonitis after gastroscopy. *Adv Perit Dial* 2005; 21: 60–62.
52. Poortvliet W, Selten HP, Raasveld MH, et al. CAPD peritonitis after colonoscopy: follow the guidelines. *Neth J Med* 2010; 68(9): 377–378.



53. Holley JL, Udekwu A, Rault R, et al. The risks of laparoscopic cholecystectomy in CAPD compared with hemodialysis patients: a study of ten patients. *Perit Dial Int* 1994; 14(4): 395–396.
54. Ekici Y, Karakayali F, Yagmurdu MC, et al. Laparoscopic cholecystectomy in patients undergoing continuous ambulatory peritoneal dialysis: a case-control study. *Surg Laparosc Endosc Percutan Tech* 2009; 19(2): 101–105.
55. Gweon TG, Jung SH, Kim SW, et al. Risk factors for peritonitis in patients on continuous ambulatory peritoneal dialysis who undergo colonoscopy: a retrospective multicentre study. *BMC Gastroenterol* 2019; 19(1): 175.
56. Al-Hwiesh AK, Abdul-Rahman IS, Hussameldeen MA, et al. Colonoscopy in automated peritoneal dialysis patients: value of prophylactic antibiotics: a prospective study on a single antibiotic. *Int J Artif Organs* 2017; 40(10): 550–557.
57. Fan PY, Chan MJ, Lin SH, et al. Prophylactic antibiotic reduces the risk of peritonitis after invasive gynecologic procedures. *Perit Dial Int* 2019; 39(4): 356–361.
58. Wu HH, Li IJ, Weng CH, et al. Prophylactic antibiotics for endoscopy-associated peritonitis in peritoneal dialysis patients. *PLoS One* 2013; 8(8): e71532.
59. Chan GC, Wong SH, Ng JK, et al. Risk of peritonitis after gastroscopy in peritoneal dialysis patients. *Perit Dial Int*. Epub ahead of print 25 May 2021. DOI: 10.1177/089686082111018608.
60. Kim JS, Jung E, Kang SH, et al. Safety of endoscopy in peritoneal dialysis patients. *Clin Transl Gastroenterol* 2021; 12(7): e00379.
61. Suzuki Y, Mizuno M, Kojima H, et al. Oral antibiotics are effective for preventing colonoscopy-associated peritonitis as a preemptive therapy in patients on peritoneal dialysis. *Intern Med* 2021; 60(3): 353–356.
62. Takkavatakarn K, Aniwani S, Kamjohnjiraphunt N, et al. Whether antibiotic prophylaxis is necessary in peritoneal dialysis patients undergoing elective colonoscopy with postprocedural peritoneal lavage. *Kidney Int Rep* 2020; 5(10): 1783–1787.
63. Chaudhry RI, Chopra T, Fissell R, et al. Strategies to prevent peritonitis after procedures: our opinions. *Perit Dial Int* 2019; 39(4): 315–319.
64. Alobaidi HM, Coles GA, Davies M, et al. Host defence in continuous ambulatory peritoneal dialysis: the effect of the dialysate on phagocyte function. *Nephrol Dial Transplant* 1986; 1(1): 16–21.
65. Duwe AK, Vas SI and Weatherhead JW. Effects of the composition of peritoneal dialysis fluid on chemiluminescence, phagocytosis, and bactericidal activity in vitro. *Infect Immun*. 1981; 33(1): 130–135.
66. Gould AL, Chahla E and Hachem C. Peritonitis following endoscopy in a patient on peritoneal dialysis with a discussion of current recommendations on antibiotic prophylaxis. *Case Rep Gastroenterol* 2015; 9(3): 302–306.
67. Nadeau-Fredette AC and Bargman JM. Gastroscopy-related peritonitis in peritoneal dialysis patients. *Perit Dial Int* 2014; 34(6): 667–670.
68. Figueiredo AE, Bernardini J, Bowes E, et al. A syllabus for teaching peritoneal dialysis to patients and caregivers. *Perit Dial Int* 2016; 36(6): 592–605.
69. Bernardini J, Price V, Figueiredo A, et al. Peritoneal dialysis patient training, 2006. *Perit Dial Int* 2006; 26(6): 625–632.
70. Nataatmadja M, Zhao J, McCullough K, et al. International peritoneal dialysis training practices and the risk of peritonitis. *Nephrol Dial Transplant*. Epub ahead of print 11 October 2021. DOI: 10.1093/ndt/gfab298. PMID: 34634100.
71. Rope R, Nanayakkara N, Wazil A, et al. Expanding CAPD in low-resource settings: a distance learning approach. *Perit Dial Int* 2018; 38(5): 343–348.
72. Yi C, Guo Q, Lin J, et al. Patient-doctor contact interval and clinical outcomes in continuous ambulatory peritoneal dialysis patients. *Am J Nephrol* 2017; 45(4): 346–352.
73. Ellis EN, Blaszkak C, Wright S, et al. Effectiveness of home visits to pediatric peritoneal dialysis patients. *Perit Dial Int* 2012; 32(4): 419–423.
74. Martino F, Adibelli Z, Mason G, et al. Home visit program improves technique survival in peritoneal dialysis. *Blood Purif* 2014; 37(4): 286–290.
75. Bechade C, Guillouet S, Verger C, et al. Centre characteristics associated with the risk of peritonitis in peritoneal dialysis: a hierarchical modelling approach based on the data of the French language peritoneal dialysis registry. *Nephrol Dial Transplant* 2017; 32(6): 1018–1023.
76. Russo R, Manili L, Tiraboschi G, et al. Patient re-training in peritoneal dialysis: Why and when it is needed. *Kidney Int Suppl* 2006; 70(103): S127–S132.
77. Hu Y, Xu L, Wang X, et al. Changes before and after COVID-19 pandemic on the personal hygiene behaviors and incidence of peritonitis in peritoneal-dialysis patients: a multi-center retrospective study. *Int Urol Nephrol* 2021; 54(2): 411–419.
78. Dong J and Chen Y. Impact of the bag exchange procedure on risk of peritonitis. *Perit Dial Int* 2010; 30(4): 440–447.
79. Piraino B, Bernardini J, Brown E, et al. ISPD position statement on reducing the risks of peritoneal dialysis-related infections. *Perit Dial Int* 2011; 31(6): 614–630.
80. Chang JH, Oh J, Park SK, et al. Frequent patient retraining at home reduces the risks of peritoneal dialysis-related infections: a randomised study. *Sci Rep* 2018; 8(1): 12919.
81. Ljungman S, Jensen JE, Paulsen D, et al. Retraining for prevention of peritonitis in peritoneal dialysis patients: a randomized controlled trial. *Perit Dial Int* 2020; 40(2): 141–152.
82. Xu Y, Zhang Y, Yang B, et al. Prevention of peritoneal dialysis-related peritonitis by regular patient retraining via technique inspection or oral education: a randomized controlled trial. *Nephrol Dial Transplant* 2020; 35(4): 676–686.
83. Broughton A, Verger C and Goffin E. Pets-related peritonitis in peritoneal dialysis: companion animals or trojan horses? *Semin Dial* 2010; 23(3): 306–316.
84. Chow KM, Pang WF, Szeto CC, et al. Playing cat and mouse with a gram-negative organism causing peritonitis. *Perit Dial Int* 2010; 30(6): 662–663.

85. Mirzai S, Rifai AO, Tidrick A, et al. A case report on *Pasteurella multocida* peritoneal dialysis-associated peritonitis: when cats think medical equipment are toys. *Case Rep Nephrol* 2019; 2019: 5150695.
86. Paul RV and Rostand SG. Cat-bite peritonitis: *Pasteurella multocida* peritonitis following feline contamination of peritoneal dialysis tubing. *Am J Kidney Dis* 1987; 10(4): 318–319.
87. Nishina M, Yanagi H, Koizumi M, et al. *Pasteurella multocida* peritonitis associated with a cat in a peritoneal dialysis patient using an automated cyclor device. *CEN Case Rep* 2012; 1(2): 73–76.
88. Makin AJ, Cartwright KA and Banks RA. Keeping the cat out of the bag: a hazard in continuous ambulatory peritoneal dialysis. *BMJ* 1991; 303(6817): 1610–1611.
89. Sedlacek M, Cotter JG, Suriawinata AA, et al. Mucormycosis peritonitis: more than 2 years of disease-free follow-up after posaconazole salvage therapy after failure of liposomal amphotericin B. *Am J Kidney Dis* 2008; 51(2): 302–306.
90. Freeman AF, Zheng XT, Lane JC, et al. *Pasteurella aerogenes* hamster bite peritonitis. *Pediatr Infect Dis J* 2004; 23(4): 368–370.
91. Campos A, Taylor JH and Campbell M. Hamster bite peritonitis: *Pasteurella pneumotropica* peritonitis in a dialysis patient. *Pediatr Nephrol* 2000; 15(1-2): 31–32.
92. London RD and Bottone EJ. *Pasteurella multocida*: zoonotic cause of peritonitis in a patient undergoing peritoneal dialysis. *Am J Med.* 1991; 91(2): 202–204.
93. Adapa S, Naramala S, Madhira BR, et al. Peritonitis secondary to uncommon gram-negative *Coccobacillus* transmitted from a cat in a patient on peritoneal dialysis. *J Investig Med High Impact Case Rep* 2019; 7: 2324709619895165.
94. Abebe M, Laveglia C, George S, et al. Pet-related peritonitis and its prevention in peritoneal dialysis: a case study. *Perit Dial Int* 2014; 34(4): 466–468.
95. Davies SJ, Zhao J, Morgenstern H, et al. Low serum potassium levels and clinical outcomes in peritoneal dialysis-international results from PDOPPS. *Kidney Int Rep* 2021; 6(2): 313–324.
96. Al Sahlawi M, Zhao J, McCullough K, et al. Variation in peritoneal dialysis-related peritonitis outcomes in the peritoneal dialysis outcomes and practice patterns study (PDOPPS). *Am J Kidney Dis* 2021; 79(1): 45–55.
97. Su CY, Pei J, Lu XH, et al. Gastrointestinal symptoms predict peritonitis rates in CAPD patients. *Clin Nephrol* 2012; 77(4): 267–274.
98. Chuang YW, Shu KH, Yu TM, et al. Hypokalaemia: an independent risk factor of Enterobacteriaceae peritonitis in CAPD patients. *Nephrol Dial Transplant* 2009; 24(5): 1603–1608.
99. Ribeiro SC, Figueiredo AE, Barretti P, et al. Low serum potassium levels increase the infectious-caused mortality in peritoneal dialysis patients: a propensity-matched score study. *PLoS One* 2015; 10(6): e0127453.
100. Liu D, Lin Y, Gong N, et al. Degree and duration of hypokalemia associated with peritonitis in patients undergoing peritoneal dialysis. *Int J Clin Pract* 2021; 75(8): e14188.
101. Virojanawat M, Puapatanakul P, Chuengsamarn P, et al. Hypokalemia in peritoneal dialysis patients in Thailand: the pivotal role of low potassium intake. *Int Urol Nephrol* 2021; 53(7): 1463–1471.
102. Szeto CC, Chow KM, Kwan BC, et al. Hypokalemia in Chinese peritoneal dialysis patients: prevalence and prognostic implication. *Am J Kidney Dis* 2005; 46(1): 128–135.
103. Afsar B, Elsurur R, Bilgic A, et al. Regular lactulose use is associated with lower peritonitis rates: an observational study. *Perit Dial Int* 2010; 30(2): 243–246.
104. Noppakun K, Narongchai T, Chaiwarith R, et al. Comparative effectiveness of lactulose and sennosides for the prevention of peritoneal dialysis-related peritonitis: an open-label, randomized, active-controlled trial. *Ann Med* 2021; 53(1): 365–374.
105. Perez-Fontan M, Machado Lopes D, Garcia Enriquez A, et al. Inhibition of gastric acid secretion by H2 receptor antagonists associates a definite risk of enteric peritonitis and infectious mortality in patients treated with peritoneal dialysis. *PLoS One* 2016; 11(2): e0148806.
106. Maeda S, Yamaguchi M, Maeda K, et al. Proton pump inhibitor use increases the risk of peritonitis in peritoneal dialysis patients. *PLoS One* 2019; 14(11): e0224859.
107. Nessim SJ, Tomlinson G, Bargman JM, et al. Gastric acid suppression and the risk of enteric peritonitis in peritoneal dialysis patients. *Perit Dial Int* 2008; 28(3): 246–251; discussion 236–247.
108. Zhong HJ, Lin D, Lu ZY, et al. Use of gastric-acid suppressants may be a risk factor for enteric peritonitis in patients undergoing peritoneal dialysis: a meta-analysis. *J Clin Pharm Ther* 2019; 44(2): 209–215.
109. Wang AY, Yu AW, Li PK, et al. Factors predicting outcome of fungal peritonitis in peritoneal dialysis: analysis of a 9-year experience of fungal peritonitis in a single center. *Am J Kidney Dis* 2000; 36(6): 1183–1192.
110. Goldie SJ, Kiernan-Triddle L, Torres C, et al. Fungal peritonitis in a large chronic peritoneal dialysis population: a report of 55 episodes. *Am J Kidney Dis* 1996; 28(1): 86–91.
111. Auricchio S, Giovenzana ME, Pozzi M, et al. Fungal peritonitis in peritoneal dialysis: a 34-year single centre evaluation. *Clin Kidney J* 2018; 11(6): 874–880.
112. Chou CY, Kao MT, Kuo HL, et al. Gram-negative and polymicrobial peritonitis are associated with subsequent fungal peritonitis in CAPD patients. *Perit Dial Int* 2006; 26(5): 607–608.
113. Robitaille P, Merouani A, Clermont MJ, et al. Successful antifungal prophylaxis in chronic peritoneal dialysis: a pediatric experience. *Perit Dial Int* 1995; 15(1): 77–79.
114. Zaruba K, Peters J and Jungbluth H. Successful prophylaxis for fungal peritonitis in patients on continuous ambulatory peritoneal dialysis: six years' experience. *Am J Kidney Dis* 1991; 17(1): 43–46.
115. Wong PN, Lo KY, Tong GM, et al. Prevention of fungal peritonitis with nystatin prophylaxis in patients receiving CAPD. *Perit Dial Int* 2007; 27(5): 531–536.

116. Thodis E, Vas SI, Bargman JM, et al. Nystatin prophylaxis: its inability to prevent fungal peritonitis in patients on continuous ambulatory peritoneal dialysis. *Perit Dial Int* 1998; 18(6): 583–589.
117. Williams PF, Moncrieff N and Marriott J. No benefit in using nystatin prophylaxis against fungal peritonitis in peritoneal dialysis patients. *Perit Dial Int* 2000; 20(3): 352–353.
118. Davenport A and Wellsted D. Pan Thames Renal Audit Peritoneal Dialysis G. Does antifungal prophylaxis with daily oral fluconazole reduce the risk of fungal peritonitis in peritoneal dialysis patients? The pan Thames renal audit. *Blood Purif* 2011; 32(3): 181–185.
119. Lopes K, Rocha A, Rodrigues A, et al. Long-term peritoneal dialysis experience: quality control supports the use of fluconazole to prevent fungal peritonitis. *Int J Artif Organs* 2013; 36(7): 484–488.
120. Kumar KV, Mallikarjuna HM, Gokulnath, et al. Fungal peritonitis in continuous ambulatory peritoneal dialysis: the impact of antifungal prophylaxis on patient and technique outcomes. *Indian J Nephrol* 2014; 24(5): 297–301.
121. Lo WK, Chan CY, Cheng SW, et al. A prospective randomized control study of oral nystatin prophylaxis for *Candida* peritonitis complicating continuous ambulatory peritoneal dialysis. *Am J Kidney Dis* 1996; 28(4): 549–552.
122. Restrepo C, Chacon J and Manjarres G. Fungal peritonitis in peritoneal dialysis patients: successful prophylaxis with fluconazole, as demonstrated by prospective randomized control trial. *Perit Dial Int* 2010; 30(6): 619–625.
123. Shukla A, Abreu Z and Bargman JM. Streptococcal PD peritonitis—a 10-year review of one centre’s experience. *Nephrol Dial Transplant* 2006; 21(12): 3545–3549.
124. Kiddy K, Brown PP, Michael J, et al. Peritonitis due to *Streptococcus viridans* in patients receiving continuous ambulatory peritoneal dialysis. *Br Med J (Clin Res Ed)* 1985; 290(6473): 969–970.
125. Yuen KY, Seto WH, Ching TY, et al. An outbreak of *Candida tropicalis* peritonitis in patients on intermittent peritoneal dialysis. *J Hosp Infect* 1992; 22(1): 65–72.
126. Cheng VC, Lo WK, Woo PC, et al. Polymicrobial outbreak of intermittent peritoneal dialysis peritonitis during external wall renovation at a dialysis center. *Perit Dial Int* 2001; 21(3): 296–301.
127. Greaves I, Kane K, Richards NT, et al. Pigeons and peritonitis? *Nephrol Dial Transplant* 1992; 7(9): 967–969.
128. Teitelbaum I. Cloudy peritoneal dialysate: it’s not always infection. *Contrib Nephrol* 2006; 150: 187–194.
129. Gould IM and Casewell MW. The laboratory diagnosis of peritonitis during continuous ambulatory peritoneal dialysis. *J Hosp Infect.* 1986; 7(2): 155–160.
130. Flanigan MJ, Freeman RM and Lim VS. Cellular response to peritonitis among peritoneal dialysis patients. *Am J Kidney Dis* 1985; 6(6): 420–424.
131. Chang JJ, Yeun JY and Hasbargen JA. Pneumoperitoneum in peritoneal dialysis patients. *Am J Kidney Dis* 1995; 25(2): 297–301.
132. Males BM, Walshe JJ and Amsterdam D. Laboratory indices of clinical peritonitis: total leukocyte count, microscopy, and microbiologic culture of peritoneal dialysis effluent. *J Clin Microbiol* 1987; 25(12): 2367–2371.
133. Mugambi SM and Ullian ME. Bacteremia, sepsis, and peritonitis with *Pasteurella multocida* in a peritoneal dialysis patient. *Perit Dial Int* 2010; 30(3): 381–383.
134. Galvao C, Swartz R, Rocher L, et al. *Acinetobacter* peritonitis during chronic peritoneal dialysis. *Am J Kidney Dis* 1989; 14(2): 101–104.
135. Morduchowicz G, van Dyk DJ, Wittenberg C, et al. Bacteremia complicating peritonitis in peritoneal dialysis patients. *Am J Nephrol* 1993; 13(4): 278–280.
136. Penven M, Laliou A, Boruchowicz A, et al. Bacteremia caused by *Elizabethkingia miricola* in a patient with acute pancreatitis and peritoneal dialysis. *Med Mal Infect* 2020; 50(4): 379–381.
137. Lee CC, Sun CY, Chang KC, et al. Positive dialysate gram stain predicts outcome of empirical antibiotic therapy for peritoneal dialysis-associated peritonitis. *Ther Apher Dial* 2010; 14(2): 201–208.
138. Buchanan R, Fan S and NicFhogartaigh C. Performance of gram stains and 3 culture methods in the analysis of peritoneal dialysis fluid. *Perit Dial Int* 2019; 39(2): 190–192.
139. de Fijter CWH. Gram stain of peritoneal dialysis fluid: the potential of direct policy-determining importance in early diagnosis of fungal peritonitis. *Perit Dial Int* 2019; 39(6): 574–575.
140. Finch RC, Holliday AP, Innes A, et al. Pharmacokinetic behavior of intraperitoneal teicoplanin during treatment of peritonitis complicating continuous ambulatory peritoneal dialysis. *Antimicrob Agents Chemother* 1996; 40(8): 1971–1972.
141. Blunden M, Zeitlin D, Ashman N, et al. Single UK centre experience on the treatment of PD peritonitis—antibiotic levels and outcomes. *Nephrol Dial Transplant* 2007; 22(6): 1714–1719.
142. Chow KM, Chow VC, Szeto CC, et al. Continuous ambulatory peritoneal dialysis peritonitis: broth inoculation culture versus water lysis method. *Nephron Clin Pract* 2007; 105(3): c121–125.
143. Tanratananon D, Deekae S, Raksasuk S, et al. Evaluation of different methods to improve culture-negative peritoneal dialysis-related peritonitis: a single-center study. *Ann Med Surg (Lond)* 2021; 63: 102139.
144. Iyer RN, Reddy AK, Gande S, et al. Evaluation of different culture methods for the diagnosis of peritonitis in patients on continuous ambulatory peritoneal dialysis. *Clin Microbiol Infect* 2014; 20(5): O294–O296.
145. Ganapathy Pillay S, Mohd Amin SDW, Masri SN, et al. Evaluation of tween 80 incorporated media to increase pathogen isolation from peritoneal fluid of CAPD patients at hospital Kuala Lumpur. *Malays J Pathol* 2021; 43(2): 261–268.
146. Kanjanabuch T, Chatsuwat T, Udomsantisuk N, et al. Association of local unit sampling and microbiology laboratory

- culture practices with the ability to identify causative pathogens in peritoneal dialysis-associated peritonitis in Thailand. *Kidney Int Rep* 2021; 6(4): 1118–1129.
147. Kanjanabuch T, Puapatanakul P, Saejew T, et al. The culture from peritoneal dialysis catheter enhances yield of microorganism identification in peritoneal dialysis-related peritonitis. *Perit Dial Int* 2020; 40(1): 93–95.
148. Park SJ, Lee JY, Tak WT, et al. Using reagent strips for rapid diagnosis of peritonitis in peritoneal dialysis patients. *Adv Perit Dial* 2005; 21: 69–71.
149. Ro Y, Hamada C, Io H, et al. Rapid, simple, and reliable method for the diagnosis of CAPD peritonitis using the new MMP-9 test kit. *J Clin Lab Anal* 2004; 18(4): 224–230.
150. Abbott IJ, Slavin MA, Turnidge JD, et al. *Stenotrophomonas maltophilia*: emerging disease patterns and challenges for treatment. *Expert Rev Anti Infect Ther* 2011; 9(4): 471–488.
151. Szeto CC, Ng JK, Fung WW, et al. Polymerase chain reaction/electrospray ionization-mass spectrometry (PCR/ESI-MS) is not suitable for rapid bacterial identification in peritoneal dialysis effluent. *Perit Dial Int* 2021; 41(1): 96–100.
152. Ahmadi SH, Neela V, Hamat RA, et al. Rapid detection and identification of pathogens in patients with continuous ambulatory peritoneal dialysis (CAPD) associated peritonitis by 16s rRNA gene sequencing. *Trop Biomed* 2013; 30(4): 602–607.
153. Ramirez MG, Ibarra Sifuentes HR, Alvizures Solares SR, et al. *Candida tropicalis* in peritoneal dialysis-related peritonitis diagnosed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. *Saudi J Kidney Dis Transpl* 2021; 32(1): 245–248.
154. Zhang J, Friberg IM, Kift-Morgan A, et al. Machine-learning algorithms define pathogen-specific local immune fingerprints in peritoneal dialysis patients with bacterial infections. *Kidney Int* 2017; 92(1): 179–191.
155. Lin CY, Roberts GW, Kift-Morgan A, et al. Pathogen-specific local immune fingerprints diagnose bacterial infection in peritoneal dialysis patients. *J Am Soc Nephrol* 2013; 24(12): 2002–2009.
156. Goodlad C, George S, Sandoval S, et al. Measurement of innate immune response biomarkers in peritoneal dialysis effluent using a rapid diagnostic point-of-care device as a diagnostic indicator of peritonitis. *Kidney Int* 2020; 97(6): 1253–1259.
157. Chamroensakchai T, Manuprasert W, Puapatanakul P, et al. Serum galactomannan index for the rapid diagnosis of fungal peritonitis in patients with peritoneal dialysis. *Kidney Int Rep* 2020; 5(4): 530–534.
158. Worasilchai N, Leelahavanichkul A, Kanjanabuch T, et al. (1→3)-beta-D-glucan and galactomannan testing for the diagnosis of fungal peritonitis in peritoneal dialysis patients, a pilot study. *Med Mycol* 2015; 53(4): 338–346.
159. Chamroensakchai T, Manuprasert W, Leelahavanichkul A, et al. *Rhodococcus* induced false-positive galactomannan (GM), a biomarker of fungal presentation, in patients with peritoneal dialysis: Case reports. *BMC Nephrol* 2019; 20(1): 445.
160. Ballinger AE, Palmer SC, Wiggins KJ, et al. Treatment for peritoneal dialysis-associated peritonitis. *Cochrane Database Syst Rev* 2014; 2014(4): CD005284.
161. Htay H, Cho Y, Pascoe EM, et al. Center effects and peritoneal dialysis peritonitis outcomes: analysis of a national registry. *Am J Kidney Dis* 2018; 71(6): 814–821.
162. Zelenitsky SA, Howarth J, Lagace-Wiens P, et al. Microbiological trends and antimicrobial resistance in peritoneal dialysis-related peritonitis, 2005 to 2014. *Perit Dial Int* 2017; 37(2): 170–176.
163. Badve SV, Hawley CM, McDonald SP, et al. Use of aminoglycosides for peritoneal dialysis-associated peritonitis does not affect residual renal function. *Nephrol Dial Transplant* 2012; 27(1): 381–387.
164. Baker RJ, Senior H, Clemenger M, et al. Empirical aminoglycosides for peritonitis do not affect residual renal function. *Am J Kidney Dis* 2003; 41(3): 670–675.
165. Lui SL, Cheng SW, Ng F, et al. Cefazolin plus netilmicin versus cefazolin plus ceftazidime for treating CAPD peritonitis: effect on residual renal function. *Kidney Int* 2005; 68(5): 2375–2380.
166. Tokgoz B, Somdas MA, Ucar C, et al. Correlation between hearing loss and peritonitis frequency and administration of ototoxic intraperitoneal antibiotics in patients with CAPD. *Ren Fail* 2010; 32(2): 179–184.
167. Wong KM, Chan YH, Cheung CY, et al. Cefepime versus vancomycin plus netilmicin therapy for continuous ambulatory peritoneal dialysis-associated peritonitis. *Am J Kidney Dis* 2001; 38(1): 127–131.
168. Kitrunghaiboon T, Puapatanakul P, Chuengsaman P, et al. Intraperitoneal cefepime monotherapy versus combination therapy of cefazolin plus ceftazidime for empirical treatment of CAPD-associated peritonitis: a multicenter, open-label, noninferiority, randomized, controlled trial. *Am J Kidney Dis* 2019; 74(5): 601–609.
169. Li PK, Ip M, Law MC, et al. Use of intraperitoneal cefepime as monotherapy in treatment of CAPD peritonitis. *Perit Dial Int* 2000; 20(2): 232–234.
170. Fontan MP, Cambre HD, Rodriguez-Carmona A, et al. Treatment of peritoneal dialysis-related peritonitis with ciprofloxacin monotherapy: clinical outcomes and bacterial susceptibility over two decades. *Perit Dial Int*. 2009; 29(3): 310–318.
171. Muthucumarana K, Howson P, Crawford D, et al. The relationship between presentation and the time of initial administration of antibiotics with outcomes of peritonitis in peritoneal dialysis patients: the PROMPT study. *Kidney Int Rep* 2016; 1(2): 65–72.
172. Oki R, Tsuji S, Hamasaki Y, et al. Time until treatment initiation is associated with catheter survival in peritoneal dialysis-related peritonitis. *Sci Rep* 2021; 11(1): 6547.
173. Dos Santos A, Hernandez RT, Montelli AC, et al. Clinical and microbiological factors predicting outcomes of nonfermenting gram-negative bacilli peritonitis in peritoneal dialysis. *Sci Rep* 2021; 11(1): 12248.

174. Lye WC, Wong PL, van der Straaten JC, et al. A prospective randomized comparison of single versus multidose gentamicin in the treatment of CAPD peritonitis. *Adv Perit Dial* 1995; 11: 179–181.
175. Varghese JM, Roberts JA, Wallis SC, et al. Pharmacokinetics of intraperitoneal gentamicin in peritoneal dialysis patients with peritonitis (GIPD study). *Clin J Am Soc Nephrol* 2012; 7(8): 1249–1256.
176. Manley HJ, Bailie GR, Frye R, et al. Pharmacokinetics of intermittent intravenous cefazolin and tobramycin in patients treated with automated peritoneal dialysis. *J Am Soc Nephrol* 2000; 11(7): 1310–1316.
177. Roberts DM, Ranganathan D, Wallis SC, et al. Pharmacokinetics of intraperitoneal cefalothin and cefazolin in patients being treated for peritoneal dialysis-associated peritonitis. *Perit Dial Int* 2016; 36(4): 415–420.
178. Peerapornratana S, Chariyavilaskul P, Kanjanabuch T, et al. Short-Dwell cycling intraperitoneal cefazolin plus ceftazidime in peritoneal dialysis patients. *Perit Dial Int* 2017; 37(2): 218–224.
179. Tosukhowong T, Eiam-Ong S, Thamutok K, et al. Pharmacokinetics of intraperitoneal cefazolin and gentamicin in empiric therapy of peritonitis in continuous ambulatory peritoneal dialysis patients. *Perit Dial Int* 2001; 21(6): 587–594.
180. Agrawal A, Agarwal SK, Kaleekal T, et al. Rifampicin and anti-hypertensive drugs in chronic kidney disease: pharmacokinetic interactions and their clinical impact. *Indian J Nephrol* 2016; 26(5): 322–328.
181. Albin HC, Demotes-Mainard FM, Bouchet JL, et al. Pharmacokinetics of intravenous and intraperitoneal cefotaxime in chronic ambulatory peritoneal dialysis. *Clin Pharmacol Ther* 1985; 38(3): 285–289.
182. Leung CB, Szeto CC, Chow KM, et al. Cefazolin plus ceftazidime versus imipenem/cilastatin monotherapy for treatment of CAPD peritonitis—a randomized controlled trial. *Perit Dial Int* 2004; 24(5): 440–446.
183. Albin H, Ragnaud JM, Demotes-Mainard F, et al. Pharmacokinetics of intravenous and intraperitoneal ceftriaxone in chronic ambulatory peritoneal dialysis. *Eur J Clin Pharmacol* 1986; 31(4): 479–483.
184. Bierhoff M, Krutwagen E, van Bommel EF, et al. Listeria peritonitis in patients on peritoneal dialysis: two cases and a review of the literature. *Neth J Med* 2011; 69(10): 461–464.
185. Boss K, Wiegand-Szramek I, Dziobaka J, et al. Intraperitoneal ampicillin treatment for peritoneal dialysis-related peritonitis with listeria monocytogenes - a case report. *BMC Nephrol* 2020; 21(1): 404.
186. Yip T, Tse KC, Ng F, et al. Clinical course and outcomes of single-organism enterococcus peritonitis in peritoneal dialysis patients. *Perit Dial Int* 2011; 31(5): 522–528.
187. Lam MF, Tang BS, Tse KC, et al. Ampicillin-sulbactam and amikacin used as second-line antibiotics for patients with culture-negative peritonitis. *Perit Dial Int* 2008; 28(5): 540–542.
188. Fitzpatrick MA, Esterly JS, Postelnick MJ, et al. Successful treatment of extensively drug-resistant *Acinetobacter baumannii* peritoneal dialysis peritonitis with intraperitoneal polymyxin B and ampicillin-sulbactam. *Ann Pharmacother* 2012; 46(7-8): e17.
189. Zaidenstein R, Weissgarten J, Dishy V, et al. Pharmacokinetics of intraperitoneal piperacillin/tazobactam in patients on peritoneal dialysis with and without pseudomonas peritonitis. *Perit Dial Int* 2000; 20(2): 227–231.
190. Pasadakis P, Thodis E, Euthimiadou A, et al. Treatment of CAPD peritonitis with clavulanate potentiated ticarcillin. *Adv Perit Dial* 1992; 8: 238–241.
191. Fuiano G, Sepe V, Viscione M, et al. Effectiveness of single daily intraperitoneal administration of aztreonam and cefuroxime in the treatment of peritonitis in continuous ambulatory peritoneal dialysis (CAPD). *Perit Dial Int* 1989; 9(4): 273–275.
192. Dratwa M, Glupczynski Y, Lameire N, et al. Treatment of gram-negative peritonitis with aztreonam in patients undergoing continuous ambulatory peritoneal dialysis. *Rev Infect Dis* 1991; 13(Suppl 7): S645–S647.
193. Gerig JS, Bolton ND, Swabb EA, et al. Effect of hemodialysis and peritoneal dialysis on aztreonam pharmacokinetics. *Kidney Int* 1984; 26(3): 308–318.
194. Cheng IK, Chan CY, Wong WT, et al. A randomized prospective comparison of oral versus intraperitoneal ciprofloxacin as the primary treatment of peritonitis complicating continuous ambulatory peritoneal dialysis. *Perit Dial Int* 1993; 13(Suppl 2): S351–S354.
195. Chang MJ, Namgung H, Choi HD, et al. Pharmacokinetics of clindamycin in the plasma and dialysate after intraperitoneal administration of clindamycin phosphoester to patients on continuous ambulatory peritoneal dialysis: an open-label, prospective, single-dose, two-institution study. *Basic Clin Pharmacol Toxicol* 2012; 110(6): 504–509.
196. Saint Paul LP, Ficheux M, Debruyne D, et al. Pharmacokinetics of 300 mg/d intraperitoneal daptomycin: new insight from the daptoDP study. *Perit Dial Int* 2018; 38(6): 463–466.
197. Lin SY, Ho MW, Liu JH, et al. Successful salvage of peritoneal catheter in unresolved methicillin-resistant *Staphylococcus aureus* peritonitis by combination treatment with daptomycin and rifampin. *Blood Purif* 2011; 32(4): 249–252.
198. Huen SC, Hall I, Topal J, et al. Successful use of intraperitoneal daptomycin in the treatment of vancomycin-resistant enterococcus peritonitis. *Am J Kidney Dis* 2009; 54(3): 538–541.
199. Perez Melon C, Borrajo Prol M, Iglesias E, et al. Daptomycin in peritoneal dialysis, intraperitoneal or intravenous. *Nefrologia* 2016; 36(4): 461–462.
200. Gilmore JF, Kim M, LaSalvia MT, et al. Treatment of enterococcal peritonitis with intraperitoneal daptomycin in a vancomycin-allergic patient and a review of the literature. *Perit Dial Int* 2013; 33(4): 353–357.

201. Kussmann M, Baumann A, Hauer S, et al. Compatibility of fosfomycin with different commercial peritoneal dialysis solutions. *Eur J Clin Microbiol Infect Dis* 2017; 36(11): 2237–2242.
202. Kussmann M, Hauer S, Pichler P, et al. Influence of different peritoneal dialysis fluids on the in vitro activity of fosfomycin against *Escherichia coli*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, and *Pseudomonas aeruginosa*. *Eur J Clin Microbiol Infect Dis* 2018; 37(6): 1091–1098.
203. Anwar N, Merchant M, Were T, et al. A prospective, randomized study of the comparative safety and efficacy of intraperitoneal imipenem versus vancomycin and netilmicin in the treatment of peritonitis on CAPD. *Perit Dial Int* 1995; 15(2): 167–171.
204. Cheng IK, Chan CY and Wong WT. A randomised prospective comparison of oral ofloxacin and intraperitoneal vancomycin plus aztreonam in the treatment of bacterial peritonitis complicating continuous ambulatory peritoneal dialysis (CAPD). *Perit Dial Int* 1991; 11(1): 27–30.
205. Lynn WA, Clutterbuck E, Want S, et al. Treatment of CAPD-peritonitis due to glycopeptide-resistant enterococcus faecium with quinupristin/dalfopristin. *Lancet* 1994; 344(8928): 1025–1026.
206. de Fijter CW, Jakulj L, Amiri F, et al. Intraperitoneal meropenem for polymicrobial peritoneal dialysis-related peritonitis. *Perit Dial Int* 2016; 36(5): 572–573.
207. Ling CW, Sud K, Van C, et al. Pharmacokinetics of culture-directed antibiotics for the treatment of peritonitis in automated peritoneal dialysis: a systematic narrative review. *Perit Dial Int* 2021; 41(3): 261–272.
208. Ma Y, Geng Y, Jin L, et al. Serum vancomycin levels predict the short-term adverse outcomes of peritoneal dialysis-associated peritonitis. *Perit Dial Int*. Epub ahead of print 13 January 2022. DOI: 10.1177/08968608211064192.
209. Vlaar PJ, van Hulst M, Benne CA, et al. Intraperitoneal compared with intravenous meropenem for peritoneal dialysis-related peritonitis. *Perit Dial Int* 2013; 33(6): 708–709.
210. Liakopoulos V, Leivaditis K, Nikitidou O, et al. Intermittent intraperitoneal dose of teicoplanin in peritoneal dialysis-related peritonitis. *Perit Dial Int* 2012; 32(3): 365–366.
211. Lupo A, Rugu C, Bernich P, et al. A prospective, randomized trial of two antibiotic regimens in the treatment of peritonitis in CAPD patients: teicoplanin plus tobramycin versus cephalothin plus tobramycin. *J Antimicrob Chemother* 1997; 40(5): 729–732.
212. Falbo Dos Reis P, Barretti P, Marinho L, et al. Pharmacokinetics of intraperitoneal vancomycin and amikacin in automated peritoneal dialysis patients with peritonitis. *Front Pharmacol* 2021; 12: 658014.
213. Lam E, Ting Kayla Lien Y, Kraft WK, et al. Intraperitoneal pharmacokinetics of vancomycin in patients on automated peritoneal dialysis. *Clin Transl Sci*. Epub ahead of print 9 November 2021. DOI: 10.1111/cts.13182.
214. De Vriese AS and Vandecasteele SJ. Vancomycin: the tale of the vanquisher and the pyrrhic victory. *Perit Dial Int* 2014; 34(2): 154–161.
215. Matuszkiewicz-Rowinska J. Update on fungal peritonitis and its treatment. *Perit Dial Int* 2009; 29(Suppl 2): S161–S165.
216. Dahl NV, Foote EF, Searson KM, et al. Pharmacokinetics of intraperitoneal fluconazole during continuous cycling peritoneal dialysis. *Ann Pharmacother* 1998; 32(12): 1284–1289.
217. Roberts DM, Kauter G, Ray JE, et al. Intraperitoneal voriconazole in a patient with *Aspergillus* peritoneal dialysis peritonitis. *Perit Dial Int* 2013; 33(1): 92–93.
218. Kussmann M, Schuster L, Zeitlinger M, et al. The influence of different peritoneal dialysis fluids on the in vitro activity of ampicillin, daptomycin, and linezolid against enterococcus faecalis. *Eur J Clin Microbiol Infect Dis* 2015; 34(11): 2257–2263.
219. Szeto CC, Ng JK, Chow KM, et al. Treatment of enterococcal peritonitis in peritoneal dialysis patients by oral amoxicillin or intra-peritoneal vancomycin: a retrospective study. *Kidney Blood Press Res* 2017; 42(5): 837–843.
220. Shalit I, Greenwood RB, Marks MI, et al. Pharmacokinetics of single-dose oral ciprofloxacin in patients undergoing chronic ambulatory peritoneal dialysis. *Antimicrob Agents Chemother* 1986; 30(1): 152–156.
221. Lee C, Walker SAN, Palmay L, et al. Steady-State pharmacokinetics of oral ciprofloxacin in continuous cycling peritoneal dialysis patients: brief report. *Perit Dial Int* 2018; 38(1): 73–76.
222. Verbanck JJ, Verlinde AM, Verbanck MI, et al. *Campylobacter jejuni* II peritonitis in a CCPD patient: cure by oral clarithromycin. *Perit Dial Int* 1999; 19(1): 85–86.
223. Ma TK, Lee KP, Chow KM, et al. *Campylobacter* peritonitis complicating peritoneal dialysis: a review of 12 consecutive cases. *Perit Dial Int* 2013; 33(2): 189–194.
224. O’Riordan J, Bhally HS, Salmon AH, et al. Successful treatment of carbapenemase producing enterobacteriaceae peritonitis: ‘old therapy for a new bug’. *Perit Dial Int* 2020; 40(1): 100–102.
225. Cheung CY, Chan SY, Yeung CS, et al. Carbapenem resistant enterobacteriaceae as a cause of peritonitis in a peritoneal dialysis patient. *Nephrology (Carlton)* 2016; 21(10): 906–907.
226. Koomanachai P, Landersdorfer CB, Chen G, et al. Pharmacokinetics of colistin methanesulfonate and formed colistin in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis. *Antimicrob Agents Chemother* 2014; 58(1): 440–446.
227. Van Matre ET, Teitelbaum I and Kiser TH. Intravenous and intraperitoneal pharmacokinetics of dalbavancin in peritoneal dialysis patients. *Antimicrob Agents Chemother* 2020; 64(5): e02089–19.
228. Cardone KE, Lodise TP, Patel N, et al. Pharmacokinetics and pharmacodynamics of intravenous daptomycin during

- continuous ambulatory peritoneal dialysis. *Clin J Am Soc Nephrol* 2011; 6(5): 1081–1088.
229. Cardone KE, Grabe DW, Kulawy RW, et al. Ertapenem pharmacokinetics and pharmacodynamics during continuous ambulatory peritoneal dialysis. *Antimicrob Agents Chemother* 2012; 56(2): 725–730.
  230. Cheng IK, Fang GX, Chau PY, et al. A randomized prospective comparison of oral levofloxacin plus intraperitoneal (IP) vancomycin and IP netromycin plus IP vancomycin as primary treatment of peritonitis complicating CAPD. *Perit Dial Int* 1998; 18(4): 371–375.
  231. Unal A, Agkus C, Kocyigit I, et al. Peritoneal dialysis-related peritonitis caused by vancomycin-resistant *Enterococcus faecium*. *Ther Apher Dial* 2011; 15(1): 115–116.
  232. Song IJ, Seo JW, Kwon YE, et al. Successful treatment of vancomycin-resistant enterococcus peritonitis using linezolid without catheter removal in a peritoneal dialysis patient. *Perit Dial Int* 2014; 34(2): 235–239.
  233. Kawasuji H, Tsuji Y, Ogami C, et al. Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients. *BMC Pharmacol Toxicol* 2021; 22(1): 13.
  234. Xu R, Yang Z, Qu Z, et al. Intraperitoneal vancomycin plus either oral moxifloxacin or intraperitoneal ceftazidime for the treatment of peritoneal dialysis-related peritonitis: a randomized controlled pilot study. *Am J Kidney Dis* 2017; 70(1): 30–37.
  235. Skalioti C, Tsaganos T, Stamatiadis D, et al. Pharmacokinetics of moxifloxacin in patients undergoing continuous ambulatory peritoneal dialysis. *Perit Dial Int* 2009; 29(5): 575–579.
  236. Moso MA and Macesic N. Peritoneal dialysis-related peritonitis with carbapenem-resistant *Klebsiella pneumoniae* and vancomycin-resistant *Enterococcus faecium*. *Open Forum Infect Dis* 2021; 8(1): ofaa525.
  237. Scheetz MH, Reddy P, Nicolau DP, et al. Peritoneal fluid penetration of tigecycline. *Ann Pharmacother* 2006; 40(11): 2064–2067.
  238. Celik A, Cirit M, Tunger A, et al. Treatment of CAPD peritonitis with oral trimethoprim/sulfamethoxazole and intraperitoneal aminoglycoside combination. *Perit Dial Int* 1999; 19(3): 284–285.
  239. Mahoney MV. Clarification of trimethoprim/sulfamethoxazole dose in CAPD. *Perit Dial Int* 2015; 35(1): 116–118.
  240. Wong PN, Lo KY, Tong GM, et al. Treatment of fungal peritonitis with a combination of intravenous amphotericin B and oral flucytosine, and delayed catheter replacement in continuous ambulatory peritoneal dialysis. *Perit Dial Int* 2008; 28(2): 155–162.
  241. Serna JH, Wanger A and Dosekun AK. Successful treatment of mucormycosis peritonitis with liposomal amphotericin B in a patient on long-term peritoneal dialysis. *Am J Kidney Dis* 2003; 42(3): E14–E17.
  242. Franconieri F, Bonhomme J, Doriot A, et al. Fungal peritonitis caused by *Rhodotorula mucilaginosa* in a CAPD patient treated with liposomal amphotericin B: a case report and literature review. *Perit Dial Int* 2018; 38(1): 69–73.
  243. Gioia F, Gomez-Lopez A, Alvarez ME, et al. Pharmacokinetics of echinocandins in suspected candida peritonitis: a potential risk for resistance. *Int J Infect Dis* 2020; 101: 24–28.
  244. Tobudic S, Donath O, Vychytil A, et al. Stability of anidulafungin in two standard peritoneal dialysis fluids. *Perit Dial Int* 2014; 34(7): 798–802.
  245. Emami S and Lew SQ. *Candida glabrata* PD-associated peritonitis: a case report. *Perit Dial Int* 2018; 38(5): 391–392.
  246. Beredaki MI, Arendrup MC, Andes D, et al. The role of new posaconazole formulations in the treatment of *Candida albicans* infections: data from an in vitro pharmacokinetic-pharmacodynamic model. *Antimicrob Agents Chemother* 2021; 65(4): e01292–20.
  247. Whitty R, Bargman JM, Kiss A, et al. Residual kidney function and peritoneal dialysis-associated peritonitis treatment outcomes. *Clin J Am Soc Nephrol* 2017; 12(12): 2016–2022.
  248. Lam E, Lien YTK, Kraft WK, et al. Vancomycin in peritoneal dialysis: clinical pharmacology considerations in therapy. *Perit Dial Int* 2020; 40(4): 384–393.
  249. Chang WM, Cheng E, Shalansky K, et al. Evaluation of intraperitoneal vancomycin in peritoneal dialysis-associated peritonitis. *Perit Dial Int*. Epub ahead of print 21 October 2021. DOI: 10.1177/08968608211051579.
  250. Stevenson S, Tang W, Cho Y, et al. The role of monitoring vancomycin levels in patients with peritoneal dialysis-associated peritonitis. *Perit Dial Int* 2015; 35(2): 222–228.
  251. Mulhern JG, Braden GL, O’Shea MH, et al. Trough serum vancomycin levels predict the relapse of gram-positive peritonitis in peritoneal dialysis patients. *Am J Kidney Dis* 1995; 25(4): 611–615.
  252. Dahlan R, Lavoie S, Biyani M, et al. A high serum vancomycin level is associated with lower relapse rates in coagulase-negative staphylococcal peritonitis. *Perit Dial Int* 2014; 34(2): 232–235.
  253. Lortholary O, Tod M, Cohen Y, et al. Aminoglycosides. *Med Clin North Am* 1995; 79(4): 761–787.
  254. Rubin J. Tobramycin absorption from the peritoneal cavity. *Perit Dial Int* 1990; 10(4): 295–297.
  255. Tang W, Cho Y, Hawley CM, et al. The role of monitoring gentamicin levels in patients with gram-negative peritoneal dialysis-associated peritonitis. *Perit Dial Int* 2014; 34(2): 219–226.
  256. van der Hulst RJ, Boeschoten EW, Nielsen FW, et al. Ototoxicity monitoring with ultra-high frequency audiometry in peritoneal dialysis patients treated with vancomycin or gentamicin. *ORL J Otorhinolaryngol Relat Spec* 1991; 53(1): 19–22.
  257. Johnson DW. Do antibiotic levels need to be followed in treating peritoneal dialysis-associated peritonitis? *Semin Dial* 2011; 24(4): 445–446.
  258. Sinswat P, Wu WJ, Sha SH, et al. Protection from ototoxicity of intraperitoneal gentamicin in guinea pig. *Kidney Int* 2000; 58(6): 2525–2532.

259. Warady BA, Reed L, Murphy G, et al. Aminoglycoside ototoxicity in pediatric patients receiving long-term peritoneal dialysis. *Pediatr Nephrol* 1993; 7(2): 178–181.
260. Chong TK, Piraino B and Bernardini J. Vestibular toxicity due to gentamicin in peritoneal dialysis patients. *Perit Dial Int*.1991; 11(2): 152–155.
261. Tokgoz B, Ucar C, Kocyigit I, et al. Protective effect of N-acetylcysteine from drug-induced ototoxicity in uraemic patients with CAPD peritonitis. *Nephrol Dial Transplant* 2011; 26(12): 4073–4078.
262. Vural A, Kocyigit I, San F, et al. Long-term protective effect of N-acetylcysteine against amikacin-induced ototoxicity in end-stage renal disease: a randomized trial. *Perit Dial Int* 2018; 38(1): 57–62.
263. Kocyigit I, Vural A, Unal A, et al. Preventing amikacin related ototoxicity with N-acetylcysteine in patients undergoing peritoneal dialysis. *Eur Arch Otorhinolaryngol* 2015; 272(10): 2611–2620.
264. Feldman L, Efrati S, Eviatar E, et al. Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine. *Kidney Int* 2007; 72(3):359–363.
265. Kranzer K, Elamin WF, Cox H, et al. A systematic review and meta-analysis of the efficacy and safety of N-acetylcysteine in preventing aminoglycoside-induced ototoxicity: implications for the treatment of multidrug-resistant TB. *Thorax* 2015; 70(11): 1070–1077.
266. Kussmann M, Ferth A, Obermuller M, et al. Compatibility of ciprofloxacin with commercial peritoneal dialysis solutions. *Sci Rep* 2019; 9(1): 6512.
267. Fernandez-Varon E, Marin P, Espuny A, et al. Stability of moxifloxacin injection in peritoneal dialysis solution bags (Dianeal PD1 1.36% and Dianeal PD1 3.86%). *J Clin Pharm Ther* 2006; 31(6): 641–643.
268. Kussmann M, Schuster L, Wrenger S, et al. Influence of different peritoneal dialysis fluids on the in vitro activity of cefepime, ciprofloxacin, ertapenem, meropenem and tobramycin against *Escherichia coli*. *Perit Dial Int*. 2016; 36(6): 662–668.
269. How PP, Fischer JH, Arruda JA, et al. Effects of lanthanum carbonate on the absorption and oral bioavailability of ciprofloxacin. *Clin J Am Soc Nephrol* 2007; 2(6): 1235–1240.
270. Kays MB, Overholser BR, Mueller BA, et al. Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin. *Am J Kidney Dis* 2003; 42(6): 1253–1259.
271. Golper TA, Hartstein AI, Morthland VH, et al. Effects of antacids and dialysate dwell times on multiple-dose pharmacokinetics of oral ciprofloxacin in patients on continuous ambulatory peritoneal dialysis. *Antimicrob Agents Chemother* 1987; 31(11): 1787–1790.
272. So SW, Chen L, Woo AY, et al. Stability and compatibility of antibiotics in peritoneal dialysis solutions. *Clin Kidney J* 2022. DOI: 10.1093/ckj/sfac012.
273. Ranganathan D, Naicker S, Wallis SC, et al. Stability of Antibiotics for Intraperitoneal administration in extraneal 7.5% icodextrin peritoneal dialysis bags (STAB Study). *Perit Dial Int* 2016; 36(4): 421–426.
274. Dooley DP, Tyler JR, Wortham WG, et al. Prolonged stability of antimicrobial activity in peritoneal dialysis solutions. *Perit Dial Int* 2003; 23(1): 58–62.
275. de Vin F, Rutherford P and Faict D. Intraperitoneal administration of drugs in peritoneal dialysis patients: a review of compatibility and guidance for clinical use. *Perit Dial Int* 2009; 29(1): 5–15.
276. Williamson JC, Volles DF, Lynch PL, et al. Stability of cefepime in peritoneal dialysis solution. *Ann Pharmacother* 1999; 33(9): 906–909.
277. Deslandes G, Gregoire M, Bouquie R, et al. Stability and compatibility of antibiotics in peritoneal dialysis solutions applied to automated peritoneal dialysis in the pediatric population. *Perit Dial Int* 2016; 36(6): 676–679.
278. Mendes K, Harmanjeet H, Sedeeq M, et al. Stability of meropenem and piperacillin/Tazobactam with heparin in various peritoneal dialysis solutions. *Perit Dial Int* 2018; 38(6): 430–440.
279. Harmanjeet H, Jani H, Zaidi STR, et al. Stability of ceftolozane and tazobactam in different peritoneal dialysis solutions. *Perit Dial Int* 2020; 40(5): 470–476.
280. Fish R, Nipah R, Jones C, et al. Intraperitoneal vancomycin concentrations during peritoneal dialysis-associated peritonitis: correlation with serum levels. *Perit Dial Int* 2012; 32(3): 332–338.
281. Triyawatanyu P, Chariyavilaskul P, Phaisal W, et al. Intraperitoneal cefazolin and ceftazidime during short-dwell exchange in peritoneal dialysis patients with peritonitis. *Perit Dial Int* 2020; 40(2): 179–184.
282. Ejlersen E, Brandi L, Lokkegaard H, et al. Is initial (24 hours) lavage necessary in treatment of CAPD peritonitis? *Perit Dial Int* 1991; 11(1): 38–42.
283. Wong SS, Lau WY, Tse YY, et al. Randomized controlled trial on adjunctive lavage for severe peritonitis. *Perit Dial Int*. 2019; 39(5): 447–454.
284. Demoulin N and Goffin E. Intraperitoneal urokinase and oral rifampicin for persisting asymptomatic dialysate infection following acute coagulase-negative staphylococcus peritonitis. *Perit Dial Int* 2009; 29(5): 548–553.
285. Tong MK, Leung KT, Siu YP, et al. Use of intraperitoneal urokinase for resistant bacterial peritonitis in continuous ambulatory peritoneal dialysis. *J Nephrol* 2005; 18(2): 204–208.
286. Gadallah MF, Tamayo A, Sandborn M, et al. Role of intraperitoneal urokinase in acute peritonitis and prevention of catheter loss in peritoneal dialysis patients. *Adv Perit Dial* 2000; 16: 233–236.
287. Innes A, Burden RP, Finch RG, et al. Treatment of resistant peritonitis in continuous ambulatory peritoneal dialysis with intraperitoneal urokinase: a double-blind clinical trial. *Nephrol Dial Transplant* 1994; 9(7): 797–799.
288. Williams AJ, Boletis I, Johnson BF, et al. Tenckhoff catheter replacement or intraperitoneal urokinase: a randomised trial in the management of recurrent continuous ambulatory



- peritoneal dialysis (CAPD) peritonitis. *Perit Dial Int* 1989; 9(1): 65–67.
289. Vlaanderen K, Bos HJ, de Fijter CW, et al. Short dwell times reduce the local defence mechanism of chronic peritoneal dialysis patients. *Nephron* 1991; 57(1): 29–35.
290. Chow KM, Szeto CC, Kwan BC, et al. Randomized controlled study of icodextrin on the treatment of peritoneal dialysis patients during acute peritonitis. *Nephrol Dial Transplant* 2014; 29(7): 1438–1443.
291. Chow KM, Szeto CC, Cheung KK, et al. Predictive value of dialysate cell counts in peritonitis complicating peritoneal dialysis. *Clin J Am Soc Nephrol* 2006; 1(4): 768–773.
292. Nochaiwong S, Ruengorn C, Koyratkoson K, et al. A clinical risk prediction tool for peritonitis-associated treatment failure in peritoneal dialysis patients. *Sci Rep* 2018; 8(1): 14797.
293. Choi P, Nemati E, Banerjee A, et al. Peritoneal dialysis catheter removal for acute peritonitis: a retrospective analysis of factors associated with catheter removal and prolonged postoperative hospitalization. *Am J Kidney Dis* 2004; 43(1): 103–111.
294. Lu W, Kwan BC, Chow KM, et al. Peritoneal dialysis-related peritonitis caused by *Pseudomonas* species: insight from a post-millennial case series. *PLoS One* 2018; 13(5): e0196499.
295. Xu R, Chen Y, Luo S, et al. Clinical characteristics and outcomes of peritoneal dialysis-related peritonitis with different trends of change in effluent white cell count: a longitudinal study. *Perit Dial Int* 2013; 33(4): 436–444.
296. Tantiyavarong P, Traitanon O, Chuengsaman P, et al. Dialysate white blood cell change after initial antibiotic treatment represented the patterns of response in peritoneal dialysis-related peritonitis. *Int J Nephrol* 2016; 2016: 6217135.
297. Szeto CC, Kwan BC, Chow KM, et al. Recurrent and relapsing peritonitis: causative organisms and response to treatment. *Am J Kidney Dis* 2009; 54(4): 702–710.
298. Burke M, Hawley CM, Badve SV, et al. Relapsing and recurrent peritoneal dialysis-associated peritonitis: a multi-center registry study. *Am J Kidney Dis* 2011; 58(3): 429–436.
299. Szeto CC, Kwan BC, Chow KM, et al. Repeat peritonitis in peritoneal dialysis: retrospective review of 181 consecutive cases. *Clin J Am Soc Nephrol* 2011; 6(4): 827–833.
300. Thirugnanasambathan T, Hawley CM, Badve SV, et al. Repeated peritoneal dialysis-associated peritonitis: a multi-center registry study. *Am J Kidney Dis* 2012; 59(1): 84–91.
301. Reis M, Ribeiro C, Gomes AM, et al. Repeat and relapsing peritonitis microbiological trends and outcomes: a 21-year single-center experience. *Int J Nephrol* 2021; 2021: 6662488.
302. Swartz R, Messana J, Reynolds J, et al. Simultaneous catheter replacement and removal in refractory peritoneal dialysis infections. *Kidney Int* 1991; 40(6): 1160–1165.
303. Crabtree JH and Siddiqi RA. Simultaneous catheter replacement for infectious and mechanical complications without interruption of peritoneal dialysis. *Perit Dial Int* 2016; 36(2): 182–187.
304. Viron C, Lobbedez T, Lanot A, et al. Simultaneous removal and reinsertion of the PD catheter in relapsing peritonitis. *Perit Dial Int* 2019; 39(3): 282–288.
305. Szeto CC, Ng JK, Wing-Shing Fung W, et al. Extended antibiotic therapy for the prevention of relapsing and recurrent peritonitis in peritoneal dialysis patients: a randomized controlled trial. *Clin Kidney J* 2021; 14(3): 991–997.
306. Szeto CC, Lai KB, Kwan BC, et al. Bacteria-derived DNA fragment in peritoneal dialysis effluent as a predictor of relapsing peritonitis. *Clin J Am Soc Nephrol* 2013; 8(11): 1935–1941.
307. Camargo CH, Cunha Mde L, Caramori JC, et al. Peritoneal dialysis-related peritonitis due to coagulase-negative staphylococcus: a review of 115 cases in a Brazilian center. *Clin J Am Soc Nephrol* 2014; 9(6): 1074–1081.
308. Prasad JM, Negron O, Du X, et al. Host fibrinogen drives antimicrobial function in *Staphylococcus aureus* peritonitis through bacterial-mediated prothrombin activation. *Proc Natl Acad Sci U S A* 2021; 118(1): e2009837118.
309. Chen HC, Shieh CC and Sung JM. Increasing staphylococcus species resistance in peritoneal dialysis-related peritonitis over a 10-year period in a single Taiwanese Center. *Perit Dial Int* 2018; 38(4): 266–270.
310. Kitterer D, Latus J, Pohlmann C, et al. Microbiological surveillance of peritoneal dialysis associated peritonitis: antimicrobial susceptibility profiles of a referral center in GERMANY over 32 years. *PLoS One* 2015; 10(9): e0135969.
311. Wang HH, Huang CH, Kuo MC, et al. Microbiology of peritoneal dialysis-related infection and factors of refractory peritoneal dialysis related peritonitis: a ten-year single-center study in Taiwan. *J Microbiol Immunol Infect* 2019; 52(5): 752–759.
312. Szeto CC, Kwan BC, Chow KM, et al. Coagulase negative staphylococcal peritonitis in peritoneal dialysis patients: review of 232 consecutive cases. *Clin J Am Soc Nephrol* 2008; 3(1): 91–97.
313. Heywood A and Bargman JM. Coagulase-negative staphylococcal peritonitis: Outcomes of cephalosporin-resistant strains. *Adv Perit Dial* 2010; 26: 34–36.
314. Fahim M, Hawley CM, McDonald SP, et al. Coagulase-negative staphylococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 936 cases. *Nephrol Dial Transplant* 2010; 25(10): 3386–3392.
315. Mitra A and Teitelbaum I. Is it safe to simultaneously remove and replace infected peritoneal dialysis catheters? Review of the literature and suggested guidelines. *Adv Perit Dial* 2003; 19: 255–259.
316. Haivas CD and Teitelbaum I. Eradication of repeated episodes of coagulase-negative *Staphylococcus peritonitis*: a multi-pronged approach. *Perit Dial Int* 2019; 39(6): 568–570.
317. Szeto CC, Chow KM, Kwan BC, et al. *Staphylococcus aureus* peritonitis complicates peritoneal dialysis: review of 245 consecutive cases. *Clin J Am Soc Nephrol* 2007; 2(2): 245–251.

318. Govindarajulu S, Hawley CM, McDonald SP, et al. *Staphylococcus aureus* peritonitis in Australian peritoneal dialysis patients: predictors, treatment, and outcomes in 503 cases. *Perit Dial Int* 2010; 30(3): 311–319.
319. Tobudic S, Kern S, Kussmann M, et al. Effect of peritoneal dialysis fluids on activity of teicoplanin against methicillin-resistant *Staphylococcus aureus* biofilm. *Perit Dial Int* 2019; 39(3): 293–294.
320. O’Shea S, Hawley CM, McDonald SP, et al. Streptococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 287 cases. *BMC Nephrol* 2009; 10: 19.
321. Santos JE, Rodriguez Magarinos C, Garcia Gago L, et al. Long-term trends in the incidence of peritoneal dialysis-related peritonitis disclose an increasing relevance of streptococcal infections: a longitudinal study. *PLoS One* 2020; 15(12): e0244283.
322. Liu Y, Cheng BC, Liu JW, et al. Viridans *Streptococcus peritonitis* in peritoneal dialysis: clinical characteristics and comparison with concurrent polymicrobial infection. *BMC Nephrol* 2018; 19(1): 271.
323. Chao CT, Lee SY, Yang WS, et al. Viridans streptococci in peritoneal dialysis peritonitis: clinical courses and long-term outcomes. *Perit Dial Int* 2015; 35(3): 333–341.
324. Htay H, Cho Y, Pascoe EM, et al. Outcomes of *Corynebacterium* peritonitis: a multicenter registry analysis. *Perit Dial Int* 2017; 37(6): 619–626.
325. Barraclough K, Hawley CM, McDonald SP, et al. *Corynebacterium* peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 82 cases. *Nephrol Dial Transplant* 2009; 24(12): 3834–3839.
326. Szeto CC, Chow KM, Chung KY, et al. The clinical course of peritoneal dialysis-related peritonitis caused by *Corynebacterium* species. *Nephrol Dial Transplant* 2005; 20(12): 2793–2796.
327. Chao CT, Huang JW and Yen CJ. A rare and under-recognized pathogen in peritoneal dialysis peritonitis: *Corynebacterium jeikeium*. *Perit Dial Int* 2013; 33(5): 580–581.
328. Schiffl H, Mucke C and Lang SM. Exit-site infections by non-diphtheria corynebacteria in CAPD. *Perit Dial Int* 2004; 24(5): 454–459.
329. McMullen AR, Anderson N, Wallace MA, et al. When good bugs go bad: epidemiology and antimicrobial resistance profiles of *Corynebacterium striatum*, an emerging multidrug-resistant, opportunistic pathogen. *Antimicrob Agents Chemother* 2017; 61(11): e01111–17.
330. Edey M, Hawley CM, McDonald SP, et al. Enterococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 116 cases. *Nephrol Dial Transplant* 2010; 25(4): 1272–1278.
331. Nzana VB, Rohit A, George D, et al. Twenty-one episodes of peritonitis in a continuous ambulatory peritoneal dialysis patient: what is the root cause? *Indian J Med Microbiol* 2018; 36(2): 282–284.
332. Piraino B. Peritoneal dialysis catheter replacement: “Save the patient and not the catheter”. *Semin Dial* 2003; 16(1): 72–75.
333. Yeung CS, Cheung CY, Chan YH, et al. Risk factors and outcomes of vancomycin-resistant enterococcus colonization in patients on peritoneal dialysis: a single-center study in Hong Kong. *Perit Dial Int* 2017; 37(5): 556–561.
334. Zacharioudakis IM, Zervou FN, Ziakas PD, et al. Vancomycin-resistant enterococci colonization among dialysis patients: a meta-analysis of prevalence, risk factors, and significance. *Am J Kidney Dis* 2015; 65(1): 88–97.
335. Bailey EM, Faber MD and Nafziger DA. Linezolid for treatment of vancomycin-resistant enterococcal peritonitis. *Am J Kidney Dis*. 2001;38(4): E20.
336. Hassoun AA, Coomer RW and Mendez-Vigo L. Intraperitoneal daptomycin used to successfully treat vancomycin-resistant enterococcus peritonitis. *Perit Dial Int* 2009; 29(6): 671–673.
337. Troidle L, Kliger AS, Gorban-Brennan N, et al. Nine episodes of CPD-associated peritonitis with vancomycin resistant enterococci. *Kidney Int* 1996; 50(4): 1368–1372.
338. Johnson CA, Taylor CA, 3rd, Zimmerman SW, et al. Pharmacokinetics of quinupristin-dalfopristin in continuous ambulatory peritoneal dialysis patients. *Antimicrob Agents Chemother* 1999; 43(1): 152–156.
339. Siva B, Hawley CM, McDonald SP, et al. Pseudomonas peritonitis in Australia: predictors, treatment, and outcomes in 191 cases. *Clin J Am Soc Nephrol* 2009; 4(5): 957–964.
340. Szeto CC, Chow KM, Leung CB, et al. Clinical course of peritonitis due to pseudomonas species complicating peritoneal dialysis: a review of 104 cases. *Kidney Int* 2001; 59(6): 2309–2315.
341. Htay H, Cho Y, Pascoe EM, et al. Outcomes of acinetobacter peritonitis in peritoneal dialysis patients: a multicenter registry analysis. *Perit Dial Int* 2018; 38(4): 257–265.
342. Li PH, Cheng VC, Yip T, et al. Epidemiology and clinical characteristics of acinetobacter peritoneal dialysis-related peritonitis in Hong Kong—with a perspective on multi-drug and carbapenem resistance. *Perit Dial Int* 2017; 37(2): 177–182.
343. Taylor G, McKenzie M, Buchanan-Chell M, et al. Peritonitis due to *Stenotrophomonas maltophilia* in patients undergoing chronic peritoneal dialysis. *Perit Dial Int* 1999; 19(3): 259–262.
344. Tzanetou K, Triantaphyllis G, Tsoutsos D, et al. *Stenotrophomonas maltophilia* peritonitis in CAPD patients: susceptibility to antibiotics and treatment outcome: a report of five cases. *Perit Dial Int* 2004; 24(4): 401–404.
345. Szeto CC, Li PK, Leung CB, et al. *Xanthomonas maltophilia* peritonitis in uremic patients receiving continuous ambulatory peritoneal dialysis. *Am J Kidney Dis* 1997; 29(1): 91–95.
346. Abbott IJ and Peleg AY. *Stenotrophomonas*, *Achromobacter*, and nonmelioid *Burkholderia* species: antimicrobial resistance and therapeutic strategies. *Semin Respir Crit Care Med* 2015; 36(1): 99–110.

347. Brown GR. Cotrimoxazole - optimal dosing in the critically ill. *Ann Intensive Care* 2014; 4: 13.
348. Junco SJ, Bowman MC and Turner RB. Clinical outcomes of *Stenotrophomonas maltophilia* infection treated with trimethoprim/sulfamethoxazole, minocycline, or fluoroquinolone monotherapy. *Int J Antimicrob Agents* 2021; 58(2): 106367.
349. Ko JH, Kang CI, Cornejo-Juarez P, et al. Fluoroquinolones versus trimethoprim-sulfamethoxazole for the treatment of *Stenotrophomonas maltophilia* infections: a systematic review and meta-analysis. *Clin Microbiol Infect* 2019; 25(5): 546–554.
350. Wu H, Yi C, Zhang D, et al. Changes of antibiotic resistance over time among *Escherichia coli* peritonitis in Southern China. *Perit Dial Int. Epub ahead of print 28 September* 2021; DOI: 10.1177/08968608211045272.
351. Jarvis EM, Hawley CM, McDonald SP, et al. Predictors, treatment, and outcomes of non-pseudomonas gram-negative peritonitis. *Kidney Int* 2010; 78(4): 408–414.
352. Hsueh PR, Badal RE, Hawser SP, et al. Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2008 results from SMART (Study for monitoring antimicrobial resistance trends). *Int J Antimicrob Agents* 2010; 36(5): 408–414.
353. Dias RCB, Vieira MA, Moro AC, et al. Characterization of *Escherichia coli* obtained from patients undergoing peritoneal dialysis and diagnosed with peritonitis in a Brazilian centre. *J Med Microbiol* 2019; 68(9): 1330–1340.
354. Lin WH, Tseng CC, Wu AB, et al. Clinical and microbiological characteristics of peritoneal dialysis-related peritonitis caused by *Escherichia coli* in southern Taiwan. *Eur J Clin Microbiol Infect Dis* 2018; 37(9): 1699–1707.
355. Wang TZ, Kodiyankal RPL and Calfee DP. Antimicrobial resistance in nephrology. *Nat Rev Nephrol* 2019; 15(8): 463–481.
356. Iredell J, Brown J and Tagg K. Antibiotic resistance in Enterobacteriaceae: mechanisms and clinical implications. *BMJ* 2016; 352: h6420.
357. Hughes S, Gilchrist M, Heard K, et al. Treating infections caused by carbapenemase-producing enterobacteriales (CPE): a pragmatic approach to antimicrobial stewardship on behalf of the UKCPA pharmacy infection network (PIN). *JAC Antimicrob Resist* 2020; 2(3): dlaa075.
358. Ma TK, Chow KM, Kwan BC, et al. Peritoneal-dialysis related peritonitis caused by *Gordonia* species: report of four cases and literature review. *Nephrology (Carlton)* 2014; 19(7): 379–383.
359. Lam JY, Wu AK, Leung WS, et al. *Gordonia* species as emerging causes of continuous-ambulatory-peritoneal-dialysis-related peritonitis identified by 16S rRNA and secA1 gene sequencing and matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS). *J Clin Microbiol* 2015; 53(2): 671–676.
360. Poliquin PG, Lagace-Wiens P, Verrelli M, et al. *Pasteurella* species peritoneal dialysis-associated peritonitis: household pets as a risk factor. *Can J Infect Dis Med Microbiol.* 2015; 26(1): 52–55.
361. Harwell CM, Newman LN, Cacho CP, et al. Abdominal catastrophe: visceral injury as a cause of peritonitis in patients treated by peritoneal dialysis. *Perit Dial Int.* 1997; 17(6): 586–594.
362. Trinh E and Bargman JM. Utility of abdominal imaging in peritoneal dialysis patients presenting with peritonitis. *Can J Kidney Health Dis* 2020; 7: 2054358120964115.
363. Szeto CC, Chow KM, Wong TY, et al. Conservative management of polymicrobial peritonitis complicating peritoneal dialysis—a series of 140 consecutive cases. *Am J Med* 2002; 113(9): 728–733.
364. Ribera-Sanchez R, Perez-Fontan M, Lopez-Iglesias A, et al. Comprehensive approach to peritoneal dialysis-related peritonitis by enteric microorganisms. comparison between single organism and polymicrobial infections. *Perit Dial Int* 2018; 38(2): 139–146.
365. Nadeau-Fredette AC and Bargman JM. Characteristics and outcomes of fungal peritonitis in a modern North American cohort. *Perit Dial Int* 2015; 35(1): 78–84.
366. Chang TI, Kim HW, Park JT, et al. Early catheter removal improves patient survival in peritoneal dialysis patients with fungal peritonitis: results of ninety-four episodes of fungal peritonitis at a single center. *Perit Dial Int* 2011; 31(1): 60–66.
367. Giacobino J, Montelli AC, Barretti P, et al. Fungal peritonitis in patients undergoing peritoneal dialysis (PD) in Brazil: molecular identification, biofilm production and antifungal susceptibility of the agents. *Med Mycol* 2016; 54(7): 725–732.
368. Tobudic S, Harrison N, Forstner C, et al. Effect of peritoneal dialysis fluids on activity of echinocandins against *Candida* spp. biofilm. *Med Mycol* 2017; 55(7): 790–793.
369. Peng LW and Lien YH. Pharmacokinetics of single, oral-dose voriconazole in peritoneal dialysis patients. *Am J Kidney Dis* 2005; 45(1): 162–166.
370. Dotis J, Kondou A, Koukloumperi E, et al. Aspergillus peritonitis in peritoneal dialysis patients: a systematic review. *J Mycol Med* 2020; 30(4): 101037.
371. Miles R, Hawley CM, McDonald SP, et al. Predictors and outcomes of fungal peritonitis in peritoneal dialysis patients. *Kidney Int* 2009; 76(6): 622–628.
372. Bunke M, Brier ME and Golper TA. Culture-negative CAPD peritonitis: the network 9 Study. *Adv Perit Dial* 1994; 10: 174–178.
373. Htay H, Cho Y, Pascoe EM, et al. Multicentre registry data analysis comparing outcomes of culture-negative peritonitis and different subtypes of culture-positive peritonitis in peritoneal dialysis patients. *Perit Dial Int* 2020; 40(1): 47–56.
374. Chen KH, Chang CT, Weng SM, et al. Culture-negative peritonitis: a fifteen-year review. *Ren Fail* 2007; 29(2): 177–181.
375. Akpolat T. Tuberculous peritonitis. *Perit Dial Int* 2009; 29(Suppl 2): S166–S169.

376. Talwani R and Horvath JA. Tuberculous peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: case report and review. *Clin Infect Dis* 2000; 31(1): 70–75.
377. Thomson Benjamin KA, Stephen V and Bogdan M. Mycobacterium tuberculosis peritonitis in peritoneal dialysis patients: a scoping review. *Nephrology (Carlton)* 2021; 27(2): 133–144.
378. Al Sahlawi M, Bargman JM and Perl J. Peritoneal dialysis-associated peritonitis: suggestions for management and mistakes to avoid. *Kidney Med* 2020; 2(4): 467–475.
379. Lye WC. Rapid diagnosis of *Mycobacterium tuberculosis* peritonitis in two continuous ambulatory peritoneal dialysis patients, using DNA amplification by polymerase chain reaction. *Adv Perit Dial* 2002; 18: 154–157.
380. Ahn C, Oh KH, Kim K, et al. Effect of peritoneal dialysis on plasma and peritoneal fluid concentrations of isoniazid, pyrazinamide, and rifampin. *Perit Dial Int* 2003; 23(4): 362–367.
381. Si M, Li H, Chen Y, et al. Ethambutol and isoniazid induced severe neurotoxicity in a patient undergoing continuous ambulatory peritoneal dialysis. *BMJ Case Rep* 2018; 2018: bcr2017223187.
382. Unsal A, Ahabap E, Basturk T, et al. Tuberculosis in dialysis patients: a nine-year retrospective analysis. *J Infect Dev Ctries* 2013; 7(3): 208–213.
383. Washida N and Itoh H. The role of non-tuberculous mycobacteria in peritoneal dialysis-related infections: a literature review. *Contrib Nephrol* 2018; 196: 155–161.
384. Fung WW, Chow KM, Li PK, et al. Clinical course of peritoneal dialysis-related peritonitis due to non-tuberculous mycobacterium - A single centre experience spanning 20 years. *Perit Dial Int*. Epub ahead of print 3 September 2021. DOI: 10.1177/08968608211042434.
385. Jiang SH, Roberts DM, Clayton PA, et al. Non-tuberculous mycobacterial PD peritonitis in Australia. *Int Urol Nephrol* 2013; 45(5): 1423–1428.
386. Bnaya A, Wiener-Well Y, Soetendorp H, et al. Nontuberculous mycobacteria infections of peritoneal dialysis patients: a multicenter study. *Perit Dial Int* 2021; 41(3): 284–291.
387. Renaud CJ, Subramanian S, Tambyah PA, et al. The clinical course of rapidly growing nontuberculous mycobacterial peritoneal dialysis infections in Asians: a case series and literature review. *Nephrology (Carlton)* 2011; 16(2): 174–179.
388. Imam O, Al-Zubaidi K, Janahi M, et al. Peritoneal dialysis-associated peritonitis caused by Mycobacterium abscessus in children—a case report. *Open Forum Infect Dis* 2021; 8(1): ofaa579.
389. Kojya S, Shiohira H, Sunagawa Y, et al. Therapeutic drug monitoring in peritoneal dialysis: a case of nontuberculous mycobacterium catheter-related infection treated with amikacin. *Clin Case Rep*. 2020; 8(6): 995–998.
390. Song Y, Wu J, Yan H, et al. Peritoneal dialysis-associated nontuberculous mycobacterium peritonitis: a systematic review of reported cases. *Nephrol Dial Transplant* 2012; 27(4): 1639–1644.
391. Bonomini M, Borrás FE, Troya-Saborido M, et al. Proteomic research in peritoneal dialysis. *Int J Mol Sci* 2020; 21(15): 5489.
392. Takeuchi T, Ohno H and Satoh-Takayama N. Understanding the immune signature fingerprint of peritoneal dialysis-related peritonitis. *Kidney Int* 2017; 92(1): 16–18.
393. Verma A, Chitalia VC, Waikar SS, et al. Machine learning applications in nephrology: a bibliometric analysis comparing kidney studies to other medicine subspecialties. *Kidney Med* 2021; 3(5): 762–767.
394. Fung WW and Li PK. Recent advances on novel diagnostic testing for peritoneal dialysis related peritonitis. *Kidney Res Clin Pract*. Epub ahead of print 21 January 2022. DOI:10.23876/j.krcp.21.204.
395. Bennett PN, Bohm C, Harasemiw O, et al. Physical activity and exercise in peritoneal dialysis: international society for peritoneal dialysis and the global renal exercise network practice recommendations. *Perit Dial Int* 2022; 42(1): 8–24.